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ABSTRACT
Novel mechanisms involved in the resistance to cytotoxic agents have been 
recently described both in fission yeast and in mammalian cells. The work described in 
this thesis was focused on novel determinants of multi-drug resistance in mammalian 
cells and their possible mechanism of action.
Human Pohl, a highly conserved subunit of the regulatory particle of the 26 S 
proteasome complex, has been shown to confer moderate resistance to 
chemotherapeutic drugs and ultraviolet light in mammalian cells by a P-gp-independent 
mechanism. The mechanism by which HA-Pohl causes drug resistance was 
investigated. Using constitutive and inducible expression of HA-tagged Pohl in 
mammalian cells, it was found that most overexpressed Pohl is not associated with the 
26S proteasome complex. The cells expressing HA-Pohl exhibited elevated protein 
levels of the two AP-1 components, c-Jun and c-Fos, associated with an increased 
stabilisation of c-Jun possibly caused by an interaction between HA-Pohl and c-Jun. 
Furthermore, HA-Pohl overexpression led to an increase in AP-1 transcriptional and 
DNA binding activities. As c-Jun and c-Fos are both degraded by the 
ubiquitin/proteasome pathway, it is proposed that Pohl is able to negatively modulate 
the ubiquitin-dependent proteolysis of transcription factors with consequent alteration 
of cellular drug susceptibility.
PWPl is member of the WD-40 repeat protein family and is the closest known 
human relative of the fission yeast pwpl^ multi-drug resistance gene. It is shown here 
that overexpression of human Pwpl in mammalian cells leads to multi-drug sensitivity 
possibly via positive modulation of the AP-1 DNA binding and transcriptional activity. 
Preliminary data obtained using an RNA anti-sense strategy, together with data 
obtained elsewhere, suggest that human Pwpl might have a role in the regulation of cell 
growth.
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Chapter 1
General introduction: multi-drug 
resistance mechanisms
Overview
This thesis describes the characterization of the 26S regulatory proteasome subunit 
Pohl in relation to the multi-drug resistance phenotype in mammalian cells. This 
study was carried out using constitutive and inducible expression systems. Additional 
work concerns the characterization of the human PWPl gene, which is the 
homologue of the fission yeast multi-drug resistance gene pwpD, and the phenotype 
of multi-drug sensitivity surprisingly conferred by the overexpression of the Pwpl 
protein in mammalian cells.
The first part of the chapter describes the impact of multi-drug resistance on cancer 
therapy and the mechanisms that are thought to be involved in this phenotype. The 
second part of the chapter focuses on some new drug resistance determinants that 
have recently been identified in fission yeast.
1.1 Known multi-drug resistance mechanisms 
Multi-drug resistance
Radiotherapy and chemotherapy are the main non-surgical approaches to the 
treatment of cancer. The main aim of these anti-cancer agents is to cause cancer cell 
death. Ionizing radiation and many chemotherapeutic agents induce DNA damage or 
cause disruption in the DNA metabolism. Different types of DNA damage may lead 
to the activation of a common signal that initiates the apoptotic cell death. The 
capacity of the cancer cells to detect cellular damage and to activate their own cell 
death programme is the principle desired result of a successful response to cancer 
therapy (Lowe et al. 1993).
Unfortunately, many solid tumours fail to respond to the therapies as resistant cell 
populations arise from the originally responsive malignancy. In some tumour type, 
such as breast cancer, cells appear to be intrinsically resistance to cytotoxic drugs, 
even before they have been exposed to the therapy.
Cancer cells are frequently able to develop cross-resistance to several unrelated drugs 
when treated with a specific genotoxic agent.
Several mechanisms have been identified that can contribute to this resistance 
phenotype.
The P-glycoprotein (P-gp) pump
P-glycoprotein (P-gp) is a plasma-membrane energy-dependent pump belonging to 
the ATP-binding cassette (ABC) super-family of transporters. It is a 170 kDa protein 
(p i70) encoded by the multi-drug resistance gene 1 (MDR-1) (Chen et al. 1986) 
(Gros et al. 1986). P-gp is composed of two halves, each containing six
transmembrane domains and an ATP binding domain. ATP binding and its 
hydrolysis are both essential for the proper functioning of the protein as a pump.
An elevated level of P-gp (p i70) in mammalian cells, due to elevated gene 
expression, with or without gene amplification of the MDR-1 gene, is a cause of 
resistance to a wide range of chemotherapeutic drugs (Ambudkar et al. 1999). The 
expression of functional P-gp leads to an energy-dependent efflux of cytotoxic drugs 
out of the cytosol, causing a reduction of the steady level of the drug inside the cell 
and a drug resistance phenotype. The currently accepted model for P-gp function is 
the “flippase” model. In the model the pump intercepts the drug as it moves through 
the lipid membrane and flips the drug from the inner to the outer leaflet and into the 
intracellular medium (reviewed by Johnstone et al. 2000). Unfortunately, it is still not 
very clear how the P-gp is able to recognise such a wide range of different drugs, 
such as anticancer drugs, HIV protease inhibitors, cyclin and linear peptides and 
other cytotoxic agents (Ambudkar et al. 1999).
P-gp is also associated with a volume-regulated chloride channel activity and this 
role seems to be distinct from its ability to act as drug transporter. In fact, the tissue 
distribution of P-gp expression suggests a primary function as a chloride channel, 
instead of, or in addition to, its activity as multi-drug transporter (Gottesman and 
Pastan 1993).
A bacterial ABC transporter, LmrA, has been described to have physiological and 
functional properties that are almost identical to those of the P-gp (van Veen et al.
1998). In fact, the two energy-dependent transporters are functionally 
interchangeable, underlying the high degree of conservation from bacterial to human 
cells.
The multi-drug resistance protein 1 (Mrp-1)
The multi-drug resistance protein (Mrpl), another transporter belonging to the ABC 
protein family, was cloned in 1992 (Cole et al. 1992) from a multi-drug resistant 
human cell line. Up-regulation of MRPl RNA expression or the post-translational 
modification of the protein may lead to multi-drug resistance to many cytotoxic 
drugs, such as doxorubicine, daunorubicin, vincristine, vinblastine and etoposide. No 
resistance to eisplatin was shown. It has been suggested that Mrp-1 could function as 
a pump, not only increasing the efflux of the drug through the plasma membrane but 
also by pumping the drugs into the cytoplasmic vescicles with the subsequent 
removal of the cytoplasmic vescicles from the cell by exocytosis (Broxterman et al. 
1995).
Furthermore, is has been also suggested that the transport of positively charged 
drugs, such as vincristine, daunorubicine and rhodamine 123, through the Mrp-1 
pump, is regulated by co-transport with glutathione (Broxterman et al. 1995).
The glutathione pathway
Glutathione is the main non-protein thiol in eukaryotic cells. The main role of 
glutathione and glutathione-dependent enzymes is to protect the cells against toxicity 
caused by chemical compounds or by normal metabolic pathways. Thus, it is 
considered the primary defence of the cell against oxidative stress. The glutathione 
pathway is involved in several cellular processes, such as drug detoxification, drug 
transport, modulation of DNA signalling and apoptosis (reviewed by McLellan and 
C.R. 1999).
As glutathione and glutathione-dependent enzymes are essential for cell survival 
following toxic insult, it is clear that they are also linked to a resistance phenotype of
human tumours to the drug therapy (Hayes and Wolf 1990). There are several 
mechanisms by which gluthathione and glutathione-dependent enzymes might lead to 
drug resistance (McLellan and C.R. 1999).
- Detoxification by the conjugation of the anti-cancer drugs with glutathione and 
their subsequent export by an energy-dependent mechanism
- Free radical scavenging
Reduction of peroxidases and detoxification of the products of the lipid 
peroxidation
- Export of un-conjugated drugs by glutathione-dependent transport through the 
multi-drug resistance protein 1 and 2 (Mrp-1 and Mrp-2)
- Regulation of signalling pathway by redox status. Redox sensitive proteins 
include AP-1, NFkB, MAP kinases, SAP kinases, c-Jun and c-Fos
Inhibition of apoptosis, the serine protease AP24 is inhibited by glutathione; a 
high level of the anti-apoptotic protein Bcl-2 causes an increase of the 
intracellular level of glutathione and promotes its nuclear localization
The apoptotic pathway and p53
Apoptosis, or programmed cell death, is a major mechanism for the maintenance of 
homeostasis of the body's systems under physiological conditions. After the apoptotic 
process has been triggered the cell undergoes a cascade of biochemical changes, 
which lead to its self-destruction.
The cytotoxicity of many anti-cancer drugs, which induce DNA damage or disrupt 
DNA metabolism, is attributable to activation of the genetic programme of cell death. 
The common capacity of various chemotherapeutic drugs to induce apoptosis
suggests that multiple mechanisms are able to activate the same pathway (Sen and 
D'Incalci 1992).
The tumour suppressor p53 is a transcription factor, also known as the "guardian of 
the genome" (Lane 1992), which by regulating apoptosis and checkpoints responses 
to DNA damage and other forms of genotoxic stress has a central role in the control 
of the genomic integrity. p53 is mutated or inactivated by some other mechanisms in 
most human tumours. p53-independent mechanisms of DNA damage-induced 
apoptosis and cell cycle arrest also exist (reviewed by Agarwal et al. 1998).
Genotoxic stress causes an increase of p53 protein level, its nuclear localization and 
sequence-specific DNA binding. As a result, p53 target genes, including Mdm2, 
Gadd53 and cyclin-dependent kinase inhibitor Cipl, are induced with consequent 
arrest at the G l, either transiently or prolonged, and G2 phase of the cell cycle in 
order to allow the DNA repair machinery to repair the damage before DNA 
replication or mitosis occur, or alternatively leading to the activation of apoptosis (Di 
Leonardo et al. 1994). The choice between cell cycle arrest and induction of 
apoptosis depends on multiple variables, inclusing the cell type, the extent of DNA 
damage and the level of p53 itself in the cells. For example low levels of p53 
promote cells survival in fibroblasts, underlying an anti-apoptotic function of p53 
(Lassus et al. 1996). Furthermore, links between p53 and other key regulators of the 
cell cycle and apoptosis, such as pRb, c-Myc, Bax and Bcl-2, have also been 
demonstrated (Agarwal et al. 1998; Miyashita et al. 1994).
Given that p53 has been shown to have a key role in determining the choice between 
cell survival and apoptosis, tumour-associated p53 mutations might be expected to 
contribute to increased cross-resistance of the cell population to DNA damaging 
agents. Thus one of the mechanisms by which cancer cells acquire drug and/or
radiation resistance is through the modulation of the apoptotic pathway (Lowe et al. 
1993X
1,2 Novel determinants o f multi- drug resistance in fission yeast
The fission yeast Schizosaccharomyces pombe is an established genetic model that 
has been used to investigate many complex eukaryotic processes such as mitosis and 
checkpoint regulation (Nurse 1990). In order to identify new determinants of multi­
drug resistance that might be conserved in human cells, over the last few years 
genetic studies in fission yeast have also addressed this area of biology.
Fission yeastpapl*
Fission yeast papl^ is a non-essential gene encoding an AP-l-like transcription factor 
containing a leucine zipper motif (Toda et al. 1991) (reviewed by Toone and Jones
1999). The basic domain that is located in the proximity of the leucine repeats is 
similar to the basic domain found in c-Jun, c-Fos and GCN4 transcription factors. 
The overall sequence homology in this region among these proteins is about 40%. 
Furthermore, the basic region is similar to the S.cerervisiae YAPl transcription factor 
sequence (yeast AP-1 like gene 7).
The purified recombinant Papl is able to bind specifically to the human collagenase 
(Col-APl) or the SV-40 (SV-APl) promoters, which both contain the AP-1 
consensus binding sequence (Toda et al. 1991). When two of the consensus 
nucleotides are mutated, Papl is no longer able to form a DNA-protein complex.
The overexpression of papl^ from a multicopy plasmid leads to resistance to 
staurosporine in fission yeast while on the contrary the p a p 7 ^ -deleted cells are 
hypersensitive to staurosporine (Toda et al. 1991). Papl is regulated by the fission 
yeast stress-activated MAP kinase Styl (Toone et al. 1998). After exposure of fission 
yeast cells to cytotoxic agents and/or to oxidative stress, Papl re-localises in the
nucleus with subsequent transcriptional activation of the target genes involved in the 
stress response. These include hbal^/bfrl^ and pm dl^  genes, encoding two energy- 
dependent ABC family transport proteins as well as other genes involved in multi­
drug resistance (Toone et al. 1998). This process is Styl-dependent and it is regulated 
at the nuclear export level, rather than the import level (Figure 2.1). The process is 
dependent on the Crml nuclear export factor and the Ran nucleotide exchange factor, 
encoded by the crml^ and the dcdl^/piml^ genes, respectively.
Fission yeast PadV
The fission yeast padl^ gene, for papl-«dependent transcriptional activator 7, was first 
described in 1995 as a positive regulator of Papl (Shimanuki et al. 1995). The padl^ 
gene is essential for cell viability. pa<77 ^ -disrupted spores can germinate, but show 
altered chromosome structure where the nucleus of the null mutants is often 
abnormally located in the cell body. The chromosomal DNA is also abnormally 
deformed and the chromatin appears more compact in comparison with the wild-type 
cells. The arrested cells can also be unusually elongated. This evidence reveals 
critical roles of the pad l^  gene both for chromosome integrity and for cell cycle 
progression (Shimanuki et al. 1995).
It was suggested that Padl might be involved in establishing the chromatin 
architecture during cell cycle progression and that it may regulate the maintenance of 
the chromosome structure through an indirect mechanism. In fact the cell cycle arrest 
in the null mutant cells could be a consequence of the formation of an abnormal 
ehromosome structure (Shimanuki et al. 1995).
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Figure 2.1 -  The stress response pathway in fission yeast
(Genes & Development 12:1453-1463)
Subsequently it was shown that pad l^  encodes a regulatory subunit of the 26S 
proteasome in fission yeast (Penney et al. 1998). Padl co-purifies with the fraction 
containing the highest levels of the 26S proteasome activity. In support of these data, 
Padl co-inununoprecipitates with the 26S regulatory subunit Mts4 from crude yeast 
extracts (Penney et al. 1998).
The fission yeast 26S proteasome is essential for cell growth and loss of its function 
leads to the arrest of the cell cycle at metaphase (reviewed by Penney et al. 1998). 
Consistent with this phenotype, the temperature sensitive mutant padl-1  shows a 
growth arrest phenotype. Furthermore the padl-1  mutant, as well as the mts2-l 
mutant (which is defective in another proteasome regulatory subunit), shows an 
accumulation of high molecular weight ubiquitinylated proteins, consistent with one 
of the main functions of the 19S regulatory complex being the recognition of the 
ubiquitinylated substrates. Taken together, these results support the idea that Padl is 
a novel component of the 19S regulatory complex of the 26S proteasome in fission 
yeast.
padl^  and drug resistance
The initial isolation of padl^ was as a gene lacking the 3' portion at the open reading 
frame encoding the last 29 amino acids, which conferred staurosporine resistance 
when overexpressed from a multicopy plasmid in fission yeast (Shimanuki et al. 
1995). In the chromosome the pad l^  gene resides in close proximity to the spkl^  
gene (jtaurosporine-resistance protein kinase i), which was initially thought to be the 
gene responsible for the staurosporine resistance (Toda et al. 1991). The resistance 
phenotype is dependent on the presence of papl^  as pap7^-disrupted cells do not 
show any resistance, padl^ overexpression appeared to cause activation of Papl-
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dependent transcription without affecting either mRNA or protein level of Papl. As 
observed in popf^-overexpressing cells, Padl induces the transcriptional activation of 
the target gene aptl^, which encodes the 25kDa molecular weight mass flavoprotein 
p25, while on the other hand the DNA binding ability of Papl was apparently not 
affected by Padl overexpression.
Given that Padl is a regulatory subunit of the 26S proteasome complex (Penney et al. 
1998), it has been suggested that the truncated padl^ gene could generate an 
abnormal protein that in some way disrupts the function of the 26S proteasome, 
resulting in the accumulation of proteins possibly involved in the drug resistance 
mechanism (Penney et al. 1998).
Fission yeast crmV
The fission yeast crmP  gene, for chromosome region maintenance 7, is an essential 
gene encoding a highly conserved 115 kDa protein related to the P-importin-like 
nuclear transport factors (Adachi and Yanagida 1989). crm7^was originally identified 
through a cold-sensitive (c^ y) mutant during a microscopic screen of fission yeast cells 
stained with 4,6-diamidino-2-phenylindole (DAPI) in order to identify gene products 
essential for maintaining higher-order chromosome structure (Adachi and Yanagida 
1989). At permissive temperature the cs crml mutant cells showed pleiotropic 
phenotypes, inclusing calcium hypersensitivity, staurosporine resistance and 
accumulation of p25 (Adachi and Yanagida 1989). crmP  was subsequently described 
as a negative regulator of Papl (Toda et al. 1992).
Fission yeast crm l^  encodes an export faetor involved in Ran-dependent nuelear 
export, as has already been shown for the homologous protein in S.cerevisiae,
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Xenopus, Drosophila and human cells. The protein localises in the nucleus, but is 
also enriched in the nuelear periphery (Adachi and Yanagida 1989). 
crmV  and drug resistance
Mutations of the crmD  gene were shown to cause resistanee to staurosporine and 
caffeine through inereased Papl-dependent transcription (Toda et al. 1992) with 
associated up-regulation of the expression of p25 expression. However, no increase 
in Papl expression level was observed. This suggested that the capacity of crmD  to 
negatively regulate Papl activity is not dependent on any modulation of Papl protein 
level. It has since transpired that Crml controls the nuclear/cytoplasmic transport of 
Papl (Toone et al. 1998). Consistent with this role, crml mutant cells show a nuclear 
accumulation of Papl with the consequent increased transcription of target genes 
involved in drug resistance.
Human CRMl
Human CRMl was first described in 1997 as a 112 kDa soluble factor that interacts 
with the nuclear pore complex (NPC). The protein contains a domain of significant 
homology with importin-p, a cytoplasmic factor that interacts with the nucleoporin 
repeat regions (reviewed by Fornerod et al. 1997a; Fornerod et al. 1997b; Ossareh- 
Nazari et al. 1997). The NPC is a 125 MDa complex embedded in the nuclear 
envelope that mediates nucleocytoplasmic traffic in eukaryotic cells. Crml protein is 
localised in the nuclear pore as well as in the nucleoplasm. It is a dynamic protein, 
which can interact with multiple components of the NPC and move between the 
nuclear pore and the cytoplasm (Fornerod et al. 1997b).
14
Human JABl
Human JABl (c-Jun-gctivation domain Mnding 7) was identified through a two 
hybrid screen for proteins able to interact with the amino-terminal activation domain 
of c-Jun (Claret et al. 1996). Jabl is able to interact with c-Jun, which is the major 
component of the heterodimerie AP-1 trancription factors, as well as with JunB but 
not with JunD or with v-Jun. Jabl has also extensively sequence similarity to the 
product of the open reading frame (ORF) F37A4.5 from C.elegans, with S.pombe 
Padl and with the human Padl homologue, Pohl.
Jabl is mainly localised in the nucleus and is able to increase the transcriptional 
activity of the AP-1 factors in mammalian cells. Furthermore, when Jabl is 
overexpressed in fission yeast cells it confers drug resistance in a Papl-dependent 
mechanism. In fact, Jabl was the first mammalian co-activator shown to be able to 
modulate the expression of endogenous genes in fission yeast (Claret et al. 1996) and 
with Padl defined as a new family of eukaryotic co-activators able to positively 
modulate some members of the AP-1 family (Claret et al. 1996).
Recently Jabl was identified as subunit 5 (CSN5) of the C0P9 signalosome complex, 
also known as JAB 1-containing signalosome, a multiprotein complex first described 
in plants but highly conserved in fission yeast and humans (see Introduction Chapter 
3) (Seeger et al. 1998).
Recent data indicate that Jabl is involved in a regulation of various cellular 
processes, including transcription, protein degradation, complex stabilisation and 
signalling. For example, Jabl is able to bind the cyclin-dependent kinase inhibitor 
p27^P^ with the subsequent translocation of the protein to the cytoplasm and an 
increase of p27®^  ^degradation by the 26S proteasome pathway (Tomoda et al. 1999). 
Jabl also interacts with the cytoplasmic domain of the p2-subunit of the integrin
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LFA-1 (Blanchi et al. 2000). Recently it has been shown that Jabl binds the 
progesterone receptor (PR) and the steroid receptor coactivator l(SRC-l), with the 
subsequent stabilization of the complex (Chauehereau et al. 2000). These data 
suggest that in general Jabl might regulate transcription by a mechanism that 
involves the bridging of receptors and coactivators.
Fission yeast int6*
Int-6 (p48) is a component of the human translation initiation factor eIF3. The murine 
int-6 gene is a site of mouse mammary tumour virus (MMTV) insertion, which leads 
to the formation of a truncated Int-6 protein with tumorigenic potential (Marchetti et 
al. 1995). A fission yeast int6^ homologue has been recently identified through a 
screen aimed at identifying genes able to confer multi-drug resistance when 
overexpressed in S.pombe cells (Crane et al. 2000). Similarly to the phenotype 
described for padD  (Shimanuki et al. 1995), the int6^ drug resistance phenotype is 
dependent on the papD  gene and int6^ overexpression leads to an increase of Papl- 
dependent transcription, without an increase in the Papl protein level or changes in 
its localisation. int6^ encodes a 57 kDa protein Int6 , which appears to be part of the 
eIF3 complex as it co-immunoprecipitates with other components of the eIF3 
complex. Furthermore, following sucrose gradient centrifugation Int6 was present in 
size fractions containing the 43S translation preinitiation complex. 
int6* is not an essential gene, but cells lacking the gene showed a slow growth 
phenotype. Normal growth was restored by the overexpression of the fission yeast 
int6^ gene, as well as the human homologue INT6 (Crane et al. 2000).
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General conclusions
It is apparent that a complex network of different pathways regulates the response of 
the cells to the cytotoxic effect exerted by chemotherapy and radiotherapy in cancer. 
In the last decades much effort from both experimental and clinical works have been 
focused on a better understanding of the mechanisms through which previously 
described mechanisms as well as recently identified drug resistance determinants 
once inactivated or deregulated can interfere with the cell death response induced by 
toxic insult and can subsequently lead to resistance to the therapy.
General aim of the work described in this thesis was to characterize two human 
genes, whose counterparts in fission yeast confer multi-drug resistance, and their 
mechanism of action in mammalian cells, in order to possibly elucidate novel 
pathways or downstream effectors underlying the pleiotropic drug resistance often 
observed in cancer.
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Chapter 2
Materials and Methods
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1.0 DNA MANIPULATION 
Polymerase chain reaction (PCR)
Template DNA was diluted to a concentration of 100 ng/pl in dH2 0 . The PCR 
mixture was prepared as follows:
Deoxynucleotide mix [5 mM each] 2 pi
Expand PCR buffer lOx 5 pi
Oligonucleotide primer [40 pM] 2.5 pi
Template DNA 1 pi
Expand polymerase (Roche) 2.5 units
dH20 to 50 pi
Thermal cycling was performed in a GeneAmp PCR system 9700 machine (Perkin- 
Elmer) as follows: 94°C for 5 minutes, 20-30 cycles of 94°C 30 seconds, annealing 
temperature 55-65°C for 30-60 seconds, 72°C for 30 seconds - 2 minutes (depending 
on the length of the sequence to amplify) and 72°C for 10 minutes before chilling at 
4°C.
Agarose gel electrophoresis
DNA samples were mixed with 0.2 volume of 6x loading buffer (30% (w/v) sucrose, 
0.1 mM EDTA, 0.01% (w/v) bromophenol blue) and loaded onto 1-1.2 % agarose 
gels in TBE buffer (89 mM Tris, 89 mM boric acid, 20 mM EDTA pH 8.0) 
containing 0.5 pg/ml of ethidium bromide. Eleetrophoresis was carried out at a 
constant voltage of 2-10 V/cm and the DNA was visualised using a UV light box.
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DNA Sequencing
DNA sequencing was performed using the dideoxynucleotide chain termination 
method. The sequencing reaction was perfomed in 10 pi final volume containing 3.2 
picomoles of oligonucletide primer and 10-50 nanograms of template DNA using 
ABl PRISM dRhodamine die terminator reagent (Perkin-Elmer). After thermal 
cycling (96°C for 10 seconds, 25 cycles at 96°C for 10 seconds, 50°C for 5 seconds 
and 50°C for 4 minutes), the DNA was ethanol precipitated and resuspended in 
bromophenol blue-containing buffer and heated at 98°C for 5 minutes. The samples 
were run on a semi-automated sequencer (ABl PRISM 377) with the assistance of 
Reg Boone and James Beesley and analysed using the Sequeneher 3.0 software 
(Manufacturer).
DNA purification from agarose gels
DNA was purified from agarose gels using a gene-clean 11 kit (BIO 101) according to 
the manufacturer’s instructions. After electrophoresis, the DNA band of interest was 
excised from the gel under long-wave UV light and weighted. 3 volumes of 6 M Nal 
solution was added to the tube, whieh was then ineubated for 5 minutes at 55°C. 5-10 
pi of glass milk were added and incubated for 5 minutes on iee. After three washes 
with 50% ethanol solution, the DNA was eluted in 20 pi of TE.
DNA ligation for cloning
After gel purification, linearised vectors and inserts were ligated at molar ratios of 
1:3 and 1:5 using lU  of T4 ligase in Ix T4 ligation buffer in a total reaction volume 
of 10 pi. Lgation reactions were performed at 16°C overnight or at room temperature 
for 1-2 hours.
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Cloning vectors 
■ Human PWPl
- Human PWPl cDNA was cloned into the fission yeast pREPSX vector, which 
drives the expression of the gene from the thiamine-repressible nm tl promoter 
(Maundrell 1993). A triple haemaglutinine (HA) epitope tag was previously 
introduced between Xhol and Sail sites in the polylinker (by Randa Craig). Human 
PWPl was amplified from a human cDNA kindly provided by Dr. Celis using the 
sense PWPl 5’ primer containing a Sail restriction enzyme site and the reverse 
PWPl 3’ primer containing a Notl site. PWPl open reading frame was fused at the 
COOH-terminus of the HA epitope tag, and the vector was named pREP3X/HA- 
PW Pl. The cDNA was sequenced using 4 different primers: PWPl 5’ mutchk, 
PWPl 3’ Pst, PWPl 5TNT and the two primers used for cloning, (PWPl 5’ and 3’) 
in order to cover the length of the entire gene (1596 bp).
- HA-PWPl was cloned in pRETRO-Off vector (Clontech), a Moloney murine 
leukaemia virus (MoMuLV)-derived retroviral veetor expressing the tetracycline- 
controlled transactivator (tTA) from the SV-40 promoter. The vector was modified in 
order to obtain a better multicloning site (MCS) as follows: the vector was digested 
with Xhol (4-1) and treated with the Klenow enzyme in order to blunt the DNA ends 
and destroy the restriction enzyme site on re-ligation. Subsequently, the vector 
lacking Xhol was digested with Notl and BamHI and ligated to a double stranded 
linker, obtained by annealing of the oligonucleotides linker 5' and linker 3', with Notl 
and BamHI half-sites at its ends. The result was a MCS containing Xhol, Mlul, Hpal, 
Clal Notl and BamHI, where the Notl site from the original vector was destroyed. 
HA-PWPl was digested with Xhol and Notl from pREP3X/HA-PWPi and ligated 
into the multi-cloning site (MCS) of the vector under the control of the tetracycline
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responsive element (TRE). The correct insertion of the gene in the vector was 
checked by sequencing, using the sense pRETOFF 5’ and the reverse pRETOFF 3’ 
primers, which are complementary to the multi-cloning site sequence of the veetor.
- In order to clone HA-PWPl into the pcDNA3.1+ mammalian expression vector 
(Invitrogen), the gene was amplified by PCR using the sense PWPl Hind/Sal 
primers, which contains Hindlll and Sail restriction enzyme sites, and the reverse 
PWPl 3’ primer with a N otl site. The vector and the PCR product were digested 
Hindlll and Notl and ligated.
- In order to clone PWPl without an HA epitope tag at the 5’ of the gene, the sense 
primer PWPl ATG (no tag), containing a Hindlll site, and the reverse primer PWPl 
3’, containing a Notl site, were used. The PCR product was digested with Hindlll and 
Notl and cloned into peDNA3.1+, which was digested with the same restriction 
enzymes. The PWPl sequence was confirmed as described above.
- PWPl was cloned in the anti-sense orientation into pcDNA3.1- (Invitrogen), which 
contains the same MCS as pcDNA3.1+, but in the opposite orientation, using Hindlll 
and Notl sites.
- In order to raise polyclonal antibodies against Pwpl, the cDNA was cloned into 
pGEX-4T-3 (Pharmacia Biotech) at the 3'-end of the GST sequence and expressed as 
a GST-PWPl fusion protein in E.Coli BL21. pREP3X/HA-PWP 1 was digested with 
Sail and Notl at the 5’ and the 3’ ends of the cDNA, which was cloned into pGEX- 
4T-3 digested with the same enzymes.
- For localisation studies in vivo, PWPl was also cloned at the COOH-terminus of 
the EGFP (enhaneed green fluorescent protein) coding sequence in the pEGFP-Cl 
vector (Clontech). The fusion protein is expressed under the control of the 
immediate early promoter of the human cytomegalovirus (CMV). The pREP3X/77A-
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PWPl and the pEGFP vector were both digested with Sail and BamHI and vector 
and insert were ligated.
- HA-PWPl was also cloned into the IPTG inducible vector, pOPRSVI (Stratagene), 
previously modified (by C. Norbury) with Xhol-Clal-Notl cloning sites, using Xhol 
and Notl sites at the 5’ and the 3’ ends of the cDNA, respectively.
- In order to identify possible interacting targets of the Pwpl protein, a two hybrid 
screen was performed. The PWPl cDNA was cloned into the pEG202 vector. In 
order to obtain PWPl sequence in frame with LexA, the gene was first digested from 
pREP3X-PWPl plasmid and cloned into the pIRES2-EGFP vector (Clontech) using 
Sail and BamHI sites. PWPl was then digested from pIRES2-EGFP/PWP1 with 
EcoRI and BamHI and ligated into pEG202 vector digested with the same enzymes.
■ Human POHl
- POHl was previously cloned into pcDNA3 (Invitrogen) using the Hindlll and Notl 
sites at the 5’ and the 3’ ends of the cDNA, respectively, with a single HA epitope 
tag at the 5’ end of the cDNA (Spataro et al. 1997).
- In order to express the protein through an inducible system, POHl was cloned into 
pOPRSV, previously modified (by C. Norbury) with Xhol-Clal-Notl cloning sites. 
POHI was excised from pREP3X/HA-POH1 and cloned into pOPRSVI using the 
Xhol and Notl sites.
- HA-POHI was cloned into pUHDlO-MCS for inducible expression in human cells. 
A PCR fragment was generated using the synthetic sense POHlAot/ and the reverse 
POHlEcoR/primers. In addition, a single HA sequence was fused in frame with the 
first codon at the 5’ end of the cDNA. The PCR fragment and pUHDlO-MCS vector
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were digested with Notl and EcoRI enzymes and ligated together. The gene was then 
sequenced.
- POHI was also cloned at the COOH-terminus of the EGFP sequence into pEGFP- 
C1 (Clontech). POHI was amplified by PCR using the PO H 15a/5’ and the 
POHlXma^’ primers. Both the PCR product and the vector were digested with Sail 
and Xmal and ligated.
2.0 BACTERIAL METHODS 
Bacterial electro-transformation
A) Preparation of electro-competent cells
A single colony of E.coli DHlOp (F" araD\39 (ara, leu)1691 M acXlA gal\J galK. 
mcrA A{mrr -  hsdPM.S -  mcrBC) X-rpshdeok O80d/flcZDM15 endAl nupG recAl) 
was inoculated into 5-10 ml of LB medium and grown overnight at 37°C. The culture 
was diluted into 400 ml of medium and the bacteria were grown at 37°C with 
vigorous shaking to an Agoo = 0.5-0.8 . The flask was then chilled on ice for 15-30 
minutes and the bacterial culture was centrifuged at 5000 rpm in a JAIO rotor for 15 
minutes at 4°C. The pellet was washed twice with 400 ml and 200 ml, respectively, 
of ice-cold sterile distilled water and centrifuged for 15 minutes at 5000 rpm in a 
JAIO rotor at 4°C. The pellet was resuspended in 10 ml of 20% glycerol and spun 
down in a JA20 rotor. Finally the cells were resuspended in 1-2 ml of 10% glycerol. 
The cells were frozen in aliquots (50-100 pi) on dry ice and then stored at -70°C up 
to 6 months.
B) Electro-transformation
The Gene Puiser electroporator (BIO-RAD) was set to 25 pF capaeity, 2.5 kV and 
the Pulse Controller unit to 400 fl. An aliquot of competent cells was gently thawed
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and kept on ice. 0.8-1 pi of DNA was added to 50 pi competent cells, transferred to a 
0.2 cm electroporation cuvette and the cells/DNA suspension was gently shaken to 
the bottom of the cuvette. A single pulse was applied to the cells with a time constant 
of 10 msec and 200 pi of LB medium was added immediately to the cells, which 
were plated on LB agar (+ selective antibiotic) plates. The plates were incubated 
overnight at 37°C.
Colony PCR
Each colony was inoculated into 0.5 ml of LB medium, containing the appropriate 
antibiotic and grown for about 1-2 hours. 5 pi of the culture was used for PCR 
reaction in a 50 pi final reaction volume. In the first 5 minutes at 94°C the bacteria 
cells were lysed and the DNA became available for the PCR reaction (20-25 cycles). 
10 pi from each PCR reaction was analysed on 1-1.5% agarose gels and positive 
colonies analysed by mini-prep.
Plasmid DNA preparations
a) Small scale preparation of plasmid DNA (QIAGEN mini-prep)
After DNA transformation, a single bacterial colony was inoculated into 5 ml of LB 
medium, containing the appropriate antibiotic (Ampicillin [100 pg/ml] or Kanamicin 
[50 pg/ml]) and grown overnight at 37°C. 2-3 ml of the culture was spun down at 
maximum speed in an eppendorf centrifuge for few minutes and the bacterial pellet 
was resuspended in 300 pi of buffer PI (Qiagen) (50mm Tris-HCl pH= 8.0, lOmM 
EDTA and lOOpg/ml RNAse A). 300 pi of buffer P2 (200 mM NaOH, 1% SDS) was 
added, mixed gently by inversion and incubated for 5 minutes at room temperature. 
300 pi of chilled buffer P3 (3.0 mM potassium acetate pH= 5.5) was added and
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incubated for 10 minutes on ice. The lysate was spun down for 10 minutes at 4°C at
13.000 rpm in a eppendorf centrifuge and the supernatant was precipitated by 
centrifugation at 13.000 rpm in an eppendorf centrifuge with 0.8 volume of propanol- 
2-ol at 4°C for 20-30 minutes. The precipitated DNA was washed with 70% ethanol 
and allowed to dry. The DNA was resuspended in 20 pi of TE (pH 8.0). For a cleaner 
DNA preparation, after incubation with the solutions P I, P2 and P3 and 
centrifugation, the supernatant was passed through a Qiagen column tip-20, which 
was previously equilibrated with the buffer QBT (750 mM NaCl, 50 mM MOPS pH 
7.0, 15% propanol-2-ol and 0.15% Triton X-100). The column was then washed 4 
times with 1 ml of buffer QC (1.0 M NaCl, 50 mM MOPS pH 7.0 and 15% propanol- 
2-ol); DNA was eluted with 0.8 ml of buffer QF (1.25 M NaCl, 50 mM Tris-HCl pH 
8.5 and 15% propanol-2-ol), collected in an eppendorf tube and precipitated using 0.7 
volumes (0.57 ml) of propanol-2-ol at room temperature centrifugation at maximum 
speed in an eppendorf centrifuge at 4°C for 30 minutes. The pellet was then washed 
with 70% ethanol and allowed to dry. The DNA was resuspended in 20 pi of TE or 
dH^O.
b) Large scale preparation of plasmid DNA (QIAGEN maxi-prep)
A single bacterial colony was inoculated into 5 ml of LB containing the appropriate 
antibiotic and allowed to grow for 6-8 hours at 37°C. The culture was diluted into 
400 ml of the same medium and grown overnight with vigorous shaking at 37°C. The 
bacteria were spun down at 5000 rpm in a 110 rotor for 15 minutes and the bacterial 
pellet was resuspended in 10 ml of buffer PI (as before). 10 ml of buffer P2 were 
added and the solution was mixed gently by 5-8 times inversion and incubated for 5 
minutes at room temperature. 10 ml of buffer chilled P3 were added, mixed gently 
and incubated on ice for 15 minutes. The lysates was spun down at 12.000 rpm using
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a J14 rotor at 4°C for 30 minutes and the supernatant was applied to a QIAGEN-tip 
500, which was previously equilibrated with 10 ml of buffer QBT (750 mM NaCl, 50 
mM MOPS pH 7.0, 15% propanol-2-ol and 0.15% Triton X-100). Then, the column 
was washed twice with 30 ml of buffer QC (1.0 M NaCl, 50 mM MOPS pH 7.0 and 
15% propanol-2-ol). The DNA was eluted with 15 ml of buffer QF (1.25 M NaCl, 50 
mM Tris-HCl pH 8.5 and 15% propanol-2-ol) and the eluate was collected in a 30 ml 
tube. The DNA was precipitated by adding 0.7 volumes of room temperature 
propanol-2-ol and centrifuged at 12.000 rpm in a 120 rotor for 30 minutes at 4°C. 
The pellet was washed once or twice with 70% ethanol, allowed to dry and 
redissolved in TE pH 8.0.
Preparation of GST-PWPl fusion protein for raising polyclonal antibodies
E.coli strain BL21 was transformed with the plasmid pGEX-4T-3/PWP1 and a single 
colony was inoculated into 10 ml of LB medium containing ampicillin [100 pg/ml] 
and grown overnight at 37°C. This culture was diluted into 400 ml of LB with 
ampicillin and grown to A595= 0.5. IPTG [0.4 mM] was added in order to induce the 
expression of the GST-fusion protein. Then, the bacteria were spun down at 5000 
rpm in a 114 rotor for 15 minutes and resuspended in 10 ml of buffer A (50 mM Tris- 
HCl pH=7.5, 100 mM NaCl, 1 mM EDTA and protease inhibitor cocktail complete 
(Roche). The cells were lysed by sonication for 20 seconds x 4 and ultracentrifuged 
at 39.000 rpm in a 70 TI rotor at 4°C for 1 hour. In order to purify soluble GST 
fusion protein after cell lysis the supernatant was incubated with 100-200 pi of 50% 
glutathione-agarose beads, resuspended in buffer A, and rotated at 4°C for 15 
minutes and then spun down and washed 5 times in buffer A. After the final wash, 
the beads were resuspended in 2x SDS electrophoresis sample buffer and
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immediately heated at 98°C for 5 minutes. To examine the insoluble fraction after 
ultracentrifugation the pellet was resuspended in 1 ml of 2x SDS sample buffer and 
heated at 98°C for 5 minutes. 20 pi of eaeh fraction was loaded on a 10% SDS 
polyacrylamide gel in order to test the overexpression of the GST fusion protein. The 
fraction containing the GST fusion protein was purified from a preparative 10% 
SDS-PAGE gel, containing a single long well for sample loading. Electrophoresis 
was performed at a constant current of 25 mA. A strip from the gel was cut and 
stained with coomassie blue in order to locate the band of the overexpressed GST 
fusion protein. The strip was aligned with the gel and the area containing the protein 
of interest was cut out. This gel strip with a few drops of PBS was passed 
sequentially through syringe needle (10, 21 and 23 guage). The sample was sent to 
Biological Resources, ICRF Clare Hall Laboratories, for rabbit immunization.
Peptide conjugation for antibody preparation
Two peptides, PWPl-NT and PWPl-CT, corresponding to the amino- and carboxy- 
terminus, respectively, of PWPl amino acid sequence were synthesised by the 
Biological Resources Department - ICRF. Both peptides were then conjugated with 
Keyhole Limpet Haemocyanin (KLH) (Calbiochem), as carrier, and then each 
peptide and carrier were weighed and the same amount of each was dissolved in 0.1 
M NaHCOg at a carrier concentration of 2 mg/ml (G.Evan, personal communication). 
A fresh vial of 25% glutaraldehyde (Sigma) was thawed and added to the 
peptide/carrier mix to a final concentration of 0.05% and left mixing at room 
temperature overnight. The solution was adjusted to pH 7.0-8.0 using NaOH. The 
conjugated peptide was then dialysed against dH20 for about 12 hours and
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lyophilised. The samples were then sent to the Biological Resources, ICRF Clare 
Hall Laboratories, for rabbit immunization.
3.0 FISSION YEAST METHODS 
Cell growth
Fission yeast manipulations were carried out as previously described (Moreno et al. 
1991; Norbury and Moreno 1997). Fission yeast cells were maintained on YE5S agar 
(5 mg/ml yeast extract (Difco), 30 mg/ml glucose, 20 mg/ml agar (Difco, Bacto) and 
225 pg/ml each of leucine, uracil, adenine, histidine and lysine hydrochloride). For 
selective maintenance of plasmids, the cells were grown on EMM2 agar (potassium 
hydrogen phthalatel4.7 mM, NazHPO^ 15.5 mM, NH4CI 93.5 mM, glucose 20 
mg/ml, MgClz5.2 mM, CaCl^O.l M, KCl 13.4 mM, Na2SO4 0.28 mM, H3BO38 .I 
pM, MnS04  2.37 pM, ZnS0 4 1.39 pM, FeCl3 0.74 pM, M0O3 0.25 pM, KI 0.6 pM, 
CUSO4O.I6 pM, citric acid 4.76 pM, nicotinic acid 81.2 pM, inositol 55.5 pM, biotin 
40.8 pM, panthothenic acid 4.2 pM and agar 20 mg/ml (Difco Bacto)) supplemented 
with the appropriate amino acids at 225 pg/ml. Liquid cultures were grown in YE5S 
or EMM2 medium. Strains were stored in YE5S with 25% glycerol at -80°C.
Measurement of cell concentration
The cell concentration in liquid cultures was estimated by measuring absorbance at 
595 nm, with an absorbance of 1.0 being equivalent to 2x10^ cells/ml.
DNA transformation
S.pombe cells were transformed by electroporation.
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Cells in mid-exponential growth in 50 ml EMM2 were harvested by centrifugation, 
washed in chilled sterile dH20 and then in chilled sterile 1 M sorbitol. The cells were 
resuspended in 250 pi of 1 M sorbitol and 50 pi aliquots were mixed with up to 1 pi 
of transforming DNA, incubated on ice for 5 minutes and then electroporated (by a 
Bio-Rad gene Puiser set to 1.5 kV, 25 pF and 200fl). 50 pi of EMM2 was added 
immediately to the cells which were then plated onto EMM2 agar with the 
appropriate supplements for plasmid selection. Plates were incubated at 30°C for 2-4 
days until colony formation.
Expression of human Pwpl
PWPl cDNA was cloned into pREP3X vector (Forsburg 1993), in which expression 
of the gene is under control of the nmtl thiamine-repressible promoter (Maundrell 
1993). The resulting plasmid was transformed into S.pombe leul-32 by 
electroporation and transformants were selected on EMM2 agar plates without 
leucine. The plates also contained 10 pg/ml of thiamine to repress expression of the 
gene from the nmtl promoter. A single colony was subsequently inoculated into 10 
ml of EMM2 medium containing thiamine and grown overnight at 30°C. Thiamine 
was removed by four washes with the same medium and the cells were grown for a 
further 24 hours at 30°C before analysis.
Protein extraction for immunoblot analysis
Whole cell lysates were prepared from 50 ml cultures in mid-exponential growth. 
The cells were harvested by centrifugation, washed once in dH20 , lysed in 1 ml of 2x 
SDS sample buffer and heated immediately at 98°C for 5 minutes.
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Drug resistance assay
EMM2 agar plates containing a series of drug concentrations of caffeine were 
prepared using a [100 mM] stock. MBC was added directly to boiling agar to 
produce 20 pg/ml stock, which was further diluted with agar to produce the 
necessary MBC concentration. Eission yeast cells in mid-exponential growth were 
counted using an automatic cell counter (Sysmex) and 1000 cells from each culture 
were spotted onto the drug-containing plates and immediately streaked with a sterile 
loop. Plates were incubated at 30°C for 3-4 days to allow colony formation.
4.0 CELL CULTURE 
Cell lines and media
Monkey COS-7, human HeLa cervical carcinoma and U2-0S osteosarcoma cells 
were grown in D-MEM medium (glutamine 4 mM, streptomycin sulphate 100 mg/1, 
penicillin 100.000 units/1, antimycotic (Butyl-p-hydroxybenzoate) 0.2 mg/1) 
supplemented with 10% fetal bovine serum (FBS) (Bioclear) or 10% tetracycline- 
free fetal bovine serum (Clontech) for Pohl inducible expression in U2-OS cells. 
HTR9 cells are derived from the human HT 1080 fibrosarcoma cell line and were 
maintained in culture in RPMI 2% glucose medium (glutamine 4 mM, streptomycin 
100 mg/1, penicillin 100.000 units/1) supplemented with 10% fetal bovine serum 
(FBS) (Bioclear) and 150 pg/ml of hygromycin B for the stable selection of 
transfectants.
Transfections: FuGENE™ 6
Cells were transfected in 9 or 3.5 cm plates at 40-60 % confluence using FuGENE^'^ 
6 reagent (Roche), according to the manifacturer's instructions.
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3 |L l1  of FuGENE™ 6 reagent for each |ig of DNA were mixed in 100 \i\ final volume 
serum free medium and incubated for 5 minutes at room temperature in sterile 
conditions. The DNA, in a volume of up to 10 pi, was dispensed into another sterile 
tube. 100 pi of the FuGENE^^ 6 serum free medium mixture was then added to the 
DNA solution and left for 15 minutes at room temperature. The resulting mixture 
was added to 4.5 or 2 ml of complete medium (containing serum) for 9 and 3.5 cm 
plates, respectively. The medium containing the FuGENE™ 6 plus DNA mixture was 
added to the cells and incubated for 6-8 hr or overnight.
At the end of incubation time, fresh medium (5 ml and 2 ml for 9 and 3.5 cm plates, 
respectively) was added to the cells, which were left in culture for further 24-48 
hours
CD2 selection by magnetic beads 
a) Preparation of anti-CD2-coated immunomagnetic beads
Under sterile conditions, 15 mg (0.5 ml) of rat anti-mouse IgG2a Dynabeads (Dynal 
M-450) were prepared from the stock of 30 mg/ml (4 x 108 beads/ml). The beads 
were washed three times in 4-5 ml of sterile-filtered PBS containing 0.1% bovine 
serum albumin (BSA), which was aspirated through a sterile Pasteur pipette after 
separation of the magnetic beads using a Dynal magnetic separator. The beads were 
then resuspended in 0.5 ml of PBS/0.1%BSA and incubated with a mouse 
monoclonal anti-CD2 antibody (OX-34, Serotec) at the concentration of 2 pg per mg 
of beads for 30 minutes at 4°C on a rotating wheel.
The beads were washed three times with PBS/0.1% BSA and re-suspended in 0.5 ml 
of PBS/0.1% BSA to give a final concentration of 30 mg/ml.
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• CD2 immunomagnetic beads selection
24 hours after transfection by FuGENE 6 , cells were washed once with sterile PBS 
and harvested with PBS containing 2.5 mM EDTA. The cells were collected by 
centrifugation at 1000 rpm (MSE Mistral 2000) for 5 minutes, resuspended in 1 ml of 
D-MEM complete medium and incubated with 10-15 pi of the prepared anti-rat CD2 
bead suspension at room temperature, giving a ratio of approximately 4 beads per 
cell. The beads/cells suspension was incubated at room temperature for 15 minutes 
with gentle agitation.
Bead-coated cells were separated using a Dynal magnetic separator and washed three 
times with sterile PBS followed each time by magnetic separation. The CD2^positive 
cells were resuspended in 1 ml of D-MEM complete medium and the number of cells 
was determined using a haemocytometer.
The positive cells were plated in complete medium for stable selection using the 
selective antibiotic, lysed for western blotting analysis or plated for drug sensitivity 
experiments.
Generation of stable transfectants
a) Polyclonal pool
- COS-7: the pcDNA3 or pcDNA3.1+ vectors expressing the gene of interest was co­
transfected with pOPRSV/CD2 plasmid at a ratio of 4:1, using FuGENE™ 6 reagent. 
24 hours later, the CD2^ cells were selected as described above and plated, and 12 or 
24 hours later fresh medium, containing 1 mg/ml G-418, was added. The cells were 
G-418 selected for about two weeks.
- U2-OS: the cells were co-trasfected with pUHD 10-MCS/HA-POH1 and 
pcDNA3.1+, to provide the G-418 resistance gene, as described for COS-7 cells.
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24 after transfection, the cells were split to a low cell density and selected for about 
two weeks with G-418 [1 mg/ml],
b) Stable clones
- COS-7 stable clones expressing HA-POHl or HA-PWPl were derived from stable 
polyclonal pools, as follows: 1000, 500 and 100 cells were plated in G-418- 
containing medium. After 2 weeks, well-isolated colonies were picked using a Gilson 
P200 pipette and expanded. Protein expression was detected by immunoblot 
analysis.
- All the other stable clones were obtained as follows: 24 hours after transfection, the 
cells from each plate were harvested and divided between three plates, to allow 
individual colony formation. The selective antibiotic was added and the cells were 
allowed to grow for about two weeks, until colonies appeared.
Flow cytometry
Cells were trypsinised and collected by centrifugation (1.000 rpm for 5 minutes in 
MSE Mistral 2000), washed once in PBS and fixed in 1 ml of 70% ice-cold ethanol, 
added while vortexing, and incubated on ice for 30 minutes. Cells were then 
collected by centrifugation, washed three times with PBS and resuspended in 1 ml of 
PBS, containing propidium iodide (Sigma, 40 pg/ml) and RNAse A (Sigma 100 
pg/ml).
Red fluorescence was measured by flow cytometry (FACScan, Becton Dickinson) 
for 10000 cells per sample. Data analysis of the sample was performed using 
CellQuest software.
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Annexin V binding assay
Annexin V binding assays were performed using the Annexine V - FITC detection 
kit (Pharmigen, Becton Dickinson), according to the manufacturer's guidelines. Cells 
were harvested in PBS/2.5 mM EDTA and washed twice on ice-cold PBS. 10  ^cells 
were resuspended in lOOpdoflx binding buffer. The cells were then incubated with 
5 pi of Annexin V - FITC and 2 pi of Propidium Iodide (PI) for 15 minutes at room 
temperature in the dark. As staining controls, unstained cells, cells stained with PI 
alone and Annexin V alone were prepared. 400 pi of Ix binding buffer was then 
added and the cells were analysed by flow cytometry (FACScan Becton Dickinson) 
within 1 hour.
Immunofluoresce
a) Indirect immunofluorescence
Cells were plated onto sterile glass coverslips and grown in 2 ml of medium in 6- 
multiwell plates the day before immunostaining. After washing in PBS, the cells 
were fixed on ice-cold 4% EM grade p-formaldehyde in PBS containing 250 mM 
Hepes pH=7.4 for 20 minutes at 4°C with agitation. The cells were then washed three 
times with PBS and permeabilized with cold PBS/0.5% Triton X-100 for 20 minutes 
at 4°C with agitation. The cells were then washed three times with PBS and 
incubated with blocking solution (PBS/0.1% Tween-20 + 10% FBS) for 0.5-1 hour at 
37°C. The primary antibody (mouse monoclonal anti-HA antibody supplier) was 
diluted in blocking solution and the cells were incubated for 1 hour at 37°C. After 
three further washes in PBS/0.1 %Tween-20, the cells were incubated with anti­
mouse FITC-conjugated secondary antibody for 30 minutes, followed by three 
washes in PBS/0.1% Tween-20, one in PBS containing Hoechst 33258 [1 pg/ml] and
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a final wash in distilled water. The glass coverslips were dried and mounted (90% 
glycerol, 50 mM tris pH 8.8 and para-phenylenediamine 1 mg/ml) on glass slides. 
Imunofluorescence was assessed using an Axioskop microsope (Carl Zeiss, 
Oberkochen) through oil immersion objectives,
b) Localization of EGFP fusion proteins
Localization of EGFP-Pwpl and EGFP-Pohl fusion proteins was performed using 
the mammalian expression vector pEGFP, which expresses the gene of interest fused 
at the C-terminus of the enhanced green fluorescence protein (EGFP) sequence. 
HeLa or COS-7 cells, previously seeded onto sterile coverslips in 6-multiwell plates, 
were transiently transfected with the vector expressing the gene of interest or the 
empty vector. After 24-48 hours, the cells were washed once with PBS and fixed on 
ice-cold 4% EM grade p-formaldehyde in PBS/250 mM Hepes pH 7.4 solution for 20 
minutes at 4°C with agitation. The cells were washed with PBS and then with PBS 
containing Hoechst 33258 [1 pg/ml] for 2-5 minutes, with final wash in distilled 
water. The glass eoverslips were dried in a sterile hood and mounted in 90% 
glycerol, 50 mM Tris pH 8.8 and para-phenylenediamine (1 mg/ml) on glass slides. 
The expression of recombinant protein or EGFP alone was assessed using an 
Axioskop microsope (Carl Zeiss, Oberkochen) through oil immersion objectives.
Dual Luciferase Reporter Assay
2x10^ COS-7 cells were plated in 3.5 cm plates and 24 hours later the cells were 
transiently co-transfected using FuGENE^^ 6 with pColLuc3 (kindly provided by Dr. 
J.Tavare) and pRL-TK-Renilla (Promega), at a ratio of 15:1. 24 hours after 
transfection, the cells were harvested, plated in triplicate in 6-multiwell plates and 
grown for further 24 hours before the assay.
36
The dual luciferase reporter assay kit (Promega) was used, according to 
manufacturer's instructions. The cells were lysed using 0.5 ml of PEL buffer Ix for 
15 minutes with shaking. The lysed cells were collected in 1.5 ml eppendorf tube and 
spun down for 1 minute at maximum speed in an eppendorf centrifuge, in order to 
eliminate cell debris.
Both firefly and Renilla luciferase activities were measured using a luminometer 
(TD-20/20 Turner designs) with a 2 second pre-measurement delay followed by a 10 
second measurement period for each reporter assay. For each sample 50 pi of LARII 
solution was predispensed into a luminometer tube, mixed by pipetting with 10 pi of 
cell lysate and emitted light measured using a luminometer. For Renilla luciferase 
activity, 50 pi of Stop & Glo solution was added to the same tube immediately after 
measuring the firefly activity, the tube was vortexed and re-read immediately.
The results were expressed as the ratio between the firefly and the Renilla activities 
(relative luciferase activity, RLA).
5.0 DRUG SENSITIVITY TESTS
a) Clonogenic survival assay
This assay was used in order to test the capacity of a cell population to form colonies, 
after exposure to a cytotoxic agent. 3000-4000 cells transiently or stably expressing 
the gene of interest or containing the empty vector were plated in 9 cm dishes. 24 
hours later, the cells were exposed to different concentrations of a drug or no drug (as 
a negative control) for 24 hours; then, they were washed once in PBS Ix and 
incubated with fresh complete medium for 10-14 days. When colonies appeared, the 
medium was decanted and the colonies were fixed with 3 ml of a fixing solution 
(75% methanol + 25% acetic acid) for about 30 minutes, followed by staining with 3
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ml of crystal violet (0.4 mg/ml) (1 hr to overnight). The plates were washed with tap 
water to remove excess of crystal violet and allowed to dry at room temperature. The 
colonies were then counted and the capacity to form colonies was expressed as the 
percentage survival in comparison with the control (cells with no drug),
b) MTS cytotoxicity assay
The MTS assay (Promega) is a colorimetric method for determining the number of 
viable cells in proliferation or chemosensitivity assays. 1000-2000 cells were plated 
in triplicate in a 96-multiwell plate (in 100 pi final volume) and, after 24 hours, serial 
dilutions of a drug were added in 100 pi final volume. The cells were incubated with 
the drug or no drug, as a negative control, for 72 hours at 37°C.
The MTS reaction was performed according to manufacturer's instructions. Briefly, 
in the dark and in sterile condition 20 pi of MTS/PMS solution (100 pi of PMS 
diluted in 2 ml of MTS) were added to each well, all containing the same volume, 
and incubated for 2 hours at 37°C. Cell viability was assessed by measuring A490 
using microplate reader (Titertek Multiskan PLUS).
6.0 PROTEIN METHODS 
SDS-PAGE
Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) was performed under 
denaturing and reducing conditions, using the discontinuous buffer system described 
by Laemmli.
The resolving gel (10-12% polyacrylamide) was prepared in 375 mM Tris-HCl pH 
8.8, 0.1% (w/v) SDS. The stacking gel (4% polyacrylamide) was prepared in a buffer 
containing 125 mM Tris-HCl pH 6.8 and 0.1% (w/v) SDS. All SDS polyacrylamide 
gels were assembled using the BIO-RAD Miniprotean vertical polyacrylamide gel
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apparatus. Samples were heated for 3-5 minutes at 98°C in 2x SDS sample buffer (60 
mM Tris-HCl pH= 6 .8 , 1% SDS, 5% glycerol, 0.001% bromophenol blue and 1% 2- 
p-mercaptoethanol) before loading on the gel.
Electrophoresis was performed at 120 V in a buffer containing 190 mM Glycine, 25 
mM Tris and 0.1% SDS.
Whole cell extracts for immunoblot analysis
Growing cells were trypsinized and washed once with PBS. The cells were lysed in 
2x SDS sample buffer (1 ml for a 9 cm confluent dish) and heated immediately at 
98°C for 5 minutes before storage at -20°C or loading on the gel.
Immunoblot analysis
After electrophoretic separation, proteins were transferred from the gel on to a 
Hybond ECL nitrocellulose membrane (Amersham) by electroblotting, using the 
BIO-RAD Trans-Blot apparatus. The electroblotting was performed at 50 Volts for 2 
hours at 4°C or 20 Volts for 16 hours at 4°C in a transfer buffer containing 20% 
methanol, 50 mM Tris and 380 mM glycine. The membrane was incubated in a 
blocking solution (PBS containing 0.3% Tween-20 and 5% of Marvel dried milk 
powder) for 1 hour or overnight with shaking. The primary antibody was diluted in 
the bloeking solution and the membrane was incubated with the diluted antibody for 
1 hour at room temperature with shaking. The membrane was washed four times in 
PBS/0.3% Tween-20 for about 1 hour and then incubated with an HRP-conjugated 
secondary antibody, diluted in blocking solution, for 30-45 minutes at room 
temperature. The membrane was washed 4 times with PB S/0.3% Tween-20 and once
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with TBS Ix before detection by ECL method.
Enhanced Chemioluminescence (ECL) detection
Oxidation of luminol results when horseradish peroxidase (HRP), which is 
conjugated to a secondary antibody, reacts with luminol and chemical enhancers. 
This reaction produces light emission, which is detectable using X-ray film (Kodak). 
Equal volumes of solution I and II (ECL, Amersham) were mixed and the membrane 
was incubated with this mix for 1 minute. The membrane was drained, covered with 
Saran-wrap and then exposed to X-ray film for the required length of time.
Membrane reprobing
To probe the membrane with second antibody, recognising a protein of a similar size 
to that detected previously, it is necessary to completely remove the antigen-bound 
primary and secondary antibodies.
The membrane was incubated with stripping buffer (100 mM p-mercaptoethanol, 2% 
sodium dodecyl sulphate and 62.5 mM Tris-HCl pH 6.7) at 60°C for 30 minutes. The 
membrane was then washed twice with an excess of PBS/0.3% Tween-20 and then 
used again for a new immunoblot analysis.
Immunoprécipitation (IP)
c-Jun - Immunoprécipitation was performed as described by Norbury et al. (Norbury 
et al. 1991). Cell lysates were prepared in lysis buffer containing 20 mM Tris pH 7.4, 
5 mM EDTA, 100 mM NaCl, 1% Triton X-100 and protease inhibitor cocktail 
(Complete, Roche) and incubated on ice for 30 minutes. Then, the lysates were spun 
down at maximum speed in an eppendorf centrifuge for 15 minutes at 4°C and the
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supernatant was incubated with primary antibody for 1 hour on ice. 0.1 volume of a 
50% suspension of protein A Sepharose (Sigma) was added and incubated for 2 
hours in a rotating wheel at 4°C. The immunecomplexes were washed 5 times using 
lysis buffer. For immunoblot analysis an equal volume of immunoprecipitate and 2x 
SDS sample buffer was mixed, heated at 98°C for 5 minutes and loaded onto a 10- 
12% SDS-PAGE gel.
MCP-21 - Immunoprécipitation was carried out as described by Hayes et a l (Hayes 
and Wolf 1990). 10 million cells were resuspended in 5 volumes of lysis buffer (50 
mM tris-HCl, 17% glycerol pH=7.5, 5 mM ATP and EDTA-free protease inhibitor 
coektail (Complete, Roche)) and sonicated on ice for 10-20 seconds x 4. The lysates 
were spun down at maximum speed in an eppendorf centrifuge for 10 minutes at 4 
°C and the supernatant was collected and incubated with the mouse monoclonal 
MCP-21 antibody for 1 hour on ice. The antigen-antibody complex was pulled down 
with 0.1 volume of a 50% protein G sepharose suspension for 4-6 hours on a rotating 
wheel at 4 °C. Then the complexes were washed 4-5 times in the following buffer: 20 
mM Tris-HCl pH 7.5, 20 mM NaCl, 0.1 mM EDTA, 1 mM MgC12, 0.5% Nonidet P- 
40, 0.1% SDS, 17% Glycerol, 5 mM ATP and EDTA-free protease inhibitor cocktail 
(Complete, Roche).
The immunoprecipitates were resuspended in 2x SDS sample buffer, heated at 98 °C 
for 5 minutes and loaded onto a 10% SDS-PAGE gel before being processed by 
immunoblotting for HA and C3 detection.
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Electrophoretic mobility shift assay (EMSA)
a) Whole cell extracts
80-90% confluent cells from a 9 cm plate were washed once with PBS and then 
collected using a scraper in about 1 ml of PBS. The cells were spun down for 1 
minute at maximum speed in an eppedorf centrifuge at 4°C, resuspended in about 60 
pi of ice-cold lysis buffer (20 mM Hepes pH 7.9, 1 mM EDTA, 0.4 M NaCl, 25% 
Glycerol, 2.5 mM DTT, 5 mM NaF, 0.5 mM Na^OV^, 0.1% NP-40 and 1 tablet of 
EDTA-free protease inhibitor cocktail (Complete, Roche)) and incubated on ice for 
30 minutes. The cells were spun at maximum speed in an eppedorf centrifuge for 15 
minutes at 4°C and the supernatant was collected.
Protein quantification was performed using the BCA* Protein Assay Reagent A 
(Pierce).
b) Nuclear Extracts
Nuclear extraction was performed as described by Dignam et al. (Dignam et al. 
1983), with some modifications. Cells were trypsinized, washed in 10 ml of ice-cold 
PBS and then in 1 ml ice-cold PBS. The cells were transferred to a 1.5 ml eppendorf 
tube and spun down for 3 minutes at 3000 rpm in an eppendorf centrifuge. 3 cell 
pellet volumes of buffer A (10 mM Hepes pH 7.9, 10 mM KCl, 1.5 mM MgClz, 0.5 
mM NaF, 0.5 mM Na^VO^, 5 mM DTT and EDTA-free protease inhibitor cocktail 
(Complete, Roche)) was added to the cells and incubated on ice for 1 hour. The cells 
were then lysed by 20-40 strokes with a dounce homogeniser. The nuclei were spun 
at 13000 rpm in an eppedorf centrifuge for 10 minute at 4°C and the nuclear pellet 
was resuspended in buffer A (same volume as before) and 3 volumes of buffer B (20 
mM HEPES pH 7.9, 20% Glycerol, 420 mM NaCl, 1.5 mM MgCl^, 0.2 mM EDTA 
and 0.5mM NaF, 0.5 mM Na^VO^, 5 mM DTT and 1 tablet of protease inhibitors
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cocktail EDTA-free) and incubated on ice for 30 minutes. The nuclei were spun at 
13000 rpm in an eppedorf centrifuge for 30 minutes at 4°C and aliquots of the 
supernatant were frozen in dry ice and stored at -70°C. Protein quantification was 
performed using the BIO-RAD protein assay (BIO-RAD).
c) End-labelling of double strand oligonucleotide
5 ng o f AP-1 consensus double strand o ligonucleotide (5 ’- 
CGCTTGATGACTCAGCCGGAA-3’) was incubated in 10 p,l reaction containing 
Ix T4 polynucleotide kinase buffer, 2.5 pCi of p^P]-yATP and 1 pi o f T4 
polynucleotide kinase for 1 hour at room temperature. The labelled oligonucletide 
was purified from the unincorporated radioactivity using the mini quick spin DNA 
columns (Roche) according to the manufacturer's instructions.
d) Electrophoretic Mobility Shift Assay (band-shift assay)
For gel shift analysis, whole cell or nuclear extracts were used. Binding reactions 
were performed at room temperature for 30 minutes with 8-10 pg of whole cell 
extracts or 5 pg of nuclear extracts. The extracts were mixed with 0.5 ng of f^P]- 
'^TP labelled AP-1 consensus probe (5’-CGCTTGATGACTCAGCCGGAA-3’) 
[Santa Cruz Biotechnology, Inc] and 1 pg of poly (dl-dC) (in order to inhibit non 
specific binding of labelled probe to proteins) in 20 pi final volume of Ix binding 
buffer (10 mM Tris-HCl (pH=7.5), 50 mM NaCl, 1 mM DTT, 1 mM EDTA, 5% of 
Glycerol). For competition experiments, an excess (50-fold) of cold double strand 
AP-1 consensus or AP-1 mutant (5’-CGCTTGATGACTGTGCCGGAA-3’) 
oligonucleotides (Santa Cruz Biotechnology, Inc) was added to the binding reaction 
for 20 minutes before the labelled probe at room temperature.
DNA-protein complexes were resolved by electrophoresis under non-denaturating 
conditions using a 4% polyacrylamide gel containing 50 mM Tris, 0.38 M glycine
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and 2 mM EDTA. The gel was subsequently dried for 2 hr and exposed to X-ray film 
overnight at -70°C with an intensifying screen or visualised using a storm 
phosphorimager system (Molecular Dynamics).
In vitro degradation assay
In vitro degradation assays were performed as described by Brandeis et al. (Brandeis 
and Hunt 1996). Cells were washed twice in PBS and twice on ice-cold hypotonic 
buffer (20 mM Hepes pH 7.5, 5 mM KCl, 1.5 mM MgC12, 1 pM dithiothreitol 
(DTT)). The buffer was completely aspirated and the cells were scraped off and 
disrupted with several strokes of a Dounce homogeniser. The cells were then spun 
down at maximum speed in an eppendorf centrifuge at 4°C for 15 minutes to remove 
cell debris and the supernatant was aliquoted and snap frozen immediately in liquid 
nitrogen and then stored at -80°C. Protein amount was measured using the BIO­
RAD protein assay (Bio-Rad).
Degradation assays were performed in 10-15 pi final volume containing an equal 
amount of protein from each cell lysate, supplemented with an energy-regenerating 
system (25 mM phosphocreatine, 10 pg/ml creatine kinase and 1 mM ATP) and 0.5- 
1 pi of the -methionine radiolabelled subustrates, human c-Jun 1.287, which lacks 
the leucine zipper domain, and c-Jun A3.122, which lacks the 8 domain (both 
synthesised using plasmids kindly provided by Dr. D.Kardassis). Reactions were 
incubated at 30°C and each reaction was stopped at the time points 0, 20, 40, 70, 100 
and 160 minutes by adding 2x SDS sample buffer and immediately heated for 5 
minutes at 98°C. The samples were loaded onto a 12% SDS-PAGE gel for protein 
separation. The gel was dried and exposed to a X-ray film using an intensifying 
screen at -80°C for the necessary length of time. The substrates were p^S]-labelled in
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vitro transcribed and translated in nuclease-free reticulocyte lysates using a TNT T7 
Quick Coupled Kit (Promega), according to the manufacturer's instructions.
Purification of His^-tagged c-Jun
U2-0S cells were plated in 9 cm dishes and transiently co-transfeeted with 2 pg of a 
vector expressing a His^-tagged human c-Jun (pMT35/HiSg-c-Jun) and 2 pg of a
vector expressing the HA-tagged Ubiquitin (pcDNA/HA-Ub). The cells were mock 
or doxycyclin [1.5-2 pg/ml] treated for 36 hours before nickel chelate affinity 
purification of the protein, which was performed as described by Treier et al. (Treier 
et al. 1994).
The cells were lysed in 2 ml/plate of 6 M guanidinium-HCl, 0.1 M sodium phosphate 
pH 8.0 and 5 mM imidazole and sonicated in order to reduce the viscosity. Cleared 
lysate or buffer alone (4 ml), as negative control, was incubated with 400 pi of 
NiSO^-charged His-bind resin (Novagen) (50% slurry) for 4 hours at room 
temperature on a rotating wheel. The slurry was then applied to a 0.8 x 4 cm 
chromatography column (Bio-Rad), which was successively washed with the 
following solutions: 1 ml of 6 M guanidinium-HCl, 0.1 M sodium phosphate pH 8.0; 
2 ml of 6 M guanidinium-HCl, 0.1 M sodium phosphate pH 5.8; 1 ml of 6 M 
guanidinium-HCl, 0.1 M sodium phosphate pH 8.0; 2 ml of 1 ml of 6 M 
guanidinium-HCl/0.1 M sodium phosphate pH 8.0 : protein buffer [1:1]; 2 ml of 1 ml 
of 6 M guanidinium-HCl/0.1 M sodium phosphate pH 8.0 : protein buffer [1:3]; 2 ml 
of protein buffer; 1 ml of protein buffer containing 10 mM imidazole. Protein elution 
was carried out with 1 ml of protein buffer containing 200 mM imidazole. The 
protein was TCA (100%) precipitated for 30 minutes on ice, followed by 
centrifugation at maximum speed in an eppendorf centrifuge at 4°C. The pellet was
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resuspended in 40 pi of 2x SDS sample buffer plus 1 pi of 1 N NaOH, in order to 
adjust the low pH of the sample, and heated at 98°C for 5 minutes. The samples were 
loaded onto a 10-12 % SDS-PAGE gel and c-Jun and the ubiquitinylated level of c- 
Jun were detected using rabbit polyclonal anti-c-Jun and HRP-conjugated 
monoclonal anti-HA antibodies, respectively.
The His-bind resin was prepared as follows: 1.2 ml of 50% slurry was washed once 
with PBS and then incubated with 1 ml of 0.4 M NiSO^ for 15-30 minutes on a 
rotating wheel at room temperature. The slurry was washed in lysis buffer and 
resuspended in 1.2 ml.
Sucrose density gradient centrifugation
Growing cells from 4 flasks (175 cm) were harvested and washed once with PBS 
before being resuspended in 300 pi of lysis buffer (10 mM tris pH 7.5, 100 mM 
NaCl, 30 mM MgCl2, 50 pl/ml cycloheximide and 5 mM ATP). The cells were 
successively passed through different size needles until complete lysis. The lysates 
were then centrifuged at 40.000 rpm (Beckman SW41 rotor) for 1 hour and 45 
minutes. The lysates were applied to a 13.5 ml 7-37% sucrose gradient prepared in 
50 mM tris acetate, 50 mM NH4CI, 12 mM MgCl2 and 5 mM ATP. Sucrose gradients 
were made up stepwise using 37, 27, 17 and 7% sucrose, starting with 37%. Each 
step was frozen before addition of the next and the gradients were stored at -20°C. 
After the lysated cell were centrifugated, 0.5 ml fractions were collected (Pharmacia 
FRAC-100) by displacement of the gradient from below using perfluorodecalin 
(Fluorochem, Old Glossop, UK). 20 pi aliquots of each fraction were subjected to 
analysis by SDS-PAGE and immunoblotting.
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7.0 YEAST TWO HYBRID SCREEN 
Plasmids
Budding yeast S.cerevisiae EGY48 strain was used in the two-hybrid interaction 
screen. This strain contains two lex A operator-responsive reporters: one is a 
chromosomally integrated copy of the LEU2 gene and the second is a plasmid 
bearing the GALl promoter-LacZ gene, which causes the yeast cells to turn blue on 
agar containing X-gal. To generate the bait protein, the human PWPl cDNA was 
cloned into pEG202 generating a fusion with the heterologous DNA binding protein 
Lex A. The major requirements for the bait protein are that it should not be actively 
excluded from the yeast nucleus and it should not possess intrinsic ability to strongly 
activate transcription. The pEG202/PWPl was transformed by the lithium acetate 
method into the EGY48. The transformed cells were selected by plating on complete 
agar -Ura -His- dropout plates, with glucose as carbon source, and incubated at 30°C 
for two to three days. In order to check if the LexA-PWPl fusion protein was able to 
activate transcription without interacting partners, the PWP7-containing cells were 
transformed with the pJG4-5 empty vector (the vector where the human cDNA 
library is expressed from) by lithium acetate. The transformed cells were selected in 
Ura -His -Trp complete agar plates (containing glucose) and allowed to grow for 2-3 
days. Then, the P-galactosidase assay was performed: 6-10 colonies were streaked in 
an YPD agar plate and allowed to grow overnight. Cells were replica plated onto - 
Ura -His -Trp -Leu dropout agar plates containing galactose/raffinose (gal/raff) (Ura, 
His, Trp, Leu (UHTL) 0.65 g/1, yeast nitrogen base 6.5 g/1, ammonium sulphate 5 g/1, 
galactose 20 g/1, raffinose 10 g/1 and agar 20 g/ plus sodium phosphate 0,1 M 
pH=7.5) and X-gal 50 pg/ml and incubated at 30°C overnight for 24 hours.
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Lithium acetate transformation
Yeast cells were grown to mid-exponential phase in 10 ml culture of SD medium 
containing the appropriate amino acid supplements. The cells were harvested by 
centrifugation at 3000 rpm in an eppendorf centrifuge for 5 minutes at room 
temperature and washed once in water. The pellet was resuspended in 1 ml of lithium 
acetate/TE Ix (Li/TE) solution, centrifuged for 30 seconds at 8000 rpm and 
resuspended in 50 pi of Li/TE. 1-2 pi (about 1 pg for single vector and 5 pg for the 
cDNA library) of transforming DNA and 5 pi of salmon sperm DNA [10 mg/ml] and 
the mixture was incubated for 10 minutes at room temperature. 300 pi of Li/TE plus 
40% PEG solution was added to the cells and incubated for 1 hour at 30°C. The cells 
were then heat shocked at 42°C for exactly 5 minutes and centrifuged immediately at 
8000 rpm in an eppendorf centrifuge for 5 minutes, washed in dHjO, resuspended in 
1 ml of YPD medium and allowed to recover at 30°C for 1 hour. The cells were 
spun down and resuspended in 100 pi of SD medium and plated onto SD agar plates 
containing the appropriate amino acid supplement.
The interaction hunt
The interaction hunt was performed using the LexA-Pwpl bait and a human cDNA 
library in pJG4-5.
Each cDNA sequence of the human HeLa cDNA library is fused to the GAL 
promoter in the pJG4-5 vector. After transformation of 2-5 pg of cDNA library by 
lithium acetate, yeast cells were first plated on SD (complete agar) -Ura -His -Trp 
dropout agar plates, containing glucose as carbon source, to select for library 
plasmids. After transformation the yeast cells were incubated at 30°C for 3-5 days, 
until colonies appeared. The cells were replica plated onto -Ura -His -Trp -Leu
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(UHTL) dropout Gal/Raff agar plates, (UHTL 0.65 g/1, yeast nitrogen bone 6.5 g/1, 
ammonium sulphate 5 g/1 galactose 20 g/1, raffinose 10 g/1 and agar 20 g/1 plus 0,1 M 
sodium phosphate pH 7.5 and X-Gal 50 pg/ml). Blue colonies found after incubation 
for 16 to 36 hours at 30°C were restreaked on complete medium plates to ensure that 
a single colony had been picked up, and then replica plated onto UHTL gal/raf X-gal 
plates to further check the positive interaction.
Rescue of cDNA library plasmids
Each positive blue colony was grown in 10 ml of complete medium (SD medium) - 
Trp overnight at 30°C. 1 ml of this yeast culture was spun down and the pellet was 
washed twice with dH20 and resuspended in 100 pi of dH20 . DNA was extracted by 
vortexing with 100 pi of phenol/chloroform and sterile glass beads. The mixture was 
mixed with a vortex for 10-15 minutes, in order to break the yeast wall, and then 
spun down and the aqueous phase was collected. The extraction was repeated and the 
genomic and plasmid DNAs were precipitated with 0.3 M sodium acetate and 70% 
ethanol. The DNA was resuspended in 20 pi of dH20 and 1 pi was used to transform 
an E.coli trp-mutant strain by electro-transformation, in order to select the vector 
containing the cDNA. A single colony was inoculated in LB medium containing 
ampicillin [50 pg/ml], allowed to grow overnight at 37°C and the plasmid DNA was 
extracted by mini-prep. The cDNA sequence was checked using the oligonucleotides 
PJG45X and PJG45E (see A.l - Appendix). In parallel, 1 pg was re-transformed into 
EGY48, containing the reporter vectors and LexA-Pwpl bait, in order to further 
check the previously detected interaction.
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Chapter 3
Further characterization of the 26S 
protcasome regulatory subunit Pohl
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Overview
In chapters 3, 4, and 5 of this thesis I describe the further characterization of the 
regulatory proteasomal subunit Pohl and the HA-Pohl-conferred pleiotropic drug 
resistance phenotype previously observed in mammalian cells.
The main aspects on which I focus are:
- The expression of HA-POHl using a constitutive and an inducible expression 
system in monkey COS-7 and human U2-0S cells, respectively
- Characterisation of the drug resistance phenotype using a wide range of drugs
in both systems
- The sub-cellular localization of HA-Pohl
The association of HA-Pohl with the 26S proteasome complex
- The molecular mechanism by which HA-Pohl causes pleiotropic drug 
resistance, including investigation of alterations in AP-1 transcription factors, 
the ubiquitinylation pathway and AP-1 stability
In this chapter I show that the stable expression of exogenous epitope-tagged HA- 
Pohl (HA-Pohl) in mammalian cells is able to confer multi-drug resistance to a wide 
range of drugs. In addition, I also describe and diseuss the cytoplasmic and nuclear 
localization of HA-Pohl and its association with the 26S proteasome.
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Introduction
POHl
POHl, for ^ad one pomologue 1, was first described in 1997 (Spataro et al. 1997) as 
the human homologue of the fission yeast multi-drug resistance gene p a d P  
(Shimanuki et al. 1995). The primary sequence similarity between the human and the 
fission yeast proteins is 68% and Pohl and Padl are also related, more distantly, to the 
c-Jun-activating-binding protein Jabl and the human 26S proteasome regulatory 
subunit S12/p40 (Figure 3.1). High degree of conservation of padU/POHl during 
evolution indicates a fundamentally important role for the corresponding proteins. 
POHl mRNA is widely expressed in many human tissues with the highest level in the 
heart and the skeletal muscle (Spataro et al. 1997). A similar pattern was previously 
observed for the S12/p40 proteasome subunit.
The functional characterization of the budding yeast padl homologue MPRl has also 
been reported (Rinaldi et al. 1998). Like its counterparts in fission yeast and human 
cells, the gene encodes a regulatory subunit of the 26S proteasome complex, named 
M prl/Rpnll (Glickman et al. 1998b). The temperature sensitive mutant strain mprl-1 
encodes a truneated protein that lacks the last 31 amino acids at the C-terminus and 
also shows pleiotropic phenotypes.
1. Cell growth defects which are complemented by the expression of the human 
HA-POHl gene
2. Overreplication of the mitochondrial and nuclear DNA
3. Accumulation of ubiquitinylated proteins, which is also consistent with the 
data reported for other mutants of the 26S regulatory subunits.
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Figure 3.1 — Pohl protein sequence alignment with fission yeast Padl and human Jabl and 
S12/p40
The residues present at identical positions in two or more proteins are highlighted in black, 
conservative substitutions in grey. The putatively ubiquitin hydrolase site in Pohl/Padl is marked 
with an arrow (^).The 28 residues present at identical position in the four proteins are marked with 
an asterisk (*).
Mprl was the first proteasomal subunit described with a possible role in mitochondrial 
biogenesis (Rinaldi et al. 1998). M prl/Rpnll was also recently reported to be required 
for the UV-induced activation of the leucine-zipper transcription factors Gcn4 (Stitzel 
et al. 2001).
POHl in S.pombe
Pohl is a fully functional homologue of fission yeast Padl (Spataro et al. 1997). When 
overexpressed from the thiamine-repressible promoter of the nm tl (no message in 
thiamine) gene, POHl was able to rescue the viability of a fission yeast haploid strain 
bearing a null mutation in the essential p a d F  gene (Apadl). When the promoter was 
repressed through the addition of thiamine into the medium, cells lost viability very 
rapidly and also showed some mitotic defects. Overexpression of HA-tagged Pohl in 
fission yeast led to resistance to the protein kinase inhibitor staurosporine. In addition, 
as observed previously for the S.pombe padl* gtriQ (Shimanuki et al. 1995), the drug 
resistance phenotype induced by HA-Pohl overexpression was dependent on papl* 
(Spataro et al. 1997).
POHl in mammalian cells
Transient overexpression in monkey COS-1 cells of the haemagglutinin (HA) epitope- 
tagged human H A-PO H l gene, under the control of the CMV promoter in the 
pcDNAS mammalian expression vector (pcDNA3/HA-P0Hl), led to resistance to 
several unrelated agents such as taxol, 7-hydroxystaurosporine (UCN-Ol) and UV 
light when compared to the cells carrying the empty vector (pcDNA3) (Spataro et al. 
1997). In contrast, no significant difference in cell survival was observed when the
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cells were exposed to ionising radiation or to hydrogen peroxide. Thus, the transient 
overexpression of HA-Pohl in mammalian cells induced a distinctive pattern of multi­
drug resistance.
In addition, the HA-Pohl-conferred multi-drug resistance phenotype in COS-1 cells 
was not accompanied by elevated expression of P-gp (Spataro et al. 1997).
Pohl has sequence similarity to the S12/p40 subunit of the 19S regulatory particle of 
the 26S proteasome complex (Spataro et al. 1997) (Figure 3.1) and was found to be a 
novel subunit of the 19S regulatory particle (Spataro et al. 1997). The Pohl 
homologues in budding and fission yeasts were subsequently shown also to be 26S 
proteasome components. Later reports have also confirmed that Padl/Pohl are 
regulatory subunit of the proteasomal complex (Glickman et al. 1998b; Holzl et al. 
2000). Most of the endogenous HA-Pohl was associated with the 26S proteasome 
complex and very little was present as a free monomer or other relative low molecular 
weight forms. This is also the case for the majority of the previously characterised 
components of the 20S core complex.
The 26S proteasome complex
Protein degradation is a key regulator of many cellular processes and it is modulated 
by both spatial and temporal controls. In eukaryotic cells there are two major 
proteolytic pathways. The lysosomal pathway mainly degrades extracellular proteins 
that have entered the cell by endocytosis or pinocytosis; the major non-lysosomal 
pathway, the so-called ubiquitin-proteasome pathway, degrades intracellular proteins 
that have been previously tagged by the protein ubiquitin.
The 26S proteasome is a multi-protein complex that is implicated in the turnover of 
mitotic cyclins, oncoproteins, the tumor suppressor protein p53, cell surface receptors.
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transcriptional regulators and mutated and damaged proteins (reviewed by 
Ciechanover 1994). The 26S proteasome was first isolated in 1986 (Hough et al. 1987) 
and it was recently confirmed that the complex derives from the association of the 20S 
proteasome and two 19S regulatory complexes, also called the PA700, at both ends of 
the 20S proteasome with a Cz-symmetry (Figure 3.2C). Both assembly and 
disassembly of the 26S proteasome are energy-dependent. There is a dynamic 
equilibrium between the free 20S and 19S forms and the 26S proteasome complex 
(reviewed by Voges et al. 1999).
The 20S proteasome
The 20S proteasome, also referred to as the core particle (CP), was isolated in 1968 
from human erythrocyte lysates as a cylinder-shaped structure. The structure was 
initially ealled ‘cylindrin” but its funetion was unknown (Harris 1968). It is 700 kDa 
complex containing subunits in the 24-28 kDa range. Eukaryotic and prokaryotic 20S 
proteasomes are broadly similar but differ in complexity; each is composed of 28 
subunits. The prokaryotic proteasome contains 14 copies of two distinct but related 
proteins a  and P ( a 7 P 7 P 7 a  7), whereas the eukaryotic proteasome consists of two 
copies each of 7 d istinct a - ty p e  and 7 distinct p -type subunits 
( a i - 0t7)(Pi-p7)(pi-p7) (a i-0C7). In both the prokaryotic and the eukaryotic complexes 
these proteins form a ring structure. Two juxtaposed rings of a-type subunits flanked 
on the top and bottom by a ring of p-type subunits form the barrel-shaped complex 
with a Cz-symmetry (Figure 3.2A). As judged by electron microscopy the 20S 
proteasome is 15 nm in height and 11 nm in diameter. The central chamber formed by 
the 4 rings may trap the proteins until they are degraded to generate peptides with a
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size ranging between 4-25 residues and an average length of 7-9 residues (reviewed by 
Voges et al. 1999).
The 19S regulatory particle
Given that access to the proteolytic compartment is restricted to unfolded proteins, 
other components associated with the 20S proteolytic structure would be expected to 
recognise and bind and unfold the target substrate.
The 19S particle is regulatory complex that can bind to each end of the cylindrical 20S 
proteasome (DeMartino et al. 1994) (Figure 3.2B). The 19S particle contains the 
ATPase subunits and acts through an energy-dependent mechanism. It has three main 
biochemical functions.
1. The recognition of the polyubiquitinated substrates (Deveraux et al. 1994)
2. An isopeptidase activity which is necessary for the recycling of the ubiquitin 
molecules from the substrate (Lam et al. 1997)
3. An anti-chaperone activity that unfolds the substrate and presents it to the 20S 
catalytic complex (Braun et al. 1999).
The 19S particle is dissociable into two subcomplexes, the base and the lid (Glickman 
et al. 1998a).
The base complex
The base complex contains all the six ATPase subunits (S7/Rptl, S4/Rpt2, S6/Rpt3, 
S10b/Rpt4, S6/Rpt5 and S8/Rpt6) and the two largest subunits (Sl/Rpn2 and 
S2/Rpn2) as well as S5a/RpnlO. Each of the six ATPase subunits contains the 230 
amino acid AAA or CAD module that is a characteristic of the family of the AAA 
ATPases. The complex formed by the 20S proteasome and the base of the 19S
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Figure 3.2 -  The 26S proteasome complex: assembly of the core (20S) proteasome with 
the 19S regulatory complex
The 19S regulatory complex, also called the ATPase complex or the proteasome activator 700 
(PA700), binds to both ends of the 20S proteasome with a C2-symmetry forming the 26S 
proteasome complex, which is now able to recognize and degrade ubiquitinylated proteins.
regulatory complex is capable of ATP-dependent protein degradation but it cannot 
recognise and degrade ubiqitinylated proteins (Voges et al. 1999).
It has been suggested that the six ATPases of the base assemble in a ring that forms 
the interface of the 19S particle with the 20S proteasome. Some studies carried out in 
Xenopus, Thermoplasma and Drosophila suggest that the six ATPases directly bind to 
the seven-member a-type subunit ring of the 20S proteasome. Several functions have 
been proposed for the role of the ATPases in the 19S regulatory particle (Voges et al.
1999X
■ The hydrolysis of the ATP by the 19S complex is thought to promote the assembly
of the 19S and the 20S complexes to form the 26S proteasome complex
■ The ATPases might have a role in the gating of the translocation channel
■ Substrate proteins are possibly bound to and unfolded by the ATPases
■ The ATPases might assist in the translocation of the unfolded substrate proteins 
into the central chamber of the 20S proteasome
The lid complex
The lid complex is essential for the recognition and the degradation of the 
ubiquitinylated substrates through the 26S proteasome. It is the distal component of 
the 19S regulatory particle and it contains 8 subunits (RpnS, Rpn5, Rpn6, Rpn7, RpnS, 
Rpn9, R pnll (Padl/Pohl) and Rpnl2) (Voges et al. 1999).
Two structural domains, the PCI (Proteasome, COP9 and eIF3) and the MPN (Mprlp, 
Pad Ip and N-terminal), have been found in all but one the subunits of the lid; neither 
motif is present in the subunits of the base (Hofmann and Bucher 1998). The PCI 
domain is about 200 amino acids long with a predicted a-helix linked to a short loop 
structure and it is found in 5 subunits of the lid (Rpn3, Rpn5, Rpn6 , Rpn7, Rpn9),
59
whereas the MPN domain is about 140 amino acids long with a predicted a/(3 structure 
and is found at the N-termini of the subunits Rpn8 and R pnll. Rpnl2 is the only 
subunit of the lid that contains neither of these two domains (reviewed by Voges et al. 
1999).
The proteasome-dependent degradation pathway is ATP-dependent. It also usually 
involves the covalent attachment of ubiquitin, which is a highly conserved and 
ubiquitous eukaryotic 76-residue polypeptide that marks proteins targeted for 
degradation. Through the sequential activity of three enzymes, the activating E l, the 
conjugating E2 and the ligase E3 enzymes, an isopeptide bond is formed between the 
a-aminogroup of a lysine residue in the substrate protein and the carboxyl-terminus of 
the ubiquitin molecule. Subsequently, the ubiquitin itself is often ubiquitinylated. This 
reaction is repeated with the subsequent formation of large polyubiquitinylated 
substrates that are specifically recognised by the 26S proteasome complex (Figure 3.3) 
(reviewed by Ciechanover 1994; Hochstrasser 1995; Voges et al. 1999). Recently it 
was also reported that tetraubiquitin is the minimum signal for efficient targeting of 
substrate proteins for 26S proteasome-dependent degradation (Thrower et al. 2000). 
The eukaryotic 26 S proteasome complex has three major peptidase activities:
■ a chymotrypsine-like activity which cleaves after hydrophobic residues
■ a trypsin-like activity which cleaves after basic residues
■ a peptidyl-glutamyl peptide-hydrolysing activity which cleaves after acidic
residues
Two additional activities, which cleave after branched chain residues and between 
small neutral amino acids have been identified in the mammalian proteasome (Voges 
et al. 1999).
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The subcellular localization of the 26S proteasome
The 26S proteasome complex as well as the free forms 20S and 19S are localised in 
both the cytoplasm and the nucleus in mammalian cells and they appear to be excluded 
from the nucleoli (Peters et al. 1994). The nuclear localization of the 26S proteasome 
together with the high amount of the activating enzyme E l and the presence of 
ubiquitin in the nucleus suggest important function for this pathway in the nucleus. 
Furthermore, it was also shown that the 26S proteasome is able to enter intact nuclei 
through the nuclear pores or during the re-assembly of the nuclear envelope after 
mitosis (Reits et al. 1997).
The 26S proteasome lid, COP9/signaIosome and eIF3 complexes
PCI and MPN domains have been found exclusively in three multi-protein complexes, 
the 26S proteasome lid, the COP9 signalosome and the eukaryotic translation initiation 
factor 3 (eIF3) (Aravind and Ponting 1998; Hofmann and Bucher 1998) (Figure 3.4). 
Similarly to the lid of the 19S regulatory particle, all the eight subunits of the C0P9 
signalosome and 5 out eleven of the eIF3 complex contain the PCI and the MPN 
domains (Glickman et al. 1998a). Unfortunately, the biochemical functions of these 
domains remain unclear.
eIF3 is involved in the formation of the 43S translation preinitiation complex. It 
mediates the dissociation of the 80S ribosome into 40S and the 60S subunits and the 
interaction between the eIF2-GTP-Met-tRNA complex, the 40S ribosome and the 
messenger RNA (mRNA) (reviewed by Wei and Deng 1999).
The C0P9 signalosome complex was first described in the plant Arabidopsis as a 
multisubunit repressor of photomorphogenesis and it is highly conserved among the 
eukaryotes (Wei et al. 1998). The mammalian C0P9 signalosome was also identified
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by Seeger (Seeger et al. 1998) as a contaminating component of a 26S proteasome 
preparation from human erythrocytes. The complex was then separated from the 26S 
proteasome preparation and later it was purified from the pig spleen (Wei and Deng 
1999).
It seems that the C0P9 signalosome is involved in the regulation of several regulatory 
processes in the cell, such as transcription, signal transduction and protein degradation.
There is a one to one relationship between the subunits of the proteasome lid and the 
COP9 complex, suggesting that both complexes might derive from a common 
ancestral complex. Two models have been proposed (Figure 3.5) (Wei and Deng
1999):
• The 26S proteasome complex is the more ancient complex and the C0P9 
signalosome has evolved from that with the subsequent diversification of its 
function (Figure 3.5 model 1).
• An ancestral protein complex gave rise to both the COP9 signalosome and the 26S 
proteasome lid complexes (Figure 3.5 model 2).
Seeger et al. proposed that the homology among the subunits of these three multi­
protein complexes may reflect a common substrate-binding site (Seeger et al. 1998); 
whereas Hofmann et al. suggested that the presence of the MPN and the PCI domains 
in the proteasome lid, eIF3 and C0P9 signalosome complexes indicates that these 
complexes may act as a regulatory particle of the proteasome core complex (Hofmann 
and Bucher 1998). In support of this proposal, the C0P9 signalosome complex was 
initially co-purified with the 26S proteasome complex (Seeger et al. 1998). Recently 
two of the eIF3 complex subunits, eIF3e (p48, also known as INT-6) and eIF3c
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(p i05), have been shown to interact with the C0P9 signalosome complex in 
Arabidopsis. eIF3e subunit co-immunoprecipitates with the C0P9 subunit CSN7 and 
the eIF3c subunit co-immunoprecipitates with the subunits eIF3b and eIF3e in the 
eIF3 complex and the subunits CSNl and CSN8 in the C0P9 complex (Yahalom et al.
2000). In addition, a direct interaction between eIF3e with eIF3c and CSN7 was also 
observed. This body of evidence suggests that although eIF3e and eIF3c are not 
components of the COP9 signalosome core complex, they are able to associate with 
the subunits of the COP9 signalosome. These interactions suggest a possible role for 
the COP9 signalosome in the control of protein translation (Yahalom et al. 2000).
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Results
Constitutive stable expression of HA-POHl in monkey COS7 cells
In order to investigate the multi-drug resistance phenotype conferred by 
overexpression of the proteasomal regulatory subunit Pohl, stable over-expression of 
HA-POHl in monkey COS-7 cells was initially pursued.
POHl fused to the 3'-end of the single HA epitope-tag was previously cloned into the 
pcDNA3 mammalian expression vector (pcDNA3/HA-POH1 ) (Spataro et al. 1997), 
which drives the expression of the gene under the control of the cytomegalovirus 
(CMV) immediate early promoter. The vector also contains a SV40 virus replication 
origin, which allows episomal replication of the vector in the presence of the SV40 
large T antigen and a higher expression level of the cloned gene.
COS-7 cells were co-transfected with the pOPRSV/CD2 plasmid, which expresses a 
truncated version of the rat CD2 protein as a cell surface marker of transfection, and 
the plasmid pcDNA3/HA-POH 1 or the empty vector pcDNA3.1+, at a ratio of 1:4. It 
was assumed that most of the cells expressing CD2 after transfection would also 
contain the empty vector or pcDNA3/HA-POHl respectively. After transfection the 
CD2^ cells were selected using the immunomagnetic beads coated with a mouse 
monoclonal anti-CD2 antibody (Figure 3.6). The CD2^-selected cells were then 
selected for the stable maintenance of the co-transfected vector (pcDNA3.1+ or 
pcDNA3/HA-POH 1 ) for two weeks with the antibiotic Geneticin (G-418). Expression 
of the HA-Pohl protein was then tested. Whole cell lysates were prepared from the G- 
418-resistant polyclonal cells transfected with the empty vector or with pcDNA3/HA- 
POHl. The detection of HA-Pohl was carried out by immunoblot analysis using an 
HRP-conjugated monoclonal anti-HA antibody (Figure 3.1 A). A band of about 37 kDa
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was detected in the cell lysates from the HA-Pohl-transfected cells. The Cdc2 protein 
was also detected as loading control using a mouse monoclonal anti-Cdc2 (A 17) 
antibody. Figure 3.7B shows the expression of both HA-Pohl and Cdc2 proteins in 
two positive stable clones, 2 and 25, which were derived from the stable polyclonal 
pool (see Materials and Methods - Chapter 2). Clone 2 cells showed the highest HA- 
Pohl expression level when compared with cells from clone 25 or from polyclonal 
pool.
HA-Pohl stable expression leads to drug resistance
A comparison between HA-Pohl endogenous expression levels and the cellular 
responses to 175 compounds in clinical use was carried out using the NCI 60 cancer 
cell line panel. A significant positive correlation was observed between high 
endogenous Pohl protein level in these cell lines and resistance to 36 of the cytotoxic 
drugs (C.Norbury, personal communication). Platinum drugs, alkylating agents and 
topoisomerase II inhibitors were among these drugs with the strongest correlation 
(Table I).
With these correlative data in mind, I investigated if the overexpression of HA-Pohl in 
the COS-7 cells was able to lead to resistance to a wider range of drugs than those 
previously tested (7-hydroxystaurosporine and taxol) (Spataro et al. 1997). To this end 
cisplatin, doxorubicin and melphalan were chosen as representative of the classes of 
drugs listed in Table I. The susceptibility of the cells to these drugs was tested by 
comparing the clonogenic survival in COS-7 cells stably expressing HA-Pohl or 
carrying the empty vector. Cells from the pcDNA3.1+ or the pcDNA3/HA-POH 1 
polyclonal pools were exposed to different concentrations of cisplatin, doxorubicin or 
melphalan for 24 hours and the capacity to form colonies was measured after 12-14
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days. Figure 3.8 shows the results of two independent experiments carried out in 
triplicate where the HA-Pohl-overexpressing cells have a survival advantage after 
exposure to cisplatin (A) and melphalan (B) in comparison with the cells carrying the 
empty vector. The HA-Pohl overexpressing polyclonal cells do not show any 
significant resistance to doxorubicin (C).
Table I - Analysis of variance shows positive correlation between endogenous Pohl 
level and resistance to cytotoxic drugs in the NCIH 60 cell line panel. Compounds 
listed in order of correlation coefficient.
Chemical name Pearson 
Corr Coef
P (Two-tail)
CBDCA
(Carboplatin)
-0.463 1.9E-04
Cis-platinum -0.426 1.8E-04
Deoxydoxorubicin -0.408 1.2E-03
Largomycin -0.396 1.7E-03
Pipobroman -0.395 1.8E-03
T riethylenemelamine -0.387 2.2E-03
Thio-tepa -0.384 2.4E-03
Mytomycin C -0.374 3.3E-03
In addition, the drug sensitivity of the cells from the two stable clones, 2 and 25, was 
examined. The MTS cytotoxicity assay was chosen because the cells from clone 2 
showed slow growth rate and low plating efficiency; however, no difference in the cell 
cycle phase distribution was observed (data not shown). The attempts to test the
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Figure 3.7 -  HA-Pohl stable overexpression in COS7 polyclonal pool and in two 
clones
Immunoblot of the exogenous expression of HA-Pohl in COST cells from polyclonal 
pool (A) or clones (B) stably transfected with pcDNA3/HA-P0Hl or the empty 
vector. Overexpressed protein was detected from whole cells extracts using HRP- 
conjugated monoclonal anti-HA antibody. For loading control mouse anti-Cdc2 
monoclonal antibody (A 17) was used.
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Figure 3.8 - HA-Pohl stable overexpression confers resistance to cisplatin and 
melphalan
Clonogenic survival curve in COS7 stably transfected with the empty vector 
(pcDNA3.1+) or the pcDNA3/HA-P0Hl plasmid. Cells were plated in triplicate and 
treated with different concentrations of cisplatin (A) or melphalan (B) or doxorubicin 
(C) for 24 hours. The cells were washed once with PBS and then refed with fresh 
medium.
The number of surviving colonies was counted after two weeks and expressed as the 
percentage of survival compared to the control (cells with no drug). SD is not shown 
when smaller than the plot symbol. Two experiments for each drug treatment are 
shown.
responses of these cells to drug treatment using the clonogenic assay were 
unsuccessful. The cells from clone 2 and clone 25 and polyclonal pool carrying the 
empty vector were treated with several dilutions of cisplatin or doxorubicin for 72 
hours (Figure 3.9). A much higher range of drug concentrations was chosen in the 
MTS assay as the same range used in the clonogenic assay was uneffective. Resistance 
to both drugs was also observed in the two HA-Pohl-overexpressing clones. The 
higher resistance observed in figure 3.9 compared to the figure 3.8 is possibly due to 
the different approaches used. The MTS assay measures the metabolically active cells 
whereas the clonogenic assay measures the capacity of the cells to proliferate and to 
form colonies. Furthermore, the cells in MTS assay were analysed after a much shorter 
time than in the clonogenic assay.
Association of Pohl with the 26 S proteasome complex
Given that HA-Pohl was described as a regulatory subunit of the 26S proteasome 
complex (Spataro et al. 1997), the possible association of the exogenous HA-Pohl 
with the 26S proteasome complex was investigated. To this end, protein complexes 
were separated by 7-37% sucrose density gradient centrifugation of extracts from 
polyclonal COS-7 cells stably expressing HA-Pohl (by R.Murray). Aliquots from the 
gradient fractions were subsequently used for immunoblot analysis (Figure 3.10). 
Exogenous and endogenous Pohl were detected using HRP-conjugated monoclonal 
anti-HA and rabbit polyclonal anti-HA-Pohl CN13 antibodies, respectively (Spataro 
et al. 1997). The endogenous protein was found in the fractions 6 and 7 where the 19S 
regulatory subunit p42 was also detected, suggesting that these fractions contained the 
26S proteasome complex. Surprisingly, most of the overexpressed HA-Pohl was
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Figure 3.9 -  HA-Pohl overexpression in clones 2 and 25 confers resistance to 
cisplatin and doxorubicin
MTS cytotoxicity assay in HA-Pohl expressing stable clones. 1000 cells were plated in 
triplicate in 96-multiwell plates. 24 hours later the cells from clone 2 (A,B) and clone 
25 (C,D) were treated with serial dilutions of cisplatin (A,C) or doxorubicin (B,D) for 
72 hours. Cell viability was scored by measuring the absorbance at 490 nm using a 
plate reader. Results are expressed as percentage of viability compared to the control 
(no drug).
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Figure 3.10 -  Overexpressed HA-Pohl is incorporated into low molecular weight 
complexes
7-37% sucrose density gradient centrifugation of cell lysates from COS-7 polyclonal cells 
stably expressing HA-Pohl. Detection of the exogenous and endogenous Pohl was carried 
out by immunoblot analysis from the gradient fractions 1 to 8 using HRP-conjugated 
monoclonal anti-HA and polyclonal anti-Pohl CN13 antibodies, respectively. The 
proteasome regulatory subunit p42 was detected as a positive control using monoclonal 
anti-p42 antibody.
detected in the lower molecular weight fractions (2 to 5) with almost undetectable 
amount in fraction 6.
In order to further investigate the association between the exogenous HA-Pohl and the 
proteasomal complex, the core (20S) subunit C3 of the 26S proteasome was 
immunoprecipitated from extracts of COS-7 cells carrying the empty vector or 
overexpressing HA-Pohl using the mouse monoclonal MCP-21 (multicatalytic 
protease) antibody (Hendil et al. 1995). HA-Pohl and C3 were then detected by 
immunoblot analysis. Lysis buffer alone was used as negative control for the 
immunoprécipitation. A faint band corresponding to exogenous HA-Pohl was 
detected only in HA-Pohl-containing cell lysate (Figure 3.11 A), whereas C3 protein 
was detected in both cell lysates (Figure 3.1 IB). The results described so far point 
towards a poor association of the exogenous HA-Pohl with the 26S proteasome 
complex.
Next, the amount of HA-Pohl associated or non-associated to the proteasomal 
complex was detected. To this end, immunoprécipitation of the core subunit C3 was 
performed again with the difference that in addition to the C3-precipitated sample the 
supernatant (un-precipitated) material was also collected after immunoprécipitation. 
The samples were then subjected to immunoblot analysis. Figure 3.12A shows a band 
corresponding to the overexpressed protein that is detectable in both the precipitated 
and the supernatant samples only from the HA-Pohl-overexpressing cells. 
Considering the amount from each sample loaded on the gel in respect to the total, the 
results shown in figure 3.12 indicate that most of the overexpressed HA-Pohl does not 
associate with the 26S proteasome complex.
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Figure 3.11 - Exogenous HA-Pohl co-precipitates with the proteasome core subunit C3
Immunoprécipitation of the 20S proteasome core subunit C3 from the C0S7 cells carrying the 
empty vector or overexpressing HA-Pohl was performed using the mouse monoclonal MCP- 
21 antibody. Detection of HA-Pohl (A) and C3 (B) proteins was carried out using mouse 
monoclonal MCP-21 and HRP-conjugated monoclonal anti-HA antibodies, respectively. Lysis 
buffer alone was used as negative control.
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Figure 3.12 -  Most of the exogenous HA-Pohl is not proteasome-associated
Immunoprécipitation of 20S proteasome core subunit C3 from C0S7 cells stably transfected 
with pcDNA3.14-/HA-P0H1 or the empty vector was performed using mouse monoclonal 
MCP-21 antibody. Pohl (A) and C3 (B) proteins were detected in the precipitated and un­
precipitated samples using HRP-conjugated monoclonal anti-HA and mouse monoclonal 
MCP-21 antibodies, respectively. Lysis buffer alone was used as negative control.
Sub-cellular localization of HA-Pohl in COS-7 cells
The localization of the exogenous HA-Pohl in COS-7 cells was studied by using both 
direct fluorescence and indirect immunofluorescence approaches.
First, expression of POHI was carried out using the pEGFP expression vector. POHI 
cDNA was fused to the 3'-end of the enhanced green fluorescence protein (EGFP) 
DNA sequence in the pEGFP vector. pEGFP empty vector and pEGFP/POHl were 
then transiently expressed in COS-7 cells were carried out. Expression of the fusion 
protein was confirmed in whole cell lysates by immunoblot analysis using a rabbit 
polyclonal anti-EGFP antibody (Figure 3.13). A band corresponding to the EGFP- 
tagged HA-Pohl protein (lane 2) was identified. In line with the expected molecular 
mass of 37 kDa for Pohl and of about 30 kDa for EGFP (lane 1), the EGFP-Pohl 
fusion protein migrated at 60-62 kDa. Next, the localization of the expressed proteins 
was analysed. The cells were grown on sterile glass coverslips in a 6-multiwell plate 
and the pEGFP or the pEGFP-POHl vectors were transiently expressed with an 
efficiency of approximately 80-90%. As detected by fluorescence microscopy, the 
EGFP-Pohl protein localised mainly in the cytoplasm with low or undetectable 
localization within the nueleus (Figure 3.14, second and third columns). The same 
result was obtained after transient transfection of the pEGFP-POHl plasmid in human 
HeLa cells (data not shown). EGFP alone is known to be able to passively diffuse 
through the nuclear membrane and localises throughout the cytoplasmic and nuclear 
compartments (Figure 3.15).
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Figure 3.13 - EGFP and EGFP-Pohl protein detection in COS-7 cells
COS-7 cells transiently transfected with pEGFP or pEGFP-POHl were lysed in 2x SDS 
sample buffer and lysates were separated by 10% SDS-PAGE. EGFP and EGFP-Pohl 
detection was carried out by immunoblot analysis using rabbit polyclonal anti-GFP antibody.
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Figure 3.14 -  Transiently expressed EGFP-Pohl is localised in the cytoplasm of COS-7 
cells
COS-7 cells were grown in sterile glass coverslips in a 6-multiwell plate. Cells were 
transiently transfected with pEGFP/POHl and 24 hours later were fixed with 4% 
paraformaldehyde. DNA was stained using Hoechst 33258 [Ipg/ml] and localization of the 
EGFP-tagged recombinant protein was detected by fluorescence microscopy.
DNA EGFP
Figure 3.15 - EGFP localization in COS-7 cells
COS-7 cells were grown in sterile glass coverslips in a 6-multiwell plate. Cells were 
transiently transfected with the pEGFP vector and 24 hours later were fixed with 4% 
paraformaldehyde. DNA was stained using Hoechst 33258 [Ipg/ml] and localization of 
EGFP was detected by fluorescence microscopy.
Surprisingly, when the stable expression of HA-Pohl in COS-7 cells was investigated 
by indirect immunofluorescence, the result was different from that obtained with the 
EGFP fusion. The cells were grown on sterile glass coverslips in a 6-multiwell plate. 
24 hours after plating, the localization of HA-Pohl was determined using mouse 
monoclonal anti-HA and anti-mouse FITC-conjugated antibodies (Figure 3.16A); anti­
mouse FITC-conjugated antibody was used alone as a negative control (Figure 3.16B). 
Co-localization of the HA-Pohl fluorescence signal and the nucleus was observed in 
addition to the cytoplasmic localization of the protein.
These data were further supported by sub-cellular fractionation (Figure 3.17). Soluble 
(S) and nuclear enriched (N) fractions of COS-7 polyclonal pools carrying the empty 
vector or overexpressing HA-Pohl were prepared as described for the nuclear extracts 
(Dignam et al. 1983) used for the electrophoretie mobility shift assay (see Materials 
and Methods - Chapter 2) with the difference that after cell lysis and separation from 
the nuclei the soluble fraction was also collected. The samples were then subjected to 
immunoblot analysis. Exogenous and endogenous HA-Pohl was detected in the 
nucleus and the cytoplasm by using HRP-conjugated monoclonal anti-HA and 
polyclonal anti-HA-Pohl CN13 antibodies, respectively. Overexpressed and 
endogenous Pohl were both detected in the both fractions with the majority of the 
signal being soluble.
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Figure 3.16 -  Exogenous HA-Pohl is localized in the nucleus and cytoplasm of COS-7 cells
Indirect immunofluorescence of COS-7 cells from polyclonal population stably overexpressing 
HA-Pohl. Cells were grown on sterile glass coverslips in a 6 multiwell plate for 24 hours, before 
being fixed in 4% paraformaldehyde, permeabilised in 0.5% Triton X-100 and stained using 
mouse monoclonal anti-HA antibody and anti-mouse FITC-conjugated secondary antibodies (A) 
or anti-mouse FITC-conjugated antibody only (B), as a negative control. DNA was stained with 
Hoechst 33258 [Ipg/ml], the cell were then mounted in 90% glycerol and fluorescence was 
detected by fluorescence microscopy.
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Figure 3.17 -  Endogenous and exogenous Pohl are expressed both in the soluble 
and the nuclear enriched fractions
Detection of HA-Pohl by immunoblot analysis of nuclear and soluble fractions from 
COS-7 cells stably expressing HA-Pohl or carrying the empty vector. A) Exogenous 
HA-Pohl was detected using HRP-conjugated monoclonal anti-HA antibody, whereas 
B) endogenous Pohl was detected using rabbit polyclonal anti-Pohl CN13 antibody.
Discussion
HA-Pohl constitutive expression and drug resistance
In order to elucidate the mechanism of drug resistance induced by HA-Pohl, stable 
expression of HA-Pohl was obtained in a polyclonal pool population and in two 
clones, 2 and 25. Unfortunately, the expression level of the exogenous HA-Pohl was 
not high when compared to the level of the endogenous protein, which was detected 
using the polyclonal anti-Pohl CN13 antibody. On the other hand, this level of 
exogenous HA-Pohl was able to confer resistance to different drugs in COS-7 cells. 
The survival advantage of the HA-Pohl-overexpressing cells following exposure to 
cisplatin and melphalan was observed in the polyclonal pool and to cisplatin and 
doxorubicin in the single cell clones. The drugs chosen for these experiments have 
different mechanisms of action. Cisplatin forms DNA adducts, either inter- or intra­
molecular, causing DNA damage; doxorubicin is an anthracyclines which inhibits 
topoisomerase II and binds directly to the DNA possibly by direct intercalation into 
the DNA strand with subsequent inhibition of the DNA synthesis; and melphalan 
belongs to the group of alkylating agents, which exert a wide range of biological 
effects possibly mediated by alkylation of the guanine in the DNA (reviewed by 
Brown and Boger-Brown. 1999).
It is worthy to note that the cells from the stable clone 2, which had the highest HA- 
Pohl expression level, also exhibited morphological changes and growth defects. 
Cultures of this clone grow slowly and contain many cells that appear to be senescent. 
The cells also appear generally larger and flatter than the un-transfected cells or other 
HA-Pohl-transfected cells. It is unclear if these growth and morphological changes are
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due to the high expression level of HA-Pohl, rather than HA-Pohl-independent clonal 
variation.
Sub-cellular localization of HA-Pohl
Stably expressed HA-Pohl is found both in the cyoplasmic and in the nuclear 
compartments of COS-7 cells, as shown by indirect immunofluorescence (Figure 
3.16B). No major difference of intensity between the two compartments was observed. 
This result is in accord with other studies on the localization of the 26S proteasome 
complex in mammalian cells. Both the 26S complex and its 20S and 19S constituents 
have been found in the nucleus and the cytoplasm of mammalian cells (Peters et al.
1994). However, it is still unclear if the process of proteolysis occurs in both 
compartments or specifically in one. There are no data regarding the localization of the 
endogenous Pohl, as the rabbit polyclonal anti-Pohl CN13 antibody does not 
recognise the protein by immunofluorescence (Spataro et al. 1997). Endogenous HA- 
Pohl is mainly associated with the 26S proteasome complex as detected in crude 
lysates of human cells (Spataro et al. 1997) and in the COS-7 cells overexpressing 
HA-Pohl (Figure 3.10). Given that, it is conceivable to assume that the endogenous 
protein may be localised both in the nucleus and in the cytoplasm of the cell, although 
this hypothesis still needs to be proved.
In contrast transiently expressed EGFP-tagged Pohl localises only to the cytoplasm. 
Just few cells showed punctuate fluorescence in the nucleus that is possibly due to a 
high transient expression level of the protein. In order to overcome possible artefacts 
due to transient expression and also to better compare this result with the localization 
of the stably expressed (HA-tagged) protein, the pEGFP-POHl plasmid was stably 
expressed in COS-7 cells. Unfortunately, it was impossible to obtain a population of
87
cells stably expressing EGFP-Pohl fusion protein as well as EGFP protein alone. This 
may reflect a previously documented toxic effect of the GFP protein in mammalian 
cells.
The two different localization patterns of HA-Pohl might be explained by the different 
epitope tags fused to the amino-terminus of the POHl sequence. The single HA tag in 
the pcDNAS vector is only 9 amino acids long. In contrast, the 30 kDa EGFP tag leads 
to a great increase of the molecular weight mass of Pohl (37 kDa). EGFP tag could 
modify the conformational structure of Pohl preventing the entry of the protein into 
the nucleus. Pohl does not seem to contain any consensus nuclear export or import 
sequences. We might assume that the protein is able to diffuse through a passive 
transport mechanism; however, HA-Pohl could also enter into the nucleus by a 26S 
proteasome-dependent mechanism, possibly through active transport. In faet, some of 
the a-subunits of the 20S core proteasome contain a p-importin-like domain (Voges 
et al. 1999) that could mediate the transport of HA-Pohl, which is located in the lid of 
the regulatory particle of the complex, to the nucleus.
Pohl and the 26S proteasome complex
Pohl is a subunit of the 19S regulatory particle of the 26S proteasome complex 
(Spataro et al. 1997). Given that the overexpression of HA-Pohl confers pleiotropic 
resistance to unrelated drugs, a possible role of proteolysis in determining the 
sensitivity of the human cells to the treatment with cytotoxic drugs has been proposed. 
In line with this idea, several temperature sensitive fission yeast proteasomal mutants 
that confer resistance to the spindle poison MBC or to a wider range of drugs have 
been identified over the last few years, suggesting that drug resistance might be a
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result of a partial destabilsation of the 19S regulatory complex (Gordon et al. 1993; 
Gordon et al. 1996; Penney et al. 1998; Wilkinson et al. 1997).
HA-Pohl has been detected in the immunopurified proteasomal preparation from lung 
cancer cells as well as in the purified 26S preparation from human erythrocytes 
(Spataro et al. 1997). Furthermore, both the fission and the budding yeast homologues 
padl^  and MPRl encode a regulatory subunit of the 26S proteasome complex (Penney 
et al. 1998; Rinaldi et al. 1998), indicating a high degree of conservation of this 
protein during evolution.
One of the main questions addressed was if the exogenous HA-Pohl is able to confer 
drug resistance by a mechanism dependent on the 26S proteasome and hence 
presumably on the proteolytic process. Only a small amount of the exogenous Pohl 
protein was associated with the 26S proteasome, whereas most of the protein was 
found in smaller complexes (Figure 3.10 and 3.11). In contrast, endogenous HA-Pohl 
was present exclusively in the 26S proteasome-containing fractions. Nevertheless, a 
small amount of exogenous HA-Pohl co-immunoprecipitated with the 20S core 
subunit C3 (Figure 3.12). The same result was also confirmed in human cells after 
inducible expression of HA-Pohl (data not shown).
These data raise the question of which fraction of the overproduced HA-Pohl, the 26S 
proteasome-associated or the non-associated, underlies the pleiotropic drug resistance 
phenotype. HA-Pohl not associated with the 26S proteasome complex might be able 
either to activate some drug resistance effectors by a 26S proteasome-independent 
mechanism or alternatively to disrupt some specific functions of the proteasome (see 
Chapter 5). Alternatively it is possible that the low amount of HA-Pohl bound to the 
proteasome complex is responsible for the multi-drug resistance phenotype, which 
could result from specific alteration of 26S proteasome function.
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Chapter 4
HA-POHl inducible expression in
human cells
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Overview
In this chapter I introduce the system used to express HA-POHl in a doxycyclin- 
inducible manner in the U2-OS human osteosarcoma cell line. Inducible expression 
of HA-Pohl is shown to induce pleiotropic drug resistance in human cells.
Introduction
The tetracycline/doxycyclin mammalian inducible expression system
The ability to tightly control gene expression can facilitate the analysis of the gene 
function. Inducible gene expression has been an advantageous tool in studying gene 
function in a wide variety of organisms, such as bacteria, yeast and Drosophila 
melanogaster.
The achievement of this goal in mammalian cells has been difficult due to the lack of 
tightness of control or to pleiotropic effects of the inducing agents, such as heat 
shock proteins, heavy metal ions or steroid hormones. The main objectives of an 
inducible system in the eukaryotic cells are a high ratio of "on:off ' gene expression 
and the ability to vary the level of induction (Gossen and Bujard 1992).
It has been previously demonstrated that the lac repressor/operator/inducer system 
from E. colt is able to function in mammalian cells. Unfortunately, the use of this 
system has been limited as the inducer isopropyl-p-D-thiogalactopyranoside (IPTG)
acts slowly and often inefficiently leading to a moderate induction of the gene of 
interest (Gossen and Bujard 1992).
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Gossen and Bujard described (Gossen and Bujard 1992) a control system in human 
HeLa cells based on the regulatory element of the TnlO-specified tetracycline (Tc) 
resistance operon from E.coli. In this system the tetracycline repressor (tetR) 
negatively regulates the transcription of the resistance-mediating gene. In bacteria, 
the tetR protein is encoded by the tetR gene and is tightly bound to the tetracycline 
operator {tetO) sequence located within the promoter region of the operon. This 
binding leads to the subsequent inhibition of expression of the genes involved in 
tetracycline resistance. In contrast, in the presence of the antibiotic tetracycline, tetR 
no longer binds to its operator {tetO) allowing gene transcription.
In order to create a protein able to stimulate a minimal promoter fused to seven 
repeats of the tetracycline operator sequence {tetO), the hybrid transactivator tTA 
was generated. tTA was created by combining the tetR sequence with the C-terminal 
region of the Herpes Simplex Virus (HSV) VP16 protein, which is essential for 
transcription of the immediate early viral genes. These synthetic promoters are silent 
in the presence of even low coneentration of tetracycline as it prevents the binding of 
the tetracycline-controlled transactivator (tTA) to the tetO sequence, presumably 
through a change in the conformation of the tetR region in the tTA chimeric protein 
(Gossen and Bujard 1992) (Figure 4.1).
This system seemed to have a number of advantages over the previous described 
systems due to:
• The specificity of the tetR for its operator sequence {tetO)
• The high affinity of tetracycline for tetR
• The well-studied chemical and physiological properties of tetracycline
• The fast activity of tetracycline as an inducer
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In 1995 Gossen et al. (Gossen et al. 1995) developed another system in which 
tetracycline, or the most potent tetracycline derivative doxycydin (Dox), acts as the 
inducer instead of as the repressor. The reverse tetracycline-controlled transactivator 
(rtTA) has reversed DNA binding properties when compared with the wild-type tetR 
or tTA. In fact, in this system the presence of tetracycline or doxycyclin is necessary 
for the binding of the reverse tetracycline transactivator (rtTA) to the tetO sequence 
and hence for the subsequent activation of the expression of the gene of interest 
(Figure 4.2). The reversed tTA sequence was generated by random mutagenesis of 
the tetR sequence. The mutants were screened for the tetracycline-dependence of the 
repression in vivo. One mutant was found able to cause the repression of the gene 
under the tetracycline operator control in presence of the inducer, possibly due to a 
change of its conformation during the induction. The mutant was referred as the 
reverse tetracycline repressor (rtetR). The reverse tetracycline-controlled TA (rtTA) 
was obtained by replacing the wild-type tetR sequence with the mutant rtetR  
sequence in the original tTA hybrid DNA sequence (Gossen et al. 1995).
One main advantage of this system is its application in in vivo studies, as the kinetics 
of induction does not depend on the biological half-life of the effector (Gossen et al.
1995).
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Figure 4.1 -  The tetracycline inducible system
The DNA binding domain of the tetracycline (Tc) repressor (tetR) fused to the transcriptional 
activator VP 16 from the herpes simplex virus (HSV) encodes the tetracycline transactivator (tTA). 
Tetracyclinee acts as repressor. A) In absence of tetracycline, the fusion protein binds to the 
tetracycline operator (tetO) through the tetR binding domain resulting in the activation of the 
expression of the gene X mediated by the VP16 activation domain. B) In presence of tetracycline, 
the tTA fusion protein is no longer able to bind to tetO due to a change of conformation with 
consequent repression of gene expression.
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Figure 4.2 - The reverse tetracycline transactivator
In this system tetracycline (Tc) or its derivative doxycyclin (Dox) act as inducer instead of as 
repressor. The reverse tetracycline-controlled transactivator (rtTA) has reversed DNA binding 
property when compared to the wild-type tetR or tTA. In presence of Tc or Dox, rTA binds to 
tetO with subsequent activation of the expression of the gene of interest.
Results
HA-POHl inducible expression systems used
The first two attempts to generate inducible expression of HA-POHl were 
unsuccessful.
- First a tetracycline repressible "Tet-off ' system was used, which was based on the 
positive regulation of gene expression by the tetracycline trans activator (tTA) 
(Gossen and Bujard 1992). The system involved the stable transfection of two 
vectors. Unfortunately, it was not possible to generate regulated expression of Pohl 
with this system possibly due to technical problems with the stable selection of the 
cells.
- As a second approach an IPTG inducible expression system was used.
This system is based on two vectors in which several elements of the bacterial lac 
operon have been modified for use in eukaryotic cells. Human HT 1080 fibrosarcoma 
cells were first stably transfected with the pS’SS vector, which expresses a modified 
la d  gene encoding the Lac repressor protein with a nuclear localization signal (NLS) 
(by S. Houlbrooke). The second vector pOPRSVI/HA-POH1 was subsequently 
transfected into the same cells. This vector directs the expression of the HA-tagged 
gene under the control of a modified Rous sarcoma virus (RSV) promoter that 
contains two copies of the lac operator sequence. The Lac repressor binds to the lac 
operator blocking the expression of the gene. When present in the medium, the 
isopropyl-P-D-thiogalactopyranoside (IPTG) synthetic inducer binds to Lac 
repressor causing a decrease of the affinity of the repressor for the operator and 
subsequent expression of the gene of interest.
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Several stable clones expressing HA-Pohl after induction with the IPTG [1 mM] for 
24 hours were obtained (data not shown). Unfortunately, the expression level of the 
exogenous protein was not high. The few drug sensitivity experiments carried out on 
these stable clones did not show any significant difference between the induced and 
the un-induced populations. Using the same system identical results were also 
obtained for the expression of other genes under study in the laboratory.
- Finally another tetracycline/doxycyclin inducible system, which is based on a 
positive (activator) and a negative (repressor) regulation of gene expression, was 
chosen. The system contains three vectors:
1. ppr^TA expresses the reverse trans activator (rtTA) that is necessary for the 
transcriptional activation of the gene of interest (Gossen et al. 1995).
2. pEFblastetRKRAB expresses the repressor KRAB. In this system the inducer 
tetracycline (or doxycyclin) controls the silencing of the eukaryotic promoter. The 
KRAB repressor domain, which is a 75 amino acids sequence derived from the 
human Kroxl zinc finger protein, is fused to a tetR DNA binding domain (Deuschle 
et al. 1995). In the absence of the inducer the chimeric protein tetR-KRAB binds to 
several cis-acting tetO sites that are placed at a distance from the tetracycline 
initiation site of an eukaryotic promoter. When present in the medium, the inducer 
binds both the tetR and the rtetR domains in the recombinant proteins with their 
subsequent conformational change. This process inhibits the binding of tetR to the 
tetO sequence, allowing at the same time the binding of the rtetR to the tetO  
sequence and subsequent transcriptional activation of the promoter (Figure 4.3).
3. pUHDlO-MCS/HA-POH 1 drives the expression of the HA-POHl gene under
the control of the CMV promoter.
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Figure 4.3 -  The d oxycyclin inducible system for HA-POHl gene expression
Inducible doxycyclin “on” system. A) In absence of doxycyclin, the reverse transactivator 
rtTA is not able to bind tetO, whereas the repressor tetR-KRAB binds to tetO and inhibits 
gene transcription. B) In presence of doxycyclin, tetR-KRAB does not binds tetO any 
longer due to a conformational change in the tetR domain. In parallel, doxycyclin also 
induces a change in the rtetR domain of the rtTA with the consequent binding of rtTA b 
tetO and activation of the transcription of HA-POHL
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Figure 4.4 -  Regulation of the inducible HA-Pohl expression
A simplified diagram of the HA-Pohl indueible system is shown in Figure 4.4. 
Inducible expression of HA-Pobl in human cells
A human U2-0S osteosarcoma stable clone co-transfected with pPrrTA and 
^^YbldiStetRKRAB vectors and selected using the antibiotic blasticidin S [5 pg/ml] 
was generously provided by Dr. S.Geley (ICRF Clare Hall). The U2-OS 
^rtTAI^tetRKRAB cells were then co-transfected with pUHDlO-MCS/HA-POH 1 and 
pcDNA3.1+ (ratio 4:1), as carrier of the G-418 resistance marker for selection of 
transfected cells. After two weeks of selection with G-418, the stable polyclonal cells 
were tested for the expression of HA-Pohl after the induction with doxycyclin [3 
pg/ml] for 16 hours. Protein detection was performed by immunoblot analysis on 
whole cell lysates using HRP-conjugated monoclonal anti-HA antibody (Figure 
4.5A). In parallel, 60-70 stable clones were screened for the expression of HA-Pohl 
after induction with doxycyclin. In total, 5 positive clones were found. Figure 3.5B 
shows the expression of HA-Pohl in some of the stable clones as detected by 
immunoblot analysis.
It has been previously described that doxycyclin at concentration as low as 10 ng/ml 
is able to induce gene expression using this system, while the concentration of 1 
pg/ml has been suggested to be optimal for gene induction (Gossen et al. 1995).
In order to find the optimal concentration of doxycyclin for the expression of HA- 
Pohl in U2-0S cells a dose response experiment was carried out. Cells from the 
polyclonal pool population were exposed to several concentrations of doxycyclin 
(0.025, 0.1, 0.5 and 1.5 |xg/ml) or no doxycyclin (Figure 4.6A). The results show that 
the concentration of 25 ng/ml was already able to induce HA-Pohl expression and, 
in addition, HA-Pohl expression level was dose-dependent. Figure 4.6 panel B
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Figure 4.5 - Doxycyclin inducible expression of HA-Pobl in stably transfected U2- 
OS cells
Immunoblot analysis of HA-Pohl induction in the human U2-OS cells. The cells from 
polyclonal pool (A) and some of stable clones (B) were mock (-) or doxycyclin (+) [2 
pg/ml] treated for 16 hours. Whole cell lysates were subjected to immunoblot analysis 
using HRP-conjugated monoclonal anti-HA antibody.
shows the inducible expression of HA-Pohl in the stable clone 33 (C33) cells using a 
range of doxycyclin from 0.1 to 2.5 |Xg/ml. Taken together these results suggest that 
doxycyclin concentrations between 0.5 and 1.5 pg/ml are optimal for the inducible 
expression of HA-Pohl; a coneentration between 1-1.5 |Xg/ml was used in most 
subsequent experiments.
Next, cells from the two stable clones C l5 and C33 were mock or doxycyclin treated 
[1.5 [ig/ml] for 24, 36 and 48 hours and the time-dependency of HA-Pohl expression 
was studied (Figure 4.7A). Doxycyclin has a half-life of 24 hours, so every day [0.75 
|ig/ml] doxycyclin was added in order to maintain its final concentration of 1.5 
|Lig/ml. The protein level of HA-Pohl was fairly constant under these conditions and 
did not change significantly between 24 and 48 hours. Furthermore, treatment of the 
cells from clone 33 with doxycyclin [1 pg/ml] for 8 days led to a constant expression 
of HA-Pohl throughout the time (Figure 4.7B). Cde2 protein was detected as loading 
control in the same cell lysates by using monoclonal anti-Cdc2 antibody (Figure 4.7, 
lower panel).
No toxic effects of doxycyclin were observed in all these experiments, even after 8 
days of treatment.
Exogenous HA-Pohl was deteeted in both the soluble and the nuclear enriched 
fraetions of the stably transfected COS-7 cells after cell fractionation (Figure 3.8). 
This result was also observed in human cells. Cells from clone 33 were moek or 
doxycyclin [1 jLtg/ml] treated for 24 hours and the nuclear and cytoplasmic fractions 
were separated as already described for COS-7 cells in chapter 3 and analysed by 
immunoblotting. Figure 4.8 shows the expression of both the overexpressed and 
endogenous HA-Pohl in both fractions.
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Figure 4.6 - Doxycyclin dose response curve of HA-Pohl expression in U2-OS cells
HA-Pohl expression was induced or not with different concentrations of doxycyclin for 
16 hours in cells from stable polyclonal pool (A) and clone 33 (B). Whole cell lysates 
were analysed by immunoblotting using HRP-conjugated monoclonal anti-HA antibody.
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Figure 4.7 - Time course of HA-Pohl expression in doxycyclin inducihle stable clones
Detection of induced HA-Pohl by immunoblot analysis. Cells from U2-0S stable clones 
15 and 33 were mock or doxycyclin treated for 0, 24, 36 and 48 hours with 1.5 pg/ml (A) 
and cells from clone 33 for 0 to 8 days with 1.0 pg/ml (B). Doxycyclin [0.75 pg/mll or 
[0.5 pg/ml] was added to the cells every 24 hours. Whole cell lysates were analysed by 
immunoblotting using HRP-conjugated monoclonal anti-HA antibody. As loading control 
Cdc2 was detected using mouse monoclonal anti-Cdc2 (A 17) antibody.
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Figure 4.8 -  Endogenous and exogenous Pohl are expressed both in the soluble 
and in the nuclear enriched fractions of human cells
Detection of HA-Pohl and Pohl by immunoblot analysis in nuclear and soluble 
fractions from mock or doxycyclin treated U2-0S cells (clone 33). A) Exogenous 
Pohl was detected using HRP-conjugated monoclonal anti-HA antibody, whereas B) 
endogenous Pohl was detected using rabbit polyclonal anti-Pohl CN13 antibody.
Inducible expression of HA-Pohl confers drug resistance in human cells
Transient expression of HA-POHl in COS-1 cells leads to a multi-drug resistance 
phenotype (Spataro et al. 1997). This result was supported by the stable expression 
of the protein in COS-7 cells, as described in chapter 3. Before further investigating 
the role of HA-Pohl overexpression in mammalian and human cells (Chapter 5), the 
ability of inducible HA-Pohl to confer drug resistance in human cells was tested. 
First, in order to exclude possible effects of doxycyclin treatment on the sensitivity 
of the cells to cytotoxic drugs, the U2-OS polyclonal cells carrying the empty vector 
pUHDlO-MCS were mock or doxycyclin [1 pg/ml] treated for 24 hours. Then, the 
two cell populations were exposed to several dilutions of melphalan (Figure 4.9A) or 
7-hydroxystaurosporine (Figure 4.9B) for 72 hours. The viability of the cells was 
detected using the MTS cytotoxicity assay. No effect of doxycyclin treatment on the 
susceptibility of the cells to other drugs was found.
Next the sensitivity of HA-Pohl transfected cells was investigated. Cells from clones 
15 and 57 were mock or doxycyclin treated for 24 hours and clone 15 cells were 
treated with 7-hydroxy staurosporine (Figure 4.10B) and clone 57 cells were treated 
with 7-hydroxystaurosporine, melphalan or doxorubicin (Figure 4.10A, C, D) for 72 
hours. Cell viability was measured using the MTS cytotoxicity assay. These results 
together with those shown in Chapter 3 establish that expression of HA-Pohl in 
human cells leads to significant resistance to a variety of unrelated drugs, as 
previously observed in mammalian and fission yeast cells (Spataro et al. 1997). The 
higher resistance to doxorubicin observed in human cells in figure 4.10D in respect 
to the one observed in COS-7 cells using the clonogenic assay (Chapter 3, Figure 
3.8) is possibly due to the different approaches used.
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Figure 4.9 -  Treatment with doxycyclin does not affect the susceptibility of U2-OS cells to 
other drugs
MTS cytotoxicity assay in U2-0S cells carrying the empty vector, mock (-) or doxycyclin (+) 
treated. 1000 cells were plated in triplicate in a 96-multiwell plate. 24 hours later the cells were 
treated with melphalan (A) or 7-hydroxystaurosporine (B) for 72 hours. Cell viability was 
determined by MTS assay. Results are expressed as the percentage viability compared to the 
control (no drug) cells.
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Figure 4.10 - Inducible expression of HA-Pobl confers pleiotropic resistance in 
human cells
MTS cytotoxic assay in U2-0S cells transfected with HA-Pohl, mock (-) or doxycyclin (+) 
treated. 1000 cells were plated in triplicate in a 96-multiwell plate. 24 hours later the cells 
from clone 57 (A) and clone 15 (B) were treated with 7-hydroxystaurosporine. Cells from 
clone 57 were treated with melphalan (C) or doxorubicin (D) for 72 hours. Cell viability 
was determined using the MTS assay. Results are expressed as the percentage viability 
compared to the control cells (no drug).
Chapter 5
HA-Pohl and AP-1 transcription
factors
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Overview
In this chapter I describe the molecular mechanism by which overexpressed HA-Pohl leads 
to pleiotropic drug resistance in mammalian cells.
Firstly, I introduce AP-1 transcription factors, the links between AP-1 and the 26S 
proteasome complex and drug resistance in human cells. Secondly, I describe the ability of 
HA-Pohl to positively modulate AP-1 transcription factor activity associated with increased 
protein levels of the two AP-1 subunits, c-Jun and c-Fos. Furthermore, evidence is 
presented that HA-Pohl may increase the protein stability of c-Jun through an interaction 
between the two proteins.
Introduction
Activating protein 1 (AP-1)
Activating protein 1 (AP-1) is a family of dimeric transcription factors complex, whose 
components include c-Jun and c-Fos, members of the bZip family proteins which contain 
conserved basic (b) and leucine zipper (ZIP) domains required for their binding to DNA. 
This motif mediates homodimerization of c-Jun and heterodimerization of c-Jun and c-Fos 
and the subsequent recognition and binding to the palindromic consensus DNA sequence 5'- 
TGAGTCA-3', referred as 12-0-Tetradecanoylphorbol 13-acetate (TPA)-responsive 
element (TRE) or AP-1 consensus site, located in the promoter region of a variety of genes 
(Angel et al. 1987b). c-Jun and c-Fos are both defined proto-oncogenes as they were 
identified as the cellular counterparts of the oncogenes v-Jun and v-Fos, respectively (Maki
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et al. 1987) (Curran and Teich 1982). c-Jun is also able to form heterodimeric complexes 
with ATF-2 (Activating Transcription Factor 2), belonging to the ATF transcription factor 
family, and CREB proteins. The resulting complexes bind to the AP-1-related cyclic AMP 
responsive element (CRE)-like site 5'-TGAGCTCA-3' (reviewed by Karin et al. 1997; 
Wisdom 1999).
A wide range of external stimuli, such as peptide growth factors, cytokines, oxidative stress, 
UV irradiation and other forms of cellular stress, generate signals that converge on the AP-1 
factors (Figure 5.1), with subsequent modulation of their activity which is regulated 
primarily at the transcriptional and post-translational levels (Figure 5.2). Based on this 
regulation, AP-1 co-ordinates a variety of signals and consequently generates diverse 
cellular responses, including cell proliferation, differentiation, development, apoptosis and 
other stress responses (reviewed by Karin et al. 1997; Wisdom 1999) (Figure 5.1).
DNA binding and transcriptional activation domains are distinct in c-Jun and c-Fos and the 
activation domains are modulated by phosphorylation. For example, c-Jun is 
phosphorylated at Ser^ ,^ Ser^ ,^ Thr^  ^ and Thr^  ^ by members of the c-Jun NH2-terminal 
kinases (JNK) family (Adler et al. 1994). JNK, originally identified as a c-Jun associated 
kinase, is a serine/threonine kinase activated by phosphorylation by various stimuli, 
including DNA damaging agents, inhibitors of protein synthesis, heat shock and osmotic 
stresses (reviewed by Kyriakis et al. 1994). Phosphorylation of c-Jun controls its activity in 
two manners (Figure 5.2). On the one hand, the tight association between JNK and c-Jun, 
which is independent on the activation status of JNK, targets c-Jun for ubiquitinylation and 
on the other hand phosphorylation at Ser^  ^by JNK is sufficient to protect the protein from 
ubiquitinylation resulting in increased protein stabilization (Fuchs et al. 1997) (Figure 5.3). 
This probably occurs through a conformational change of c-Jun after phosphorylation 
which consequently affects its affinity for JNK.
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Figure 5.1 -  AP-1 transcription factors: stimuli and responses
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Figure 5.3 -  c-Jun regulation by JNK
A) JNK tightly binds to the Ô domain of c-Jun independently on its activation status. This 
association leads to ubiquitinylation of c-Jun and its subsequently degradation. B) After stress, 
JNK kinase, activated by phopshorylation via the MAP kinase pathway, phosphorylates c-Jun 
at serine and threonine phosphoacceptor sites. c-Jun is in turn activated at the transcriptional 
level and stabilized.
A few lines of evidence have demonstrated that in fibroblasts the mitogenic response of the 
cell is mediated through AP-1 activity, resulting in modulation of cell growth and 
proliferation (Brown et al. 1998; Kovary and Bravo 1991; Maki et al. 1987). c-Jun and c- 
Fos play also a major role in the cellular response to UV irradiation by protecting the cell 
from UV-induced cell death (Wisdom, 1999) (Schreiber et al. 1995). It was recently 
reported that c-Jun modulates cell proliferation and UV responses by distinct mechanisms, 
both involving modulation of the transcription of the cyclin D1 gene (Wisdom, 1999) 
(Wisdom et al. 1999). Regulation of cell proliferation does not require c-Jun 
phosphorylation, whereas phosphorylation of c-Jun at Ser^  ^and Ser^  ^sites with subsequent 
activation of the protein is necessary to protect the cell from UV-induced cell death.
c-Jun degradation pathways
c-Jun is a short-lived protein with a half-life of approximately 90 minutes (Treier et al.
1994). Tight temporal control of the activity of many regulators of gene transcription, 
including c-Fos, p53, c-Mos and c-Myc, shares this feature (Rogers et al. 1986). 
c-Jun and c-Fos are both degraded by the 26S proteasome complex (Treier et al. 1994; 
Papavassiliou et al. 1992; Ciechanover et al. 1991). However, several aspects of the 
regulation of AP-1 turnover are controversial, perhaps suggesting the participation of 
multiple pathways. Treier et a l showed that c-Jun is ubiquitinylated and degraded by the 
26S proteasome pathway in vivo (Treier et al. 1994) and in addition that the ô domain, a 27 
amino acid sequence located at NHg-terminus of the protein, is essential for c-Jun 
ubiquitinylation and its subsequent proteolysis. In line with these findings, the oncogenic 
counterpart v-Jun, which lacks the ô domain due to an in frame-deletion, was shown to have 
elevated protein stability in comparison to c-Jun (Treier et al. 1994). JNK binds to the Ô 
domain of c-Jun and consequently targets its substrate for ubiquitinylation (Fuchs et al.
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1996). In contrast, in vitro studies of AP-1 ubiquitinylation using reconstituted enzyme 
systems showed that c-Jun lacking the 8 domain and c-Fos lacking the PEST motif, a 
common sequence involved in the rapid destruction of short-lived proteins (Rogers et al. 
1986), can be efficiently ubiquitinylated (Hermida-Matsumoto et al. 1996). It was also 
reported that degradation of c-Jun by the 26S proteasome pathway does not require 
ubiquitinylation of the protein in vitro (Jariel-Encontre et al. 1995). Another number of 
substrates, including ornithine decarboxylase, is degraded by the 26S proteasome in a 
ubiquitin-independent manner. c-Jun might contain intrinsic signals for ubiquitin- 
independent recognition by the 26S proteasome complex and subsequent degradation. In 
addition, a role for calpains (calcium-dependent cystein proteases) in the degradation of c- 
Jun and c-Fos has been shown. However, these proteases may have only limited 
involvement in AP-1 turnover, as they are restricted to the cytoplasm (Jariel-Encontre et al.
1995).
Taken together, these data imply that the regulation of c-Jun and c-Fos turnover is complex 
and controversial but also establish that the major proteolytic pathway for their regulation 
involves the 26S proteasome pathway. Whether ubiquitinylation is an absolute requirement 
for the proteolyisis in vivo of these proteins, and whether different pathways co-exist, 
possibly depending on the physiological conditions of the cell or the cell type, are still open 
issues.
One interesting general observation that has recently come to light is the inverse correlation 
between the stability of transcriptional activators and their activation domain potency in 
vivo (Molinari et al. 1999). It seems that the rate of degradation of transcription factors by 
the 26S proteasome pathway strongly depends on the degree of their activity, as highly
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potent transcription activators are processed very rapidly in mammalian cells. In order to be 
degraded these activators must interact with their targets.
AP-1 and drug resistance
Some studies have suggested a role for AP-1 factors in the modulation of drug resistance in 
cancer cell lines. Multi-drug resistance MCF-7 breast cancer cells exhibited elevated 
expression of c-jun and c-fos genes together with elevated transcriptional and DNA binding 
activities of AP-1 (Daschner et al. 1999). AP-1 modulation of the MDR-1 gene, which 
contains a putative AP-1 binding site in its promoter region with consequent increase of 
MDR-1 mRNA and protein level have also been documented. Furthermore, c-Jun mRNA 
level and DNA binding activity of AP-1 were also reported to be elevated in etoposide 
resistant human leukemia cells (Ritke et al. 1994). Other reports have shown a positive 
correlation between AP-1 activation and glutathione-S-transferase levels in drug resistant 
cancer cell lines (Moffat et al. 1994; Puchalski and Fahl 1990).
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Results
HA-Pohl increases the activity of AP-1 transcription factors
The main question addressed in this chapter is by which molecular mechanism 
exogenously overexpressed HA-Pohl confers multi-drug resistance in mammalian 
cells. Genetic studies previously carried out in fission yeast showed that the drug 
resistance phenotype induced by HA-Pohl in S.pombe (like that of fission yeast 
Padl) is dependent on the AP-1-like transcription factor Papl (Spataro et al. 1997). 
To this end, the ability of overexpressed HA-Pohl to modulate the activity of the 
AP-1 transcription factors in mammalian cells was studied using two different 
approaches. The ability of AP-1 transcription factors to bind to its consensus DNA 
sequence was studied using an electrophoretic mobility shift assay, whereas 
transcriptional activity of AP-1 was measured using an AP-1-regulated promoter in 
a luciferase reporter assay.
To measure the DNA binding activity of AP-1, whole cell extracts (WCE) were 
prepared from polyclonal COS-7 cells stably expressing HA-Pohl or carrying the 
empty vector. As a positive control for AP-1 DNA binding, cells carrying the empty 
vector were also treated with the tumour promoter phorbol-12-myristate 13-acetate 
(PMA) for 6 hours. Phorbol esters are activators of protein kinase C and also potent 
inducers of AP-1 activity (Angel et al. 1987b). Equal amounts of whole cell extracts 
from both cell populations were incubated for 30 minutes at room temperature with 
a 21-bp [^^P]-labelled double stranded oligonucleotide (Figure A .l - Appendix), 
which contains the 8-bp AP-1 consensus DNA sequence 5' - TGAGTCAG - 3'. 
DNA/protein complexes were electrophoretically separated from free 
oligonucleotides under non-denaturing conditions. A more intense band
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correspondent to DNA/AP-1 complex appeared in PMA-treated and HA-Pohl- 
overexpressing cells in comparison with PMA-untreated cells carrying the empty 
vector (Figure 5.4A), demonstrating up-regulated binding of AP-1 to its cognate 
DNA sequence. As discussed above, AP-1 activity is regulated at both the 
transcriptional and the post-translational level. To investigate at which level the AP- 
1 DNA binding activity was modulated, the protein level of c-Jun, the main 
component of AP-1, was detected in whole cell extracts by immunoblot analysis 
using a rabbit polyclonal anti-c-Jun antibody (Figure 5.4B). In line with the elevated 
AP-1 DNA binding activity observed in these cells, approximately 20-fold and 3- 
fold increases of c-Jun protein level were observed in PMA-treated cells and HA- 
Pohl-overexpressing cells, respectively (Figure 5.4C). Detection of Cdc2 protein 
was also performed as a loading control using a monoclonal anti-Cdc2 (A 17) 
antibody (Figure 5.4B lower panel).
Given that c-Jun and c-Fos are nuclear transcription factors, AP-1 DNA binding 
activity was next assayed using nuclear extracts from polyclonal COS-7 cells 
expressing HA-Pohl or carrying the empty vector (Figure 5.5). For competition 
experiments, nuclear extracts were also pre-incubated with a 50-fold excess of 
unlabelled ("cold") AP-1 consensus or mutant oligonucleotides, in which the 
consensus nucleotides CA are changed in TC (Figure A.l - Appendix), for 20 
minutes before adding the labelled probe (Figure 5.5A). In accord with the previous 
result, cells expressing exogenous HA-Pohl showed an approximately 4-fold 
increase in AP-1 DNA binding in comparison with cells carrying the empty vector. 
This experiment also established that the DNA/AP-1 complex is AP-1 specific, as 
when an excess of unlabelled consensus probe was added to the binding reaction as
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Figure 5.4 - HA-Pohl overexpression leads to increased AP-1 binding activity and c- 
Jun protein level in COS-7 cells
An electrophoretic mobility shift assay was performed using whole cell extracts (WCE) 
prepared from polyclonal populations stably transfected with empty vector (pcDNA3.1+), 
mock or PMA (6 hours) treated, or pcDNA3/HA-P0H1 vector. B) Immunoblot analysis of 
c-Jun protein level in WCE as in A using rabbit polyclonal anti-c-Jun antibody. Cdc2 
protein was detected as loading control using mouse monoclonal anti-Cdc2 antibody. C) 
Densitometric analysis of c-Jun protein level from panel B. * non-specific band
* Non-specific band
competitor, the binding of AP-1 to its DNA sequence was abolished. In contrast the 
presence of an excess of unlabelled AP-1 mutant oligonucleotide did not affect the 
binding reaction. Additionally, 2.3- and 3.5-fold increases of c-Jun and c-Fos 
protein levels were observed by immunoblot analysis using rabbit polyclonal 
antibodies against c-Jun and Fos, respectively (Figure 5.5B and C). Detection of 
Hapl DNA repair endonuclease in the same nuclear extracts was also performed as 
loading control (Figure 5.5B).
These results were further supported by the positive modulation at AP-1 DNA 
binding activity and protein level observed after doxycyclin inducible expression of 
HA-Pohl in human U2-OS cells (Figure 5.6 A and B).
Next, the possible effect of overexpressed HA-Pohl on AP-1 transcriptional activity 
was investigated using an AP-1-dependent luciferase reporter assay. This assay is 
based on transient co-transfection of the reporter and internal control plasmids. The 
reporter pColLuc3 (kindly provided by Dr. J.Tavare) drives the expression of firefly 
luciferase under the control of the collagenase promoter, which contains the TPA- 
responsive element (TRE) and is strongly modulated by AP-1 transcription factors 
(Angel et al. 1987b). The pRh-TK-Renilla plasmid, constitutively expressing 
Renilla luciferase from the thymidine kinase (TK) gene promoter, was used as 
internal control for transfection efficiency (Figure 5.7). Firefly and R enilla  
luciferases have different evolutionary origin and use different substrates allowing a 
sequential measurement of their activities from a single sample. COS-7 cells 
carrying the empty vector or overexpressing HA-Pohl (polyclonal pool, clone 2 and 
clone 25) (Figure 5.8A) and inducible human U2-0S cells (clones 15, 33 and 57), 
mock or doxycyclin treated for 24 hours (Figure 5.8B), were transiently co-
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Figure 5.5 - HA-Pohl overexpression leads to up-regulation of both AP-1 binding activity 
and c-Jun and c-Fos protein levels in COST cells
A) Electrophoretic mobility shift assay using nuclear extracts (NE) prepared from COST 
polyclonal cells stably transfected with empty vector (pcDNA3.1+) or pcDNA3/HA-POHL 5 
pg of NE were incubated with 0.5 ng of ^^P-labelled AP-1 consensus oligonucleotide for 30 
minutes at room temperature. For competition experiments, a 50-fold excess of unlabelled AP- 
1 consensus or mutated oligonucleotides were pre-incubated with NE at room temperature 20 
minutes before adding the labelled probe. B) Immunoblot analysis of c-Jun and c-Fos protein 
levels in NE (60 pg). Detection of c-Jun and c-Fos was carried out using rabbit polyclonal anti- 
c-Jun and anti-c-Fos antibodies, respectively. As a loading control DNA repair endonuclease 
Hapl was detected. C) Densitometric analysis of c-Jun and c-Fos protein levels from panel B.
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Figure 5.6- Inducible expression of HA-Pobl up-regulates AP-1 protein levels and 
DNA binding activity in buman cells
An electrophoretic mobility shift assay was performed using nuclear extracts (NE) 
prepared from U2-0S clone 33 cells, mock (-) or doxycyclin (+) treated. For competition 
experiments 50-fold excess of unlabelled AP-1 consensus or mutated oligonucleotides 
was used. B) Detection of c-Jun and c-Fos protein level in nuclear extracts (40 pg) from 
U2-0S clone 33 cells, mock or doxycyclin treated, by immunoblot analysis. As loading 
control DNA repair Hapl protein was detected.
* Non-specific band
transfected with the reporter and control plasmids at a ratio of 15:1. 48 hours later 
the cells were lysed and assayed for both luciferase activities using the dual 
luciferase reporter kit. The results, expressed as fold-increase of AP-1-dependent 
relative luciferase activity (RLA) (the ratio between firefly and Renilla activities) 
(Figure 5.8) were not striking but always consistent with an average of 2-fold 
increase in AP-1 transcriptional activity after either constitutive (Figure 5.8A) or 
inducible overexpression of HA-Pohl in mammalian cells (Figure 5.8B).
It is noteworthy that COS-7 cells from clone 2, which previously showed a better 
expression level of exogenous HA-Pohl and a greater survival advantage in 
response to drug treatment in comparison to other HA-Pohl-overexpressing 
populations (Chapter 3), here also exhibited the highest AP-1-dependent luciferase 
activity (6-fold increase) (Figure 5.8A), as confirmed in two independent 
experiments.
Taken together, these data demonstrate that exogenously expressed HA-Pohl 
positively modulates DNA binding and transcriptional activities of AP-1 
transcription factors in mammalian cells.
Ubiquitinylation of AP-1 in HA-Pobl expressing cells
Both c-Jun and c-Fos are ubiquitinylated and degraded by the 26S proteasome 
pathway (Ciechanover et al. 1991; Papavassiliou et al. 1992; Stancovski et al. 1995; 
Treier et al. 1994). Since Pohl is a regulatory subunit of the 26S proteasome 
complex (Spataro et al. 1997), involved in ubiquitin-dependent protein degradation, 
it was of interest to determine whether up-regulation of AP-1 activity is caused via 
modulation of c-Jun and c-Fos ubiquitinylation in HA-Pohl overexpressing cells.
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Figure 5.7- Constructs used for AP-1-dependent luciferase reporter assay 
pColLucS vector drives the expression of firefly luciferase under the control of the 
collagenase promoter, which contains the 9-bp consensus AP-1 responsive element 
TGAGTCA. pRL-TK-jRgw///a, in which the promoter from the thymidine kinase (TK) gene 
drives constitutive expression of Renilla luciferase, is used as an internal control of 
transfection
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Figure 5.8 - HA-Pohl overexpression increases AP-1 transcriptional activity
Luciferase reporter assay for AP-1 transcriptional activity. COS-7 cells from the 
polyclonal pool and stable clones 2 and 25 expressing HA-Pohl or cells carrying the 
vector alone (A) and U2-0S inducible clones mock or doxycyclin treated (B) were co­
transfected with pColLucS and the pRL-TK~Renilla plasmids at a ratio of 15:1. Firefly 
and Renilla luciferase activities were measured using the dual Luciferase Reporter Kit 
(Promega). Results are expressed as fold-increase of the relative luciferase activity (the 
ratio between the firefly and the Renilla activities) in cells overexpressing HA-Pohl in 
comparison with cells carrying the empty vector (A) or doxycyclin un-treated (B). 
Standard deviation is indicated by the dark blue shading in (A).
First, total protein ubiquitinylation was measured in polyclonal COS-7 cells carrying 
the empty vector or overexpressing HA-Pohl. Cells were lysed in 2x SDS sample 
buffer and protein ubiquitinylation was analyzed by immunoblot using polyclonal 
anti-ubiquitin antibody. HA-Pohl overexpression did not have any effect on total 
protein ubiquitinylation (Figure 5.9). This experiment further demonstrated that 
ubiquitinylation of total proteins was inefficiently detected by the anti-ubiquitin 
antibody used. In line with this the detection of ubiquitinylated c-Jun and c-Fos 
attempted after immunoprécipitation was unsuccessful.
To overcome this technical problem, pcDNAl/HA-Ub plasmid (kindly provided by 
Dr. N.Masson) expressing HA-tagged Ubiquitin was used. Human U2-OS cells 
from clone 57, mock or doxycyclin treated for 24 hours, were transiently transfected 
with pcDNA/HA-Ub. As a control of transfection efficiency, equal numbers of cells 
were lysed in 2x SDS sample buffer and HA-ubiquitin was detected by immunoblot 
analysis using HRP-conjugated monoclonal anti-HA antibody (Figure 5.10A). c-Jun 
was then immunoprecipitated in parallel from whole cell lysates using a rabbit 
polyclonal anti-c-Jun antibody, and c-Jun ubiquitinylation and expression were both 
detected by immunoblot analysis using HRP-conjugated monoclonal anti-HA and 
rabbit polyclonal anti-c-Jun antibodies, respectively. The results indicate that 
overexpression of HA-Pohl does not affect the general level of c-Jun 
ubiquitinylation in human cells, although a band of about 60 kDa that might 
correspond to tetraubiquitinylated c-Jun was reduced in cells treated with 
doxycyclin (Figure 5.10A and B).
The experiment was repeated in order to detect ubiquitinylated forms of both c-Jun 
and c-Fos after their immunoprécipitation (Figure 5.11). A lower level of
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Figure 5.9 - HA-Pohl overexpression does not affect general protein 
ubiquitinylation in COS-7 cells
A) Immunoblot analysis of total protein ubiquitinylation in whole cell lysates of COS-7 
cells carrying the empty vector or stably expressing HA-Pohl. Protein ubiquitinylation 
was detected using a rabbit polyclonal anti-ubiquitin antibody. B) Detection of 
overexpressed HA-Pohl in the same whole cell lysates as in A using HRP-conjugated 
monoclonal anti-HA antibody.
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Figure 5.10- Ubiquitinylation level of c-Jun in human cells overexpressing HA- 
Pohl
c-Jun ubiquitinylation in U2-0S cells from clone 57 mock (-) or doxycyclin (+) 
treated for 48 hours after transient transfection of pcDNA/HA-Ub vector encoding 
HA-Ubiquitin. A) Anti-HA immunoblot of whole cell extracts. B) c-Jun detection in 
a-c-Jun immunoprecipitates. C) Detection of c-Jun ubiquitinylation level in 
immunoprecipitates using HRP-conjugated monoclonal anti-HA antibody.
ubiquitinylated c-Jun bands was observed in doxycyclin-induced cells in 
comparison with un-induced cells (Figure 5.1 IB), whereas ubiquitinylation of c-Fos 
did not show any significant difference between un-induced and induced cells. As a 
control of transfection efficiency the total level of HA-ubiquitinylation in the 
different cell lysates before immunoprécipitation was also detected, which was 
indicative of equivalent transfection efficiency in the different cell populations 
(Figure 5.11 A). The protein level of c-Jun in a-c-Jun immunoprecipitates is also 
shown, however it was not possible to detect c-Fos in a-c-Fos immunoprecipitates 
since the protein migrates in close proximity to the IgG band (Figure 5.11C). 
Detection of c-Jun ubiquitinylation was further repeated but the results were not 
always reproducible.
Another approach for the study of c-Jun ubiquitinylation was next used. Human U2- 
OS cells were mock or doxycyclin treated for 24 hours and then transiently co­
transfected (1:1 ratio) with pcDNA/HA-Ub and pMT35/c-Jun-HiSg, which encodes 
human c-Jun fused to a His^-tag sequence at its COOH-terminus. c-Jun-HiSg was 
purified from extracts of mock or doxycyclin treated cells by nickel chelate affinity 
chromatography. Lysis buffer alone was used as negative control for protein 
purification. Although c-Jun protein level, as detected by immunoblotting using a 
rabbit polyclonal anti-c-Jun antibody, seemed to differ between doxycyclin 
untreated and treated cells (Figure 5.12A), its ubiquitinylation level, detected using 
HRP-conjugated monoclonal anti-HA antibody, did not appear to be different 
(Figure 5.12B).
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Figure 5.11 - Ubiquitinylation level of c-Jun and c-Fos in U2-OScells overexpressing 
HA-Pohl
Immunoprécipitation of c-Jun and c-Fos and detection of their ubiquitinylation levels in U2- 
OS cells from clone 57 mock (-) or doxycyclin (+) treated after transient transfection with 
pcDNA/HA-Ub. A) Anti-HA immunoblot of whole cell extracts B) Detection of c-Jun and c- 
Fos ubiquitinylation level in a-c-Jun and a-c-Fos immunoprecipitates using HRP-conjugated 
monoclonal anti-HA antibody. C) c-Jun detection in a-cJun immunoprecipitates.
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Figure 5.12 -  Ubiquitinylation level of c-Jun is not affected by HA-Pohl over expression
c-Jun ubiquitinylation level in U2-0S cells from clone 57 mock (-) or doxycyclin (+) treated 
for 48 hours. A) Purification of c-Jun-HiSg by nickel chelate affinity chromatography after 
transient co-transfection of cells with c-Jun-HiSg and HA-Ubiquitin expressing vectors. c-Jun 
was detected by immunoblot analysis using a rabbit polyclonal anti-c-Jun antibody. B) 
Detection of c-Jun-His^ ubiquitinylation level after purification by nickel chelate 
chromatograpgy and immuniblotting using an HRP-conjugated monoclonal anti-HA 
antibody. Detection of doxycyclin induced HA-Pohl is also shown.
HA-Pohl co-immunopredpitates with c-Jun
By studying the possible effect of overexpressed HA-Pohl on ubiquitinylation of 
AP-1 subunits another result came to light. In panel B of Figure 5.12, which shows 
ubiquitinylation of the c-Jun-HiSg protein purified from human cells, a band of 37 
kDa corresponding to overexpressed HA-Pohl was detected in lysates from 
doxycyclin treated cells. This result was surprising as the purification of c-Jun-HiSg 
was performed in presence of guanidinium, which is highly denaturating. That 
might suggest that the His^-tagged protein purification was not clean and other 
proteins might also be present in the preparation or alternatively that the two 
proteins might associate through an interaction not dissociable under denaturating 
conditions, such as a covalent link. To investigate a possible interaction further, a 
more conventional approach was chosen. c-Jun was immunoprecipitated from 
human cells, mock or doxycyclin treated for 24 hours, and then c-Jun and HA-Pohl 
were detected using rabbit polyclonal anti-c-Jun and HRP-conjugated monoclonal 
anti-HA antibodies, respectively (Figure 5 .ISA and B). A band corresponding to 
HA-Pohl was detected in c-Jun immunoprecipitates from doxycyclin-treated cells 
(panel B, lane (+)), indicative of an association between the two proteins, whereas 
endogenous Pohl was not able to bind to c-Jun, as detection of Pohl using rabbit 
polyclonal anti-Pohl CN13 antibody (panel C) did not show any specific signal. 
These results are in support of the previous observation (Figure 5.12) and further 
demonstrate that exogenous but not endogenous Pohl is able to associate with c- 
Jun. Whether or not the two proteins interact directly remains to be established.
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Figure 5.13- Exogenous HA-Pohl co-immunoprecipitates with c-Jun in human 
extracts
Immunoprécipitation of c-Jun from U2-0S clone 33 cells, mock (-) or doxycyclin (+) 
treated for 48 hours. Immunecomplexes were subjected to immunoblot analysis and 
detection of c-Jun (A), HA-Pohl (B) or Pohl (C) using rabbit polyclonal anti-c-Jun or 
HRP-conjugated monoclonal anti-HA, rabbit polyclonal anti-Pohl CN13 antibodies, 
respectively. Lysis buffer alone was used as negative control.
HA-Pohl overexpression increases c-Jun protein stability
To further investigate how HA-Pohl overexpression might cause up-regulation of c- 
Jun protein level and consequently increase AP-1 activity, c-Jun protein stability 
was next studied. To this end, U2-OS cells were mock or doxycyclin treated for 48 
hours and cell extracts were prepared in order to perform an in vitro degradation 
assay.
Two different substrates (both a generous gift from Dr. D. Kardassis) were used.
• pcDNAl/c-Juni_287 encodes human c-Jun lacking the leucine zipper domain; 
the protein can still be ubiquitinylated and degraded by the 26S proteasome 
pathway
• pcDNAl/c-JunA3.i22 expresses human c-Jun lacking the 0-domain, which 
contains the site of ubiquitinylation; the substrate is used as a negative control 
since the protein cannot be ubiquitinylated or degraded by the proteasome
Both plasmids were used to generate f  ^ S]-labelled in vitro translated protein using 
the TNT quick transcription/translation system which exploits T7 promoter of the 
pcDNAl vector.
Equal amounts of each extract were incubated with an energy-regenerating system 
and ATP before adding the [^^S]-labelled in vitro translated c-Juni.287 or c-JunA3.i22- 
In vivo c-Jun is a short-lived protein with a half-life of 90 minutes (Treier et al. 
1994), therefore time points of 0, 20, 40, 70, 100 and 160 minutes were chosen. The 
reactions were performed at 30°C and at each time point were stopped through the 
addition of an equal amount of 2x SDS sample buffer. Samples were subsequently 
separated by 12% SDS-PAGE. The substrate c-Juni.287 was degraded in cell extracts 
from mock treated cells showing a half-life of approximately 90 minutes, in accord 
with the one previously reported (Treier et al. 1994). In contrast, extracts from cells
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treated with doxycyclin showed a slower degradation rate of c-Jnni.zg?, indicative of 
an elevated stability of the protein in cells overexpressing HA-Pohl (Figure 5.14A). 
As expected, the protein level of the negative control substrate c-JunA3.i22 did not 
change over the same time course. Densitometric analysis of c-Juni.287 protein level 
is also presented and expressed as the mean of the results observed in two 
independent experiments (Figure 5.14B). It is worthy to note the disappearance of 
the three upper bands in respect to c-Juni.287 corresponding to the phosphorylated 
forms of c-Jun, which was observed already after 20 minutes during the time-course 
in the doxycyclin-treated cells only.
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Figure 5.14 - HA-Pohl overexpression increases c-Jun protein stability
A) In vitro degradation assay of human c-Jun,.287. lacking the leucine zipper domain, and 
human c-Jun A 3.,22, deleted in the Ô domain, as a negative control, after ^^S-labelled in 
vitro protein translation using TNT T7 quick transcription/translation system. Samples 
were collected at time points 0, 20, 40, 70, 100 and 160 minutes. B) Densitometric 
analysis of c- Jun,_2g7 protein level obtained in two independent experiments. Results are 
expressed as a percentage of degraded substrate in respect to the amount of protein at time 
0 .
Discussion
It is shown here that constitutive or inducible overexpression of the highly 
conserved 26S proteasome regulatory subunit Pohl in monkey COS-7 and human 
U2-OS cells, respectively, led to elevated AP-1 transcriptional and DNA binding 
activities and in addition to an up-regulation of c-Jun and c-Fos protein levels.
In line with these results, the overexpression of S.pombe Padl is able to elevate the 
transcriptional activity of Papl (Shimanuki et al. 1995), and pleiotropic resistance 
conferred by exogenously expressed HA-Pohl/Padl and other determinants of drug 
resistance in S.pombe is genetically dependent on papl'^ (see Chapter 1.2) (Claret et 
al. 1996; Crane et al. 2000; Shimanuki et al. 1995; Spataro et al. 1997; Toda et al. 
1992). In contrast, modulation neither of Papl protein level nor of its DNA binding 
activity after exogenous expression of Padl or other determinants of drug resistance 
in S.pombe was reported (Crane et al. 2000; Shimanuki et al. 1995; Toda et al. 
1992). In addition, a recent report described a role played by the budding yeast Pohl 
homologue R pn ll in the activation of the AP-1-like transcription factor Gcn4 
following exposure to UV light (Stitzel et al. 2001).
This body of evidence highlights the key role played by the basic leucine zipper 
transcription factor Papl in the modulation of drug resistance in S.pombe. It also 
suggests that different determinants, if overexpressed or deregulated, are able to 
activate a common pathway with the consequent transcriptional activation of 
downstream targets which positively mediate cell survival. The results presented 
here also provide evidence that at least some aspects of this response to cytotoxic 
agents are conserved between fission yeast and human cells.
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Elevated stability of c-Jun and a possible alteration of its steady state 
ubiquitinylation level was also observed in HA-Pohl overexpressing eells. As 
shown in figure 5.14, the increased stability of c-Jun was coincident with the 
dephosphorylation of the protein in the doxycyclin-treated cells. This would be in 
contrast with the JNK-dependent phosphorylation of e-Jun in vivo at ^^Ser and 
particularly ^^Ser and its subsequent stabilization and transcriptional activation 
(Fuchs et al. 1997). Nevertheless, the nature of the c-Jun phosphorylated forms in 
the reticulocyte lysates still awaits clarifications. The 26S proteasome regulatory 
particle of which Pohl is a component (Glickman et al. 1998b; Spataro et al. 1997) 
is necessary for the recognition of ubiquitinylated substrates (Deveraux et al. 1994) 
and the 26S proteasome is the major site of degradation of both c-Jun and c-Fos. 
This body of evidence together with the modulation of AP-1 by HA-Pohl presented 
here sheds light on a possible regulatory network involving proteolysis, 
transcriptional regulation and drug resistance.
Exogenously expressed HA-Pohl but not endogenous Pohl co-immunoprecipitated 
with c-Jun. In line with this finding, Padl/Pohl and Jabl were reported to share 
similarity at their NHz-terminus. Jabl (CSN5) is a subunit of the COP9 signalosome 
complex and was initially identified as a protein able to interact with the NH2- 
terminus of e-Jun and as a transcriptional co-activator of c-Jun (Claret et al. 1996; 
Seeger et al. 1998). In addition, Jabl can confer drug resistance when expressed in 
S.pombe through a Papl-dependent mechanism and the protein was defined as the 
first mammalian co-activator able to modulate gene expression in yeast (Claret et al. 
1996). The complexes in which Pohl and Jabl are associated, the 26S proteasome 
lid and C0P9 signalosome, share common structural features (Aravind, 1998;
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Hofmann, 1998) and they have been proposed to have a common evolutionary 
origin (Wei and Deng 1999).
Bearing in mind all these data, it is reasonable to propose a general model in which 
elevated levels of HA-Pohl confer pleiotropic drug resistance through modulation 
of AP-1 activity in mammalian cells. HA-Pohl may increase the protein stability of 
c-Jun, and possibly c-Fos, through either direct or indirect interaction with c-Jun 
resulting in up-regulation of AP-1 activity. This in turn would lead to elevated 
expression of downstream target genes possibly involved in positive modulation of 
cell survival or down-regulation of cell death. In line with this hypothesis, AP-1 
activity has been reported to be elevated in some multi-drug resistance cancer cell 
lines (Moffat et al. 1994; Daschner et al. 1999; Ritke et al., 1994) and in some cases 
has been associated with an up-regulation of the glutathione-S-transferases, whose 
role in drug detoxification is well established (McLellan and Wolf 1999).
Although these results suggest a molecular mechanism for the drug resistance 
mediated by HA-Pohl, they do not establish whether or not this resistance is 
mediated by the 26S proteasome. As shown in Chapter 3, just a minimal part of the 
exogenously expressed HA-Pohl seemed to be associated with the 26S proteasome 
in COS-7 cells. As shown by sucrose gradient the remaining exogenous protein 
appeared to be part of smaller sized complexes, although no data on the nature of 
these complexes are yet available.
Two alternative, but not mutually exclusive models are proposed (Figure 5.12). 
Model 1 involves a proteasome-independent pathway in which HA-tagged Pohl that 
is not associated with the 26S proteasome is able to bind c-Jun, either directly or 
indirectly, with subsequent inhibition of c-Jun turnover.
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Model 2 involves a proteasome-dependent mechanism. A small amount of 
overexpressed HA-Pohl can associate with the 26S proteasome lid, by competing 
with endogenous Pohl or in addition to it. This in turn may result in the disruption 
of 26S proteasome function, possibly by shifting the general equilibrium existing 
among the subunits of the lid, which is no longer able to recognize specific 
ubiquitinylated substrates, such as c-Jun.
Model 1 is preferred for the following reasons. Overexpressed HA-tagged Pohl in 
COS-7 cells is mainly found in comparatively small complexes not associated with 
the 26S complex, whereas all endogenous Pohl is associated with the 26S 
proteasome complex. At the same time, exogenous but not endogenous Pohl can co- 
immunoprecipitate with c-Jun suggesting an interaction between the two proteins. 
This interaction might also lead to the inhibition of c-Jun recognition by the E3- 
ligase and the subsequent reduction of c-Jun ubiquitinylation, as observed in figures 
5.10 and 5.11. Nevertheless, the modulation of c-Jun ubiquitinylation needs still to 
be fully demonstrated.
According to previous reports, approximately 0.1-1.0% of c-Jun is ubiquitinylated at 
any one time in vivo in line with other proteins that are degraded by ubiquitin- 
mediated proteolysis (see Treier et al. 1994). The low abundance of 
multiubiquitinylated substrates reflects their rapid turnover with a half-life of 
approximately 1 minute. With these data in mind, if the HA-Pohl-induced 
modulation of c-Jun occurred at level of ubiquitinylation, it is possible that the 
resulting change in steady state ubiquitinylated c-Jun could not be easily detectable. 
Furthermore, the equilibrium between substrate ubiquitinylation and 
deubiquitinylation, through the activities of isopeptidases or ubiquitin C-terminal 
hydrolases (reviewed by Ciechanover 1994), might be shifted towards the
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deubiquitinylation process. The final result would be no steady state accumulation 
of ubiquitinylated c-Jun. In these models only ubiquitin-dependent degradation of c- 
Jun is considered, whereas in vitro evidence of c-Jun ubiquitin-independent 
degradation has also been reported (Jariel-Encontre et al. 1995). Modulation of c- 
Jun stability by HA-Pohl through an ubiquitin-independent pathway could occur in 
either case.
Alternatively, a combination of models 1 and 2 could be proposed. HA-Pohl not 
associated with the 26S complex may disrupt the 26S proteasome activity, 
presumably interfering with the recognition of ubiquitinylated c-Jun and the 
consequent deubiquitinylation through the activity of the hydrolases. The amino acid 
sequence of Pohl and its fission yeast homologue Padl have a putative ubiquitin 
hydrolase motif, in which the catalytic residue is cysteine 120 (Figure 3.1); it was in 
fact previously proposed that Pohl could function as a ubiquitin hydrolase (Voges et 
al. 1999). However, preliminary experiments in which the putatively catalytic 
cysteine residue of Pohl was mutated to alanine (TGT to GCC) showed that 
Pohl (C l20A) is still able to confer drug resistance and to functionally complement a 
-deletion mutant in S.pombe, suggesting that the cysteine residue is not required 
for essential and drug resistance functions in S.pombe (Crane 2000).
143
i
I
à
.3 o V o
+
u
I
r
Iu
%I
B o
2
IiS
1
<
l l
i{
Ià
I
n
V. III
I
I ,
I I
g) 6
i S
!
î i
II
y  
.s ;
II"O ^ 
§ @ 
.g-':
a
■g K
H
I
I
Î
O
-o
I
K
VO^  \oI/i M
4i 1)
a t
I
1
I
I
§
O
fS
0) 0> 'O TJ
1 1
fa <  aa u
Chapter 6
The human WD-repeat Pwpl protein 
and drug sensitivity
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Overview
In chapters 6 and 7 I describe and discuss the characterisation of human Pwpl. This 
study was initiated following the identification of the S.pombe pw pP  as multi-drug 
resistance gene (Crane 2000). This study investigated whether the related human 
PWPl might be involved in multi-drug resistance in mammalian cells.
In this chapter I mainly introduce the WD-repeat protein family and describe what is 
known about one member of this family Pwpl in different species {S.pombe, 
S.cerevisiae and human). I show that the fission yeast and the human genes are not 
functional homologues and that overexpression of human hPW Pl in mammalian 
cells leads to pleiotropic drug sensitivity rather than drug resistance. The possible 
mechanism leading to this phenotype is also discussed.
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Introduction
The WD-repeat family
The WD-repeat is a large family of regulatory proteins characterised by a divergent 
unit repeated four to eight times within each polypeptide. Each repeat motif usually 
ends with the sequence Trp-Asp (WD). Proteins of this family are found in all 
eukaryotes but not in the prokaryotes. The WD-repeat family is also called the p- 
transducin family since this motif was first identified in the p-subunit of the 
heterotrimeric GTP-binding proteins (G proteins), which are involved in signal 
transduction (reviewed by Neer et al. 1994; van der Voom and Ploegh 1992).
The repeated unit consists of a region of variable length followed by a core of more 
or less constant length bracketed by two characteristic pattern elements, GH (Gly- 
His) andWD.
{X6.94- [ G H - X 23.41 -W D ]}
Most repeats are 36-46 amino acids long from WD to WD suggesting that this may 
represent the primordial length within which insertions or deletions have 
subsequently taken place. The WD repeat unit can be divided in the relatively 
conserved elements A and B which are separated by regions that are variable in 
sequence and length. The most important features of the repeat are the LxGH 
sequence in element A and the [DN]xxxxx[W,F,Y] [D,N] pattern in element B. The 
connecting regions nl and n2 contain many charged residues and prolines. It seems 
that element A is dispensable since it is absent from some members of the family 
such as Pwpl and Cdc20. In these cases no sequence conservation between regions 
upstream of part B has been observed (Neer et al. 1994).
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What is the function of the WD-repeat motif in the proteins? Its presence implies 
some common structural feature that may or not involve a functional relationship. In 
fact, the members of the WD-repeat family do not share any functional relationship 
and the cellular localization of these proteins is also different (reviewed by Neer et 
al. 1994; van der Voorn and Ploegh 1992). In addition, most of the members of the 
WD-repeat family are regulatory proteins (Neer et al. 1994). Given that tryptophan 
(Trp) is the least abundant and least mutable amino acid present in nature, it 
occupies a unique place in the protein structure and evolution. The presence of 
tryptophan in the WD-repeat motif would point towards a particular role in the 
function of these proteins and it has been suggested that the Trp residue could be 
involved in "stacking" interactions (Duronio et al. 1992).
WD-repeat proteins can also interact with other proteins through the WD-repeat 
motif with the subsequent formation of multiprotein complexes. For example, G|3- 
subunit in the heterotrimeric GTP-binding proteins associates tightly with Gy- 
subunit and simultaneously interacts with more than 15 different proteins (reviewed 
by Smith et al. 1999)). It has also been observed in yeast that some WD-repeat 
proteins genetically interact with members of the tetratricopeptide repeat (TPR) 
protein family. TPR-proteins contain multiple repeats 34 amino acids long of 
unknown function (van der Voorn and Ploegh 1992). As for the WD-repeat proteins, 
members of the TPR family are involved in many cellular regulatory processes and 
show different sub-cellular localizations. It has been suggested that the WD and the 
TPR motifs could form the basis of protein-protein interactions (van der Voorn and 
Ploegh 1992). Although both families exist in humans, it is still not clear whether 
members of the WD and the TPR families can interact in human and the possible 
nature of this interaction.
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The o p  subunit is the only WD-repeat protein whose crystal structure is known 
(Garcia-Higuera et al. 1998; Sondek et al. 1996). The seven WD repeats are 
arranged in a ring in order to form a propeller structure with seven blades. Each 
blade of the propeller consists of a four-stranded anti-parallel p sheet oriented in 
such a way that the outer surfaces of the torus are composed of the sheet edge, 
whereas the turns protrude from the two flat surfaces. It is likely that all the WD- 
repeat proteins form propeller structures, even if the WD-repeat motif is not 
essential to form a propeller. In fact, other families of proteins with no homology to 
the WD-repeat proteins form propellers whose blades are very similar to those in the 
Gp subunit (reviewed by Garcia-Higuera et al. 1998).
PWPI in different species 
5. cerevisiae PWPI
S. cerevisiae PWPI (ScPWPl) (periodic tryptophan protein 1) was first identified in 
1992 (Duronio et al. 1992) as a gene divergently transcribed from the Myristol- 
CoA:protein N-myristoyltransferase (NMTl) locus. The NMTl gene encodes an 
enzyme that catalyses the co-translocation attachment of the myristate via an amide 
bond to the Glyz residue at the NHj-terminal of some eukaryotic and viral proteins. 
These proteins are usually involved in the regulation of cell growth and 
differentiation. The translational start of PWPI and NMTl is 664 nucleotides distant 
and the genes are transcribed in the opposite orientation (Duronio et al. 1992).
The ScP^vpl amino acid sequence contains two acidic domains located in the amino- 
terminal and the carboxy-terminal of the protein (residues 23-109 and 524-276). 
Furthermore, the ScPwpl amino acid sequence has eight variable-length internal 
repeats, each containing an invariant tryptophan residue, a feature of proteins
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belonging to the WD-repeat protein family (Duronio et al. 1992). A positive charged 
cluster (residues 268-287) containing a putative nuclear localization signal (NLS) 
Lys-Lys-Lys-Ser-Lys (residues 273-277) was also identified. It has been proposed 
that basic highly charged region may be a feature of the regulatory proteins, such as 
the transcription factors (Brendel and Karlin 1989).
ScPWPl is a non-essential gene, but the deletion mutants grow slowly compared to 
wild type budding yeast (Duronio et al. 1992). The deletion mutants show also a 
reduced global protein synthesis.
ScPwpl shares similarity at the amino acid sequence level with Prp4 (pre-mRNA 
processing) (Duronio et al. 1992). Prp4, encoded by the essential gene PRP4, is a 
member of the WD-repeat family with predicted serine/threonine kinase activity and 
is the first putative protein kinase found to be involved in the process of mRNA 
splicing (Alahari et al. 1993; Gross et al. 1997). Prp4 is a component of the U4/U6 
snRNP particle, which mediates the splicing of nuclear pre-mRNA. The structural 
similarity between the Prp4 and the Pwpl sequences suggests that the two proteins 
may belong to the same subgroup of the WD-repeat family with a putative 
nucleotide binding activity (Duronio et al. 1992). It was speculated that the aromatic 
Trp residues might function similarly to the aromatic phenylalanine (Phe) residue, 
which is found in RNA-binding proteins containing the ribonucleoprotein consensus 
sequence and interacts directly with nucleotides (Duronio et al. 1992).
Human PWPI
Human PWPI (jaPWPl) was first described in 1994 (Honore et al. 1994). The 
protein has an open reading frame (ORF) of about 1.6 kb and a molecular mass of 
79.4 kDa. It contains 9 Trp residues some of which are localised in conserved
150
repeats and a putative nuclear localization signal (NLS) (KKKGK). The 2.4 kb 
mRNA is ubiquitously expressed with high amount in placenta, liver, skeletal 
muscle, kidney and pancreas. It was shown by cell fractionation that hPwpl protein 
was more abundant in the nucleus than in the cytoplasm of the human cell (Honore 
et al. 1994). The protein sequence also contains some putative phosphorylation sites 
and by cell f^P]-phosphate labelling and bidimensional (2-D gel) electrophoresis it 
was observed that the protein was, in fact, phosphorylated (Honore et al. 1994).
S. pombe pw pP
S.pombe pw pN  (SppwpP) was recently identified as a novel multi-drug resistance 
determinant during a fission yeast cDNA library screen (Crane 2000). 
Overexpression of fission yeast pwpN  under the control of the nm tl thiamine- 
repressible promoter from pREP3X vector (Maundrell 1993) caused resistance to 
MBC, caffeine, cadmium and staurosporine. The multi-drug resistance phenotype 
conferred by SpPwpl was dependent on fission yeast Papl (Crane 2000), previously 
observed for other determinants of multi-drug resistance in fission yeast (see 
Introduction Chapter 1).
Overexpressed HA-tagged SpPwpl in fission yeast localised in the cytoplasm and 
after sucrose density gradient centrifugation the protein was detected in fractions 
containing very large sized complexes.
S.cerevisiae PW Pi-deleted cells grew slowly in comparison with the wild-type 
(Duronio et al. 1992). In contrast, fission yeast pwpN  is essential, as the disruption 
of its open reading frame (ORE) caused lost of cell viability (Crane 2000).
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Results
Human HA-PWPl in fission yeast
S.pombe pw pP  was recently described as multi-drug resistance gene (Crane 2000). 
Fission yeast pw pP  and human PWPI share 34% of identity at the amino acid level 
(Figure 6.1), so the possibility that this phenotype was conserved from yeast to 
human was explored.
To investigate if human PWPI is a functional homologue of S.pombe pw pP , the 
human gene was first expressed in fission yeast cells. The full-length human cDNA 
sequence, a generous gift of Dr. J.Celis (Arhaus University, Denmark), was 
amplified using polymerase chain reaction (PCR) and cloned in the fission yeast 
expression vector pREP3X (by S.Carrobbio), which expresses the gene under the 
control of the nmtl thiamine-repressible promoter (Maundrell 1993). The pREP3X 
vector was previously modified by insertion of a triple HA-epitope tag sequence in 
its multicloning site (by R.Craig) and the 5'-end of hPWPl sequence was fused to 
the 3 -end of the HA sequence. The vector pREP3X/HA-hPWP 1 was transformed by 
electroporation into S.pombe leul-32 cells and the plasmid-containing cells were 
selected by plating them onto EMM2 agar plates lacking leucine. Cells were then 
grown in presence or in absence of thiamine [10 [ig/ml] for at least 16 hours in order 
to allow the expression of the gene and hPwpl protein was detected by immunoblot 
analysis using an HRP-conjugated monoclonal anti-HA antibody (Figure 6.2). The 
exogenous human protein migrated approximately at 80 kDa, in accord with the size 
of 79.4 kDa of the human protein (Honore et al. 1994). In contrast, when the nmtl 
promoter was repressed through the addition of thiamine no expression of the HA- 
hPwpl protein was observed (Figure 6.2).
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Figure 6.1 - Protein sequence alignment oî PWPI homologues from yeast and 
human cells
The residues present at identical positions in two or more proteins are highlighted 
in black and the conservative substitutions in grey.
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Figure 6.2 -  Expression of human HA-hPwpl in S.pombe cells
Immunoblotting of human HA-tagged Pwpl in fission yeast. Cells carrying the 
pREP3X/HA-hPWPl plasmid were grown with (+) or without (-) thiamine for 16 hours. 
Detection of HA-hPwpl protein was performed by immunoblot analysis using HRP- 
conjugated monoclonal anti-HA antibody.
EMM2 MBC [15 pg/ml] Caffeine [17.5 mM]
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Figure 6.3 -  Expression of human Pwpl in S.pombe does not confer pleitropic drug 
resistance
S.pombe leul-32 cells transformed with pREP3X, pREP3X/HA-pwpH and pREP3X/HA-PWPl 
were grown for 16 hours in the absence of thiamine. Serial dilutions of each culture (10000, 
1000, 100 and 10 cells) were plated as indicated onto EMM2 agar containing no drug (left 
panel), 15 pg/ml MBC (middle panel) or 17.5 mM caffeine (right panel). Plates were incubated 
at 30°C for 3-4 day and photographed.
Next, the capacity of the human protein to confer pleitropic resistance to cytotoxic 
drugs in fission yeast was investigated. Fission yeast cells were transformed with the 
empty vector (pREPSX) or the vector expressing the HA-tagged S.pombe pw pP, as 
a positive control, or human PWPI. The transformed cells were plated onto the agar 
plates containing MBC, caffeine or no drug (Figure 6.3). As previously shown 
(Crane 2000), overexpressed S.pombe pw pP  is able to confer pleiotropic resistance 
after exposure of the cells to MBC and caffeine, whereas overexpressed hPWPl did 
not induce this phenotype.
S.pombe pwpN  is an essential gene and the expression of the human gene in 
S.pombe pw pi "^-deleted mutants was not able to rescue the viability of the cells 
(Crane 2000).
These results taken together suggest that the S.pombe and human pwpN/PWPl 
genes are not functional homologues.
Stable expression of hPwpl in mammalian cells
To characterise human PWPI in mammalian cells, tetracycline repressible 
expression (see Introduction of Chapter 4) was first attempted in human cells using 
pRetro OFF vector. In this "Tet-off" system tetracycline acts as repressor. This 
system was attractive because a single vector contains all the essential elements for 
regulatable gene expression (see A.4 - Appendix).
1. The tTA gene encoding the tetracycline transactivator which regulates the 
expression of the gene of interest
2. A multicloning site (MCS) for the cloning of the gene of interest which is 
expressed under the control of a tetracycline responsive element (TRE) within 
the promoter
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3. A puromicine resistance gene for stable selection of the transfectants
HA-tagged hPWPl cDNA was cloned into pRetro OFF vector and expressed in the 
NCI-H460 human small cell lung cancer line, chosen because it is comparatively 
sensitive to cytotoxic drugs (C.Norbury, personal communication). Unfortunately, 
none of the puromycine-resistant clones obtained expressed HA-hPwpl protein, as 
detected by immunoblot analysis using an antibody against the HA-epitope tag of 
the protein. Expression of HA-Pwpl was detected only once after transient 
transfection of the plasmid in these cells (data not shown). Transient transfection of 
the plasmid in human HeLa cells was also performed but again no expression was 
seen. Given that the calf serum present in the medium culture may contain small 
amounts of tetracycline, the possibility that this tetracycline might inhibit expression 
of the gene was also addressed. Therefore, tetracycline-free serum was tested but the 
results were unchanged.
Next, the human gene was expressed using isopropyl-P-D-thiogalactopyranoside 
(IPTG) inducible expression in the human HT 1080 fibrosarcoma cell line. A 
significant number of positive clones stably expressing HA-hPwpl after induction 
with IPTG were obtained. Despite this, the degree of induction by IPTG was only 
very modest. In accord with this result, it has been reported that IPTG acts as a slow 
and often inefficient inducer leading to moderate induction of gene expression 
(Gossen and Bujard 1992).
Subsequently, to obtain a better expression level of the exogenous protein inducible 
expression was substituted with constitutive expression of HA-hPwpl. The HA- 
hPWPl open reading frame was cloned into the pcDNA3.1+ mammalian expression 
vector (pcDNA3.1 /HA-hPWP 1 ) and the empty pcDNA3.1+ vector or 
pcDNA3.1/HA-hPWPl were co-transfected with the pOPRV-CD2 plasmid into
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monkey COS-7 cells at a ratio of 4:1. 24 hours later the CD2^ cells were selected 
using anti-CD2 magnetic beads (see Figure 3.6 in Chapter 3). Cells containing the 
empty vector or the HA-hPwpl-expressing vector were then selected for two weeks 
with G-418, in order to generate stable polyclonal populations, and expression of 
HA-hPwpl in whole cell lysates from the two cell populations was then analysed by 
immunoblotting. A band with a molecular mass of approximately 80 kDa was 
detected only in the cell lysates from HA-Pwpl expressing cells using HRP- 
conjugated monoclonal anti-HA antibody (Figure 6.4A). Several stable clones were 
subsequently derived from the polyclonal pool (see Materials and Methods - Chapter 
2) and the expression of HA-Pwpl in three of them is also shown (Figure 6.4B). 
With the aim of identifying also the endogenous protein, polyclonal antibodies 
against human Pwpl were prepared using two different approaches. First, a fusion 
protein of hPWPl and glutathione-S-transferase (GST) was generated using the 
pGEX-4T-3 vector. The GST-hPWPl expressing plasmid was then transformed into 
E.coli BL21 and expression of the fusion protein was induced through the addition 
of IPTG for two hours. After cell lysis and separation of the proteins by SDS-PAGE, 
the induced GST-Pwpl fusion protein was detected by Coomassie blue staining 
(Figure 6.5A). Next, bacterial cells were fractionated after induction with IPTG and 
the overexpressed GST-fusion protein was mainly found in the insoluble fraction 
(Figure 6.5B). This fraction was further used to purify the GST-hPwpl protein with 
the purpose of raising polyclonal antibodies against it. Unfortunately, in two 
independent preparations the anti-hPwpl antibodies were not able to specifically 
recognise the human protein by immunoblot analysis, after expression either in 
COS-7 or in fission yeast cells. Therefore, a second approach was used. Peptides 
were designed corresponding to the amino-terminus and the carboxy-terminus of the
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Figure 6.4 -  Stable expression of HA-hPwpl in mammalian cells
Immunoblot analysis of HA-hPwpl protein. Whole cell lysates were prepared from 
COS-7 polyclonal pools stably expressing HA-hPwpl or carrying the empty vector 
(pcDNA3.1+) (A) and some stable clones derived from the polyclonal population (B). 
Detection of the protein was carried out using HRP-conjugated monoclonal anti-HA 
antibody.
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Figure 6.5 - Expression of the GST-hPwpl recombinant protein in E.coli
Coomassie brilliant blue staining of GST-hPwpl fusion protein expressed in E.coli BL21. 
A) E.coli BL21 transformed with pGEX-4T-3/hPWPl were grown in LB medium to an 
A395 of 0.5. Cells were mock (-) or IPTG [0.5 mM](+) treated for 2 hours in order to 
induce GST-hPwpl expression and then lysed in 2x SDS sample buffer. Aliquots from 
each sample were separated by 10% SDS-PAGE and stained with Coomassie blue. B) 
After IPTG induction, the bacterial cells were also fractionated by ultracentrifugation and 
the pellet (P) and the supernatant (S) were collected, lysed in 2x SDS sample buffer and 
separated by 10% SDS-PAGE. The proteins were stained by Coomassie brilliant blue.
protein. After synthesis (ICRF Biological Resources) the peptides were conjugated 
with Keyhole Limpet Haemocyanin (KLH), used as carrier, and then used for rabbit 
immunization. The antibodies were tested by immunoblot analysis and the rabbit 
polyclonal antibody CN35 was able to recognise the endogenous hPwpl (Figure 
6 .6A). A short and a long exposure of immunoblot in panel A of the Figure are 
shown and in addition to the band of about 80 kDa corresponding to hPwpl two 
more slowly migrating bands were identified (lower panel in A). This pattern was 
always observed using this antibody. Detection of HA-tagged hPwpl was also 
carried out in the same cell lysates as a positive control (B).
hPwpl overexpression confers pleiotropic drug sensitivity
The drug susceptibility of cells stably expressing HA-hPwpl was investigated using 
clonogenic survival assays. The survival of COS-7 cells carrying the empty vector 
or over-expressing HA-hPwpl was compared after exposure to a given cytotoxic 
drug for 24 hours. Figure 6.7 shows that overexpression of HA-tagged hPwpl 
causes sensitivity to unrelated drugs, such as cisplatin, 7-hydroxystaurosporine 
(UCN-01) and vincristine sulphate. Given that these drugs have diverse mechanisms 
of action, I refer to this phenotype as a multi-drug sensitive phenotype.
These results were unexpected. Although the overexpression of the human gene in 
S.pombe did not confer pleiotropic drug resistance (Figure 6.3), it was anticipated 
that the overexpression of human PWPl in mammalian cells might be able to trigger 
the same cellular response induced by the S.pombe gene after exposure of the cells 
to drugs.
Given that the phenotypes observed in human and fission yeast cells were opposite, 
it was addressed if the HA-epitope tag fused to the amino-terminus of hPwpl was
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Figure 6.6 -  Detection of hPwpl protein in COS-7 cells using rabbit polyclonal 
anti-Pwpl CN35 antibody
Immunoblot analysis of COS7 cell lysates from polyclonal pools stably expressing 
HA-hPwpl or carrying the empty vector (pcDNA3.1+). Whole cell lysates were 
processed by immunoblot using rabbit polyclonal anti-PwplCN35 antibody (A) or 
HRP-conjugated monoclonal anti-HA antibody (B).
somehow disrupting the function of the protein resulting in a dominant-negative 
phenotype. To this end, the un-tagged hPWPl cDNA was cloned into pcDNA3.l4- 
(pcDNA3.1/hPWPl) and stably expressed in COS-7 cells using the same 
transfection strategy previously used for the HA-tagged gene. At this stage it was 
not possible to detect endogenous or un-tagged Pwpl by immunoblot analysis 
because the initial preparations of polyclonal anti-Pwpl antibodies were 
unsuccessful. On the other hand, as it was observed that HA-tagged hPW Pl and 
POHl were efficiently expressed from the pcDNA3.1 vector, the drug susceptibility 
of cells expressing un-tagged hPwpl was tested. COS-7 cells carrying the empty 
vector or overexpressing un-tagged hPwpl were exposed to several concentrations 
of cisplatin and cell survival or cell viability was measured by clonogenic survival 
and MTS cytotoxicity assays, respectively (Figure 6.8). Un-tagged hPwpl induced 
sensitivity to cisplatin as previously observed for the HA-tagged protein, suggesting 
that the HA epitope tag is not responsible for hPwpl-conferred sensitivity.
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Figure 6.7 - HA-hPwpl stable expression confers pleiotropic drug sensitivity in 
mammalian cells
Clonogenic survival curves for C0S7 cells stably transfected with the empty vector 
(pcDNA3.1+) or pcDNA3.1/HA-hPWPl. 3000-4000 cells were plated in triplicate and 
treated with different concentrations of cisplatin (A), 7-hydroxystaurosporine (B) or 
vincristine sulphate(C) for 24 hours. Cells were then washed once with PBS and refed 
with fresh medium. The number of surviving colonies was counted after about 2 weeks 
and expressed as the percentage of the control (cells with no drug).
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Figure 6.8 - The HA-epitope tag fused to the hPWPl gene is not responsible for the 
drug sensitivity phenotype
A) Clonogenic survival curve for COS-7 stably transfected with the empty vector 
(pcDNA3.1+) or pcDNA3.1+/hPWPl and exposed to different concentrations of 
cisplatin for 24 hours. B) MTS cytotoxicity assay for the cells as in A. The number of 
surviving colonies or viable cells was expressed as the percentage of the survival or the 
viability of the control (cells with no drug) in A and B, respectively.
Discussion
The study of the human PWPl gene in relation to its putative role in multi-drug 
resistance was undertaken because fission yeast pwpl'^ was recently identified as 
multi-drug resistance gene (Crane 2000). No data regarding a putative role of the 
S.cerevisiae PWPl gene in drug resistance have been described.
Here it is first shown that S.pombe pwpl^ and human PWPl are not functional 
homologues. Expression of the human gene in fission yeast did not show any 
phenotype and expression of human PWPl from a multicopy plasmid could not 
restore viability to fission yeast pwpf ^ -deletion mutants (Crane 2000).
Surprisingly, the presence of exogenously expressed human Pwpl led to a survival 
disadvantage of COS-7 cells after exposure to cytotoxic drugs. Although the identity 
at the amino acid level between the S.pombe and the human proteins is just 34% and 
the two counterparts are not functional homologues, it had seemed possible at the 
outset of this study that the fission yeast ^-conferred drug resistance phenotype 
might be conserved in mammalian cells. The drug sensitivity could not be explained 
by any deleterious effect of the HA epitope tag fused to the amino-terminus of 
hPwpl.
How then can the drug sensitivity phenotype be explained?
Two views are possible.
1. A divergent evolution between the fission yeast and human pwpiyPW Pl genes 
occurred. The signal generated from Pwpl is interpreted differently in the two 
species.
2. Human PW Pl is not the human gene most closely related to pwpl^ and 
possibly the true homologous has yet to be found.
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Treatment with a variety of cytotoxic drugs has been documented to induce 
apoptosis in the cells generally by causing cellular or DNA damage. It could be 
reasonable to assume that human Pwpl acts as a intermediary of the apoptotic 
response triggered by cytotoxic stress in mammalian cells. This view could be in 
accord with no evidence of apoptosis in fission yeast, where pw pl^  induces the 
Pap 1-dependent stress response that leads to a survival advantage. Apoptosis could 
be a recent response generated in more complex organisms in order to escape 
irreparable cellular damage or intolerable environmental stress conditions. Although 
fission yeast is often used as a potent genetic tool in order to investigate complex 
processes in eukaryotic cells (Nurse 1990), such as regulation of mitosis and cell 
cycle, not all pathways or gene functions are conserved.
On the other hand, human PWPl could not be the closest counterpart of S.pombe 
pwpl'^.
Distinction between these possibilities will require further information.
The functional role of Pwpl in the cell is not known. Studies on S.cerevisiae have 
suggested that Pwpl might have a regulatory role, possibly in cell growth and/or 
gene transcription (Duronio et al. 1992). The Pwpl protein has a positive charged 
domain in the central part of its amino acid sequence, where the putative localization 
signal KKKGK is also localised (Duronio et al. 1992), which seems to be a feature 
of many regulatory proteins, such as transcription factors (Brendel and Karlin 1994). 
This putative regulatory role of Pwpl is also in line with the evidence that most 
members of the WD-repeat protein family are regulatory proteins involved in a 
variety of cellular processes, including cell division, cell fate determination, gene
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transcription, transmembrane signaling, mRNA modification and vesicle fusion 
(Neer et al. 1994).
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Chapter 7
Further characterization of the 
human PWPl gene
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Overview
In this chapter I describe further studies aimed at a better understanding of the 
general function of hPwpl in human cells. I describe the sub-cellular localization of 
HA-tagged hPwpl and discuss factors underlying this localization. In addition, I 
also present preliminary results obtained using anti-sense RNA expression and the 
two-hybrid screen.
Results
Sub-cellular localization of HA-Pwpl in COS-7 cells
To better characterize human Pwpl in mammalian cells several questions were 
addressed. First, sub-cellular localization of the protein was studied using two 
different approaches. COS-7 cells stably expressing HA-hPwpl were grown on 
sterile glass coverslips in a 6-multi-well plate. The cells were subjected to indirect 
immunofluorescence using mouse monoclonal anti-HA and FITC-conjugated anti­
mouse antibodies (Figure 7.1 A). The cells were also stained with FITC-conjugated 
anti-mouse antibody alone as a negative control (Figure 7 .IB). Exogenously 
expressed HA-hPwpl was detected by fluorescence microscopy and was present 
both in nuclear and cytoplasmic compartments of the cells, with a stronger signal in 
the cytoplasm.
Next, the localization of the protein was studied using a method independent of 
antibody detection. To this end a fusion protein of hPWPl and enhanced green 
fluorescent protein (EGFP) sequences was generated using the pEGFP vector. The
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Figure 7.1 -  Stably overexpressed HA-hPwpl in COS-7 cells is localized throughout the 
nucleus and cytoplasm
Indirect immunofluorescence in COS-7 cells from polyclonal pool stably overexpressing HA- 
hPwpl. Cells were grown on sterile glass coverslips in a 6-multiwell plate for 24 hours and 
fixed in 4% paraformaldehyde, permeabilised in 0.5% Triton X-100. Cell were then stained 
using mouse monoclonal anti-HA antibody and FITC-conjugated anti-mouse antibody (A). As 
a negative control the cells were also stained with FITC-conjugated anti-mouse antibody alone 
(B). DNA was stained with Hoechst 33258 [Ipg/ml] and the cells were then mounted in 90% 
glycerol and examined by fluorescence microscopy.
pEGFP-hPWPl vector was then transiently expressed in COS-7 cells and its 
localization of the EGFP-Pwpl fusion protein was detected by fluorescence 
microscopy. The protein was clearly found only in the cytoplasm, which contrasted 
with the nuclear and cytoplasmic localization described above (Figure 7.2).
The sequence of hPwpl contains a putative nuclear localization signal (NLS) 
(Honore et al. 1994), which is also conserved in the budding and fission yeast 
proteins (Crane 2000; Duronio et al. 1992). Motifs of this sort allow proteins to 
enter the nuclear compartment of the cell by an energy-dependent mechanism 
involving p-importins (reviewed by Hodel et al. 2001). Given that the presence of 
this motif in a protein suggests its possible localization and function in the nuclear 
compartment of the cell, the exclusion of the EGFP-Pwpl fusion protein from the 
nucleus was further elucidated. The fungal antibiotic leptomycin B (LMB) is able to 
inhibit the nuclear/cytoplasmic transport by its direct binding to Crml, which is a 
highly conserved export factor'(Adachi and Yanagida 1989; Fornerod et al. 1997a; 
Fornerod et al. 1997b; Ossareh-Nazari et al. 1997; Stade et al. 1997; Toda et al. 
1992). This in turn affects the binding of Crml to the nuclear export signal (NES) 
sequence of cargo proteins, preventing their translocation from the nucleus to the 
cytoplasm and consequently leading to a nuclear accumulation of these proteins 
(Fornerod et al. 1997b; Kudo et al. 1998; Nishi et al. 1994; Ossareh-Nazari et al. 
1997). The possibility that the cytoplasmic localization of EGFP-Pwpl reflected 
rapid Crml-dependent protein export was next addressed. To this end, COS-7 cells 
were transiently transfected with pEGFP-hPWPl and 24 hours later were mock or 
LMB treated for 45 minutes or for 2.5 hours. DNA was stained using Hoechst 33285 
and localization of the fusion protein was assayed by fluorescence microscopy. 
Figure 7.3 shows that treatment of the transiently transfected cells with leptomycin
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B partially changed the localization of the EGFP-hPwpl fusion protein. Panel A 
shows a cytoplasmic localization of the protein in the mock treated cells, whereas 
panel B (45 minutes) and panel C (2.5 hours) show that the fluorescence appears to 
be diffused throughout the cell. In conclusion, although exclusive nuclear 
localization of the protein was not observed after treatment with leptomycin B, the 
change of the localization pattern of the EGFP-hPwpl suggests a possibly indirect 
but Crml-dependent nuclear export mechanism.
HA-hPwpl overexpression increases the activity of the AP I complex
Fission yeast pw pF  is able to increase the transcriptional activity of Papl (Crane 
2000) and the drug resistance conferred by Pwpl is Papl-dependent. Bearing in 
mind that the phenotypes conferred by the human and fission yeast genes are 
opposite, the possible role of human Pwpl in the modulation of AP I activity in 
mammalian cells was explored.
Both transcriptional and DNA binding activities of the mammalian AP-1 complex 
were investigated. First, the DNA binding activity of AP-1 was measured in 
COS-7 polyclonal cells carrying the empty vector or overexpressing HA-hPwpl. 
Whole cell extracts were prepared from both cell populations and incubated for 
30 minutes with a [^^P]-labelled double strand oligonucleotide containing the AP- 
1 DNA binding consensus sequence ATGACTCAG (Figure A .l - Appendix). 
Free DNA labelled-oligonucleotides and DNA/AP-1 complexes were then 
separated by non-denaturing acrylamide electrophoresis. In competition 
experiments the samples were incubated with a 50-fold excess of unlabelled AP-1 
consensus or mutant oligonucleotide (in which the consensus nucleotides CA are 
changed to TG) for 20 minutes before adding the labelled probe. As shown in the
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DNA GFP-PWPl Merge
Figure 7.2 -  Transiently expressed EGFP-Pwpl is cytoplasmic
Localization of EGFP-hPwp in COST cells. Cells were grown on sterile glass coverslips in a 
6-multiwell plate. Transient transfection of the pEGFP/hPWPl plasmid was carried out 
using FuGENE reagent and 24 hours later the cells were fixed with 4% paraformaldehyde. 
DNA was stained with Hoechst 33258 [Ipg/ml] and localization of EGFP-hPwpl was 
detected by fluorescence microscopy.
DNA EGFP-PWPl DNA EGFP-PWPl
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Figure 7.3 -  Treatment with leptomycin B partially changes the localization pattern of 
transiently expressed EGFP-hPwpl
COS7 cells were grown on sterile glass coverslips in a 6-multiwell plate. Transient 
transfection of the pEGFP/hPWPl vector was carried out using FuGENE reagent and 24 
hours later the cells were mock (A) or leptomycin B treated for 45 minutes (B) or 2.5 hours 
(C). Cells were then fixed with 4% paraformaldehyde and DNA was stained with Hoechst 
33258 [Ipg/ml]. Localization of EGFP-hPwpl was detected by fluorescence microscopy.
Figure 7.4, exogenous HA-hPwpl increased the formation of DNA/AP-1 
complex in COS-7 cells. The detected complex was AP-1 specific since its 
formation was abolished when an excess of unlabelled AP-1 consensus 
oligonucleotide was added to the samples.
In contrast, the presence of an excess of AP-1 mutant oligonucleotide did not 
affect the AP-l/DNA band-shift.
Next, the transcriptional activity of AP-1 was analysed using a luciferase reporter 
assay. COS-7 polyclonal cells carrying the empty vector or overexpressing HA- 
hPwpl were transfected with the reporter pColSLuc plasmid, expressing firefly 
luciferase under the control of the collagenase promoter (kindly provided by Dr. 
J.Tavare). This promoter contains a 9-bp consensus AP-1 DNA sequence and is 
modulated by AP-1 (Angel et al. 1987a; Angel et al. 1987b). The control pRL- 
TK-i?en///fl plasmid, which expresses Renilla luciferase under control of the 
constitutive thymidine kinase (TK) promoter, was co-transfected at a ratio of 
15:1, as an internal control for transfection efficiency. The activity of both firefly 
and Renilla luciferases was measured using the dual luciferase reporter assay kit 
(Promega) and the results were expressed as the ratio between the firefly and the 
Renilla activities, referred as the relative luciferase activity (RLA). hPwpl- 
overexpressing cells had an AP-1 transcriptional activity 3-fold (A) or 5-fold (B) 
higher than cells carrying the empty vector, as observed in two independent 
experiments (Figure 7.5).
In conclusion, overexpression of human PWPl in mammalian cells was able to 
increase both DNA binding and transcriptional activities of AP-1 transcription 
factors. This evidence is in accord with the Papl transcriptional activation 
observed in fission yeast after overexpression of SppwpD (Crane 2000).
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Figure 7.4 -  Overexpression of HA-hPwpl increases AP-1 DNA binding activity
AP-1 DNA binding activity was performed by electrophoretic mobility shift assay using 
whole cell extracts (WCE) prepared from polyclonal cell population stably transfected with 
the empty vector (pcDNA3.1+) or pcDNA3/HA-hPWPl. For competition experiments, 50- 
fold excess of unlabelled (“cold”) AP-1 consensus or mutant oligunucleotides was added 
(+) to the binding reaction for 20 minutes before adding the labelled AP-1 consensus probe.
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Figure 7.5 -  AP-1 transcriptional activity is increased by overexpression of HA- 
hPwpl
Polyclonal pool COS-7 cells stably transfected with the pcDNA3.1/HA-hPWPl vector or 
the empty vector were transiently co-transfected with pCol3-Luc and pRL-TK-Renilla 
plasmids at a ratio of 15:1. The cells were then assayed for the activities of both firefly 
and Renilla luciferase using the dual luciferase reporter kit (Promega). The results are 
expressed as relative luciferase activity (RLA) which is the ratio between the firefly and 
the Renilla activities. Standard deviation is shown as a dark blue shading. Two 
independent experiments are shown.
Anti-sense RNA expression strategy
Fission yeast pwpF  is essential an essential gene (Crane 2000). To this end and in 
order to investigate if decreased level of endogenous hPwpl expression might 
lead to drug resistance, an anti-sense RNA strategy was chosen (Figure 7.6). 
hPWPl cDNA was excised from pcDNA3.1 +/hPWP 1 and was cloned into 
opposite orientation into the pcDNA3.1- vector (InVitrogen), whose multicloning 
site is in the opposite orientation to that of pcDNA3.1+. The resulting plasmid 
was named peDNA3.1-/PWPl-AS. This plasmid should direct expression from 
the anti-sense strand of hPW Pl. pcDNA3.1-/PWPl-AS was stably transfected 
into COS-7 cells and after selection polyclonal G-418-resistant cells were 
obtained. 6 different stable elones were also derived from this polyclonal pool.
The cells transfected with anti-sense hPWPl grew slowly in comparison with un­
transfected cells, empty vector or hPWPl-transfected cells. This slow growth 
phenotype was reminiscent of that observed in S.cerevisiae PWPi-deleted cells 
(Duronio et al. 1992). In order to investigate this phenotype in more detail growth 
kinetics were determined (Figure 7.7). The growth of COS-7 polyclonal cells 
carrying the empty vector was compared with that of polyclonal (A) and clonal 
(B) cells expressing anti-sense hPWPl. Equal numbers of cells were plated in 
duplicate in a 6-multiwell plate and the following day the cells were harvested 
(day 0) and counted using a haemocytometer. The cells were then counted at days 
1, 3, 5 and 7 in the experiment in panel A and at days 2, 7 and 9 in the experiment 
in panel B. The results show that cells stably expressing the anti-sense hPwpl had 
a doubling time approximately twice that of cells carrying the empty vector.
In parallel, the cell cyele profile in these cells was analysed by flow cytometry, 
but no major differences in the cell cycle phase distribution among cells carrying
178
hPWPl sense
3
Hindlll Notl
pcDNA3.1+/
hPWPl
3 ’
5’
Endogenous 
h P W P l  coding 
region
5 ’ hPWPl anti-sense 3 ’
Notl Hindlll
mRNA
Transfection in C0S7 cells 
and selection of polyclonal pool
I Exogenously expressed 
anti-sense h P W P l
CMV promoter
mRNA 
Antisense RNA
Protein is 
not translated
Double stranded RNA 
is degraded
Figure 7.6 -  The RNA anti-sense strategy
the vector, polyclonal cells expressing HA-hPwpl or anti-sense hPwpl were 
observed (data not shown).
A possible explanation for this slow growth phenotype might be that the 
frequency of apoptosis was somehow increased by reduction of hPwpl 
expression. To address this hypothesis, the percentage of apoptotic or 
preapoptotic cells was measured in anti-sense hPwpl cells and cells carrying the 
empty vector using an Annexin V/propidium staining method (see Chapter 2). 
However, no significant difference between the two cell populations was found 
(data not shown).
These results indicate that neither increased apoptosis nor cell cycle-specific 
defect was responsible for slow growth seen in anti-sense hPwpl cells.
The nuclei of anti-sense Pwpl cells were also observed by microscopy with the 
aim of identifying any possible abnormality at the nuclear level. The cells from a 
polyclonal pool carrying the empty vector or expressing anti-sense Pwpl were 
grown on glass coverslips in a 6-multi-well plate for 24 hours. Then, the nuclei 
were stained using Hoechst and analysed by microscopy. The Figure 7.8 shows 
that about 20% of the anti-sense hPwpl cells have fragmented nuclei versus 5% 
found in cells carrying the empty vector.
Human Pwpl and interacting partners
Given that Pwpl belongs to the WD-40 repeat family (Duronio et al. 1992) and 
that the WD-repeat motif is thought to mediate protein-protein interactions (Neer 
et al. 1994; van der Voorn and Ploegh 1992), the size of complex fractions 
containing hPwpl was investigated. To this end, the proteins from the COS-7 
polyclonal cells expressing HA-hPwpl were separated by 7-37% sucrose density
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Figure 7.7 -  Antl-sense Pwpl cells have a slow growth phenotype
The growth rates of polyclonal COS-7 cells carrying the empty vector (pcDNA3.1+), 
polyclonal (A) and two clones (B) of COS-7 cells stably transfected with pcDNAS.l- 
/PWPl-AS were determined. The number of the cells oin each population were counted 
using a haemocytometer at days 0, 1 ,3 ,5  and 7 (A) or at days 0, 2, 7 and 9 (B).
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Figure 7.8 -  Anti-sense Pwpl cells have a high percentage of fragmented nuclei
Polyclonal pools carrying the empty vector or anti-sense hPwpl were grown on sterile 
glass cover-slips in a 6-multiwell plate. 24 hours later the cells were fixed with 4% 
paraformaldehyde and the nuclei were stained with Hoechst 33258 [Img/ml]. The nuclei 
were observed by microscopy and counted and the number of fragmented nuclei is 
expressed as the percentage of the total counted.

gradient centrifugation (by R.Murray). An aliquot of each fraction was subjected 
to immunoblot analysis using HRP-conjugated monoclonal anti-HA antibody, 
(data not shown). HA-hPwpl was detected mainly in fractions 1 and 2, which 
contain the smallest size complexes. This result suggests that hPwpl is possibly 
part of a complex with an estimated size of approximately 300 kDa molecular 
mass.
On the basis of these results, a yeast two-hybrid screen was next performed in 
order to identify putative hPwpl interacting proteins, which might in turn shed 
light on the possible functions of Pwpl in the cell.
To generate the two-hybrid "bait", human PWPl cDNA was cloned in frame with 
the DNA binding protein LexA in the vector pEG202 and transformed into 
S.cerevisiae EGY48 cells. These cells contain two LexA  operator-responsive 
reporters. One is a ehromosomally integrated copy of the LEU2 gene and the 
second is a plasmid bearing the GALl promoter-EacZ, which causes the yeast 
cells to turn blue on agar containing X-gal.
The main requirements for a bait protein are firstly that it should not be actively 
excluded from the yeast nucleus and secondly that it should not possess an 
intrinsic ability to strongly activate gene transcription (Ausubel et al. ). The latter 
requirement was examined for hPwpl. The empty pJG4-5 vector, used to clone 
the human cDNA library, was transformed into EGY48-Pwpl cells and the 
vector-containing cells were selected on agar plates lacking uracil and histidine. A 
P-galactosidase assay was then performed and no blue colonies were identified, 
suggesting that hPwpl cannot induce gene expression on its own. Whether the 
protein acts as a co-activator of transcription still remains to be investigated.
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Next, an interaction hunt was performed. The sequences from the cDNA library 
were cloned under control of GALl galactose-inducible promoter in the pJG4-5 
vector. After transformation of the human cDNA library into yeast cells 
containing the LexA-hPwpl fusion protein bait and the two LexA reporters, if a 
protein X encoded by the cDNA library is able to interact with the LexA-Pwpl 
fusion protein, which is bound to the LexA-responsive element, gene 
transcription will be activated. In contrast, if no interaction occurs there should be 
no transcription of the reporter genes (Figure 7.9).
Human HeLa cDNA library was transformed into the EGY48-Pwpl yeast cells 
that were then selected on agar plates lacking histidine, uracil and tryptophane, p- 
galactosidase assays were then carried out in order to detect any positive 
interaction between hPwpl and proteins encoded by the library plasmids. In two 
independent experiments an average of 15 colonies that became blue after 
incubation with X-Gal at 30°C were identified and isolated. The signal was never 
strong and furthermore always appeared 24-36 hours after the incubation with X- 
Gal. The cDNA-containing plasmid was rescued from each of the colonies 
obtained in the first screen and subjected to sequencing analysis. Three sequences 
only were obtained: empty vector, annexin II and cytochrome oxidase 
Unfortunately, each of those sequences was represented in a list of the most 
c o m m o n  f a l s e  p o s i t i v e  s e q u e n c e s
(http://www.fccc.edu.research.labs.golemis.intro.html) found in the yeast two- 
hybrid screens. To further check if these cDNAs were false positives, they were 
re-transformed into EGY48-Pwpl yeast cells but no signal was observed, 
indicative of no interaction.
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Unfortunately, no protein(s) interacting with hPwpl were identified and the only 
conclusion drawn was that hPwpl does not seem to be a transcription factor.
More efforts are necessary in order to identify any putative partner interacting 
with the human Pwpl
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Figure 7.9 -  The yeast two-hybrid screen: the interaction hunt
A) EGY48 cells contain two LexA operator-responsive reporters, one is a 
ehromosomally integrated copy of LEU2 gene and the other is a plasmid bearing a 
GALl promoter-LacZ fusion gene. The cells also constitutively express a chimeric 
protein, containing the DNA binding domain of lexA fused to the bait protein. B) The 
cells as in A have been transformed with an activation domain (act) fused to the 
cDNA library. The encoded protein does not interact with the bait and the two LexA 
reporters are not activated. C) The library-encoded protein interacts with the bait 
protein with consequent activation of the two reporters which leads to cell growth on 
medium lacking leucine and blue colour on medium containing X-gal.
Discussion
It is here shown that human Pwpl, which is localised in both the cytoplasmic and 
nuclear compartments of COS-7 cells, is able to positively modulate the activity 
of the AP-1 transcription factors. It is still not clear if hPWPl is an essential gene; 
however the results from the anti-sense strategy suggest a role for hPwpl in the 
regulation of cell growth. In addition, the protein seems to be part of low 
molecular weight complexes but unfortunately no interacting protein(s) has been 
identified so far.
hPwpl and AP-1 transcription factors
The ability of human Pwpl to positively modulate both DNA binding and 
transcriptional activity of AP-1 is in accord with the evidence that overexpressed 
S.pombe pwpl'^ is able to increase the level of p25 protein level (Crane 2000), 
encoded by the Pap 1-target gene aptl"^ (Toda et al. 1992), which is indicative of 
an elevated activity of the AP-1-like transcription factor Papl. However, there are 
no data regarding a possible modulation of Papl DNA binding activity after 
overexpression of fission yeast pwpl'^ (Crane 2000).
These results taken together may suggest that the increased sensitivity observed in 
COS-7 cells overexpressing human Pwpl after exposure to cytotoxic drugs 
(described in Chapter 6) could reflect elevated AP-1 activity which in turn leads 
to transcriptional activation of downstream targets.
It seems that although overexpression of fission yeast pwpl* causes multi-drug 
resistance (Crane 2000), whereas overexpressed human PWPl leads to multi-drug 
sensitivity (Chapter 6), the general mechanism through which these proteins
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respond to cytotoxic insults has been conserved. If this is the case, then a 
diversification of the downstream response triggered by AP-1/Papl activation 
must have occurred between yeast and human cells during evolution.
Elevation of apoptosis might cause survival disadvantage after treatment with 
cytotoxic drugs via the AP-1 transcription factors. AP-1 activity has been 
implicated in the regulation of a variety of cellular processes (reviewed by 
(Wisdom 1999; Wisdom et al. 1999). In fact, AP-1 has a key role in the 
regulation of cell proliferation and growth and it has also a protective role from 
the UV-induced cell death (reviewed by Karin et al. 1997; Wisdom 1999). A 
strong and prolonged induction of c-Jun has been also reported in consequence of 
stress inducing stimuli, including UV and ionising radiation, hydrogen peroxide 
and tumour necrosis factor a  (TNFa), which can trigger apoptosis (see Bossy- 
Wetzel et al. 1997). Although it seems a paradox, AP-1 plays a role also in 
apoptosis. Cell death induced by growth factors withdrawal or by genotoxic 
agents, such as UV and x-ray, is mediated by AP-1 activity (Colotta et al. 1992; 
Gillardon et al. 1994; Goldstone and Lavin 1994) as well as c-Jun transcriptional 
activity is also required to trigger apoptosis in immortilized fibroblasts (Bossy- 
Wetzel et al. 1997).
This body of information together with the evidence discussed above can suggest 
that the Pwpl-induced cell sensitivity in response to cytotoxic stress might be 
mediated by AP-1 which in turn trigger apoptosis via transcriptional activation of 
cell death factors or of inhibitors of cell proliferation or of survival promoting 
factors.
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HA-hPwpl sub-cellular localization
In regard to the sub-cellular localization Honore’ et al. previously concluded that 
human Pwpl was more abundant in the nucleus of human cells than in the 
cytoplasm (Honore et al. 1994). In accord with that, I showed that exogenous 
stably expressed HA-tagged Pwpl was localised both in the cytoplasm and 
nucleus of COS-7 cells, with a stronger signal in the nucleus. By comparison, 
transiently expressed BGFP-tagged Pwpl was excluded from the nucleus. Given 
the fact that the Pwpl amino acid sequence contains a putative nuclear 
localization signal (KKKGK (Duronio et al. 1992)), it seems likely that the 
protein is able to enter into the nuclear compartment through the importin 
P-dependent mechanism via active transport. As discussed for the localization of 
HA-Pohl in Chapter 3, the EGFP-epitope tag fused to the amino-terminus of 
hPwpl could modify the conformation of the protein with consequent inhibition 
of its nuclear translocation. Alternatively, the different localization pattern 
observed for the HA-Pwpl and EGFP-Pwpl proteins might simply reflect to a 
stable expression of the first compared to transient expression of the second, 
which could give rise to artefacts. Treatment of cells transiently overexpressing 
EGFP-Pwpl with leptomycin B resulted in re-distribution of the protein from the 
cytoplasm to the entire cell. This indicates on the one hand that EGFP-tagged 
hPwpl is also able to enter into the nucleus and on the other that the localization 
of hPwpl might be modulated at the level of nuclear export, as leptomycin B 
inhibits nuclear/cytoplasmic traffic dependent on Crml export factor (Fomerod et 
al. 1997b; Kudo et al. 1998; Nishi et al. 1994; Ossareh-Nazari et al. 1997). There 
is no readily identifiable nuclear export signal (NFS) in the Pwpl sequence.
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however the nuclear/cytoplasmic trafficking could be regulated indirectly, 
presumably mediated by a hPwpl interacting protein.
hPwpl and interacting proteins
No interaction partners for Pwpl in different species have been previously 
identified. Here, I describe two halves of a same attempt aimed to identify a 
possible hPwpl interacting partner using a two-hybrid screen analysis but 
unfortunately they were unsuccessful. Nevertheless, it was also shown that the 
protein is part of a small size complex. This data is not in accord with the 
evidence that fission yeast Pwpl was found in fractions containing complexes 
with even larger size than polysomes after sucrose density gradient centrifugation 
(Crane 2000). This difference might further support the notion that the functions 
of S.pombe pwpl* and human PWPl have not been conserved during evolution. 
In fact, the two counterparts are not functional homologues and furthermore when 
overexpressed they lead to opposite cell responses after the exposure of the cells 
to a given cytotoxic drug (Chapter 6), although they are both able to mediate their 
responses through Papl/AP-1 transcription factors. Therefore, it is less surprising 
that the two proteins are also localised to different areas of the cell and are part of 
complexes of different sizes in the cell.
The RNA anti-sense strategy
The slow growth phenotype observed after human Pwpl anti-sense RNA 
expression in COS-7 cells suggests a possible role of the protein in cell growth 
regulation, although the results did not fully answer the question if the human 
gene is essential. This evidence is in accord with the phenotype observed in
189
S.cerevisiae, where the PWPi-deletion mutants grow three-fold more slowly than 
wild-type cells, although the gene is not essential (Duronio et al. 1992). In 
contrast, S.pombe pwpl* is an essential gene (Crane 2000). However, it was here 
not demonstrated a decreased level of the endogenous Pwpl in COS-7 cells 
transfected with pcDNA3.1 -/PWP1 - AS as the anti-Pwpl antibody was available 
only recently.
The retardation in the cell growth observed in hPwpl anti-sense cells was not due 
to a specific cell cycle delay or to elevated apoptosis. In addition to this growth 
phenotype, the cells in culture appeared also generally unhealthy and the nuclei 
had a higher percentage of fragmentation compared to control cells. The 
significance of this phenotype and the mechanism by which stage the reduced 
level of endogenous Pwpl in the cell, if any, could cause these defects need still 
to be elucidated.
The preliminary results described here together with a few lines of evidence, such 
as the phenotype observed in the PWP7-deleted mutants in S.cerevisiae (Duronio 
et al. 1992), the presence of highly charged residues in the amino acid sequence 
of Pwpl (Duronio et al. 1992), and the regulatory role of each member of the 
WD-repeat family in the cellular processes (Neer et al. 1994), further support the 
hypothesis that hPwpl might be involved on the regulation of cell growth or 
possibly of gene transcription (Duronio et al. 1992).
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General conclusions and further
directions
191
The work described in this thesis, concerning the characterization of novel human 
determinants of drug resistance in mammalian cells, highlights the key role played 
by transcriptional regulation in the cellular responses to cytotoxic insults, 
although the downstream responses can be diverse and even opposite.
During the course of this work it was established that at least some mechanistic 
aspects of multi-drug resistance mechanism are conserved between fission yeast 
and human cells. The highly conserved 26S proteasome regulatory subunit 
Poh 1/Pad 1 appears to function as transcriptional co-activator of the basic leucine 
zipper AP-1/Papl transcription factors when overexpressed. This evidence 
together with previous reports strongly suggests that Pohl can regulate the drug 
susceptibility of cells via modulation of the ubiquitin-dependent proteolysis of 
transcription factors. However, the downstream effector mechanisms are still 
unidentified. Ongoing studies are aimed at identifying targets of the HA-Pohl- 
induced pleiotropic drug resistance mediated by AP-1 using a micro array 
transcriptional profiling approach and HA-POHl doxycyclin inducible human 
cells. In order to address the general function of Pohl as regulatory subunit of the 
26S proteasome and any dependency of Pohl-induced pleiotropic drug resistance 
on the 26S proteasome complex several aspects could be addressed. The 
interaction of exogenous HA-Pohl with c-Jun (Figure 5.13) and the evidence that 
most HA-Pohl is not incorporated into the 26S proteasome (Figure 3.10) may 
suggest a proteasome-independent mechanism. Purification of recombinant Pohl 
would be useful for the development of in vitro assays that will allow exploration 
of the role of Pohl in the recognition of ubiquitinylated substrates, such as c-Jun 
and c-Fos, and their consequent proteolysis. It would be also valuable to test the
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possibility that Pohl acts as a ubiquitin hydrolase. The identification of additional 
Pohl interacting proteins other than c-Jun using a two hybrid screen approach 
should be quite straightforward. Furthermore, although it was previously 
demonstrated that HA-Pohl is able to functionally complement pWJ-deleted 
mutants and to confer drug resistance (Spataro et al. 1997), the possibility that the 
HA epitope tag fused to the amino-terminus of the protein causes a disruption of 
Pohl function and subsequently drug resistance has not yet been addressed. This 
may explain the differing abilities of the exogenous and endogenous Pohl to 
associate with the 26S proteasome complex and to interact with c-Jun. Studying 
the drug susceptibilities of the cells overexpressing Pohl or HA-Pohl in parallel 
could be a simple way to address this topic. Given that proteolysis defects 
associated with growth defects have been reported in the fission yeast temperature 
sensitive padl-1  mutant (Penney et al. 1998), it would be also interesting using 
the anti-sense RNA strategy to examine the effects of reduction of Pohl protein 
level on ubiquitin-dependent proteolysis and growth. At the same time, it will be 
interesting to determine whether a reduced level of Pohl confer drug sensitivity.
PWPl was shown to confer multi-drug sensitivity in mammalian cells and to 
activate AP-1 activities when overexpressed, suggesting transcriptional activation 
of proteins involved in apoptosis or in the inhibition of cell survival. Farlier 
speculations on the function of Pwpl led to the hypothesis that Pwpl might be 
involved in cell growth and/or transcriptional regulation. Many of the questions 
addressed in this study are still unsolved and to elucidate the possible mechanism 
through which Pwpl affects drug sensitivity it will be necessary to focus more on 
the normal function of Pwpl in the cell.
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First, it will be important to identify Pwpl-interacting proteins in order to know 
more about the Pwpl-containing complex and its possible function in the cell. 
The previous attempts using a two-hybrid screen analysis were unsuccessful 
possibly because more colonies need to be screened. The identification of 
downstream targets of the AP-1 activation induced by Pwpl using microarray 
transcriptional profiling analysis, as for Pohl, would shed light on the mechanism 
underlying the Pwpl-induced drug sensitivity of the cells. Because of the late 
availability of the anti-Pwpl antibody and consequent lack of time it was not 
possible to determine whether the slow growth phenotype observed in the anti­
sense Pwpl COS-7 cells is strictly due to a reduced expression level of Pwpl. 
Such an experiment is now possible and would be an early priority in the 
extension of the work described here.
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A .l) Sequences
- Oligonucleotide primers 
I C R F  n  N a m e S e q u e n c e
1 94947 PWPl 5’ gagacgtcgacaaccgcagccgccaggtgacg
2 94948 PWPl 3’ ctagcgcggccgcttaagactccatgggtgtatc
3 1122113 VWVlHind/Sa/ gaccataagcttgtcgaccaccatgaaccgca
gccgccaggtg
4 1122114 PWPl (3HA) gattgcggatccgcggccgcttaagcgtaatctgg
aacgtcatatggatagcatagtccgggacgtcatagggatac
gcatagtcaggaacatcgtatgggtatctagaagactccatg
ggtgtatc
5 105066 PWPl HindPLA3 caccataagcttcaccatgggccgcatcttttac
6 (Richard) PWPIATG (no Tag) gagacctcgagccaagcttccgatgaaccgcagcc
gccaggtgacg
7 97356 PWPl mutchk cctggaggatggtgacccagag
8 97358 PWPl 3’Pst tctatctgcccactgaatcgcc
9 115202 PWPl 5’int ggatgcacgttcagataagccaa
10 101911 RETOFF 5’ cgccatccacgctgttttgacc
11 124795 RETOFF 3’ cacctccccctgaacctgaaac
12 124795 Linker 5’ agcttcgaattctgcaaggatctctagag
13 124796 Linker 3’ tcgactctagagatcctgccagaattcga
14 116171 POHl Sal5’ gcatgtcgacatggacagacttcttagacttgga
15 116172 Ÿ O m  Xma3’ gcatcccgggttatttaaatacgacagtatccaa
17 1244868 ^ O m  EcoRB' gcatgacttaagttatttaaayacgacagt
18 1244869 POHl NotI5’ acgccagcctgcggccgcatgtacccatacgatgttcc
tgactatgcggacagacttcttagacttag
19 83047 PJG45X gaagtccaaagcttctcgag
20 83048 PJG45E attatgcctctcccgaattc
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- AP-1 oligonucleotides
AP-1 consensus 5’-cgc ttg atg act cag cog gaa-3’ 
3’-gcg aac tea tga gtc ggc ctt-5’
Santa Cruz (5C-2501)
AP-1 mutant 5 ’-ego ttg atg act tgg ccg gaa-3’ 
3’-gcg aac tac tga acc ggc ctt-5’
Santa Cruz (.sc-2514)
- Peptides
PWPl-NT
PWPl-CT
KETPDKVELSKEEVKR
SRSSDTPME
189 mg 
77 mg
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A.2) Vectors 
- Vectors used for cloning
Name Description
pREP3 Fission yeast expression vector
pcDNA 3.1+/- Constitutive expression
pRETRO OFF Tetracycline repressible expression
pOPRSVI CAT IPTG-inducible expression
pGEX-4T-3 GST-fusion bacterial expression
pUHD10-3MCS Tetracycline/doxycyclin
regulatable expression
pIRES2-GFP GFP expression
pEGFP-Cl GFP-fusion protein expression
pEG202 LexA-fusion for yeast two hybrid screen
- Other plasmids
Name Description
pCD2/CMV Transient co-transfection and CD2 selection
pCol-LUC3 Luciferase assay
pRL-TK-Renilla Luciferase assay
pcDNA/HA-Ub c-Jun/c-Fos ubiquitinylation
pMT35/cJun-HiSg c-Jun ubiquitinylation
pcDNAl/ c-Juni_287 c-Jun in vitro degradation assay
pcDNAl/c-Jun A3.122 c-Jun in vitro degradation assay
pcDNAl/c-Jun dominant neg. Transient transfection for drug sensitivity
218
A.4) Antibodies 
- Primary
A n t i b o d y S o u r c e T y p e C o n c e n t
r a t i o n /
D i l u t i o n
H A - Roche rat 12.5
p e r o jd ix id a s monoclonal ng/ml
e  h i g h antibody
a f f in i t y
( 3 F 1 0 )
F l a g  M 2 Sigma Mouse
monoclonal
1:1000
H a p - 1 The
Binding
site
Sheep
polyclonal
1:1000
c - J u n  ( H - Santa Cruz rabbit 1:50 IP
7 9 ) Biotechnol polyclonal 1:100
[2 0 0  p g /m l ] ogy antibody WB
c - J u n / A P - 1 Clontech rabbit 1:50 IP
(A b - 1 ) polyclonal 1:100
[1 0 0  |x g /m l] antibody WB
c - F o s  (4 ) Santa Cruz rabbit 1:100
[2 0 0  p g /m l ] Biotechnol
ogy
polyclonal
antibody
M C P - 2 1 ICRF mouse 1:500 IP
[1 .9  |x g /p l] Research monoclonal 1:1000
Monoclon antibody WB
a l Ab
service
C D 2  O X - 3 4 Serotec mouse 2 pg/ml
[0 .3  |xg /|x l] monoclonal
antibody
C d c 2  (A 1 7 ) G.Gammo 
n an d  
T.Hunt
mouse
monoclonal
2 pg/ml
P o h l  C N 1 3 Spataro et 
al 1997
rabbit
polyclonal
antibody
1:200
G F P  B 3 4 Covance murine 1:1000
[ I m g /m l ] monoclonal
antibody
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HA H A .ll  
(16B12)
Covance mouse
monolconal
antibody
1:200 or 
1:500 IF
Pw pl CN35 This study rabbit 1:200
polyclonal
c-Jun/AP-1 Santa Cruz 4-8 pg/ml
(N)X 200 Biotechno
|ig/0.1 ml nogy
Secondary
Antibody Source Dilution
anti-rabbit Sigma 1:1000 or
peroxidase 1:2000
conjugates
Anti-sheep Sigma 1:1000
peroxidase
conjugated
anti-mouse Sigma 1:1000 or
peroxidase 1:2000
conjugates
anti-mouse Sigma 1:800
FITC-
conjugated
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Overview
In this chapter I describe the molecular mechanism by which overexpressed HA-Pohl 
leads to pleiotropic drug resistance in mammalian cells.
Firstly, I introduce AP-1 transcription factors, the links between AP-1 and the 26S 
proteasome complex and drug resistance in human cells. Secondly, I describe the ability 
of HA-Pohl to positively modulate AP-1 transcription factor activity associated with 
increased protein levels of the two AP-1 subunits, c-Jun and c-Fos. Furthermore, 
evidence is presented that HA-Pohl may increase the protein stability of c-Jun through 
an interaction between the two proteins.
Introduction
Activating protein 1 (AP-1)
Activating protein 1 (AP-1) is a family of dimeric transcription factors complex, whose 
components include c-Jun and c-Fos, members of the bZip family proteins which 
contain conserved basic (b) and leucine zipper (ZIP) domains required for their binding 
to DNA. This motif mediates homodimerization of c-Jun and heterodimerization of c- 
Jun and c-Fos and the subsequent recognition and binding to the palindromic consensus 
DNA sequence 5-TGAGTCA-3', referred as 12-0-Tetradecanoylphorbol 13-acetate 
(TPA)-responsive element (TRE) or AP-1 consensus site, located in the promoter region 
of a variety of genes (Angel et al. 1987b). c-Jun and c-Fos are both defined proto­
oncogenes as they were identified as the cellular counterparts of the oncogenes v-Jun 
and v-Fos, respectively (Maki et al. 1987) (Curran and Teich 1982). c-Jun is also able to
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form heterodimeric complexes with ATF-2 (Activating Transcription Factor 2), 
belonging to the ATF transcription factor family, and CREB proteins. The resulting 
complexes bind to the AP-1-related cyclic AMP responsive element (CRE)-like site 5’- 
TGAGCTCA-3' (reviewed by Karin et al. 1997; Wisdom 1999).
A wide range of external stimuli, such as peptide growth factors, cytokines, oxidative 
stress, UV irradiation and other forms of cellular stress, generate signals that converge 
on the AP-1 factors (Figure 5.1), with subsequent modulation of their activity which is 
regulated primarily at the transcriptional and post-translational levels (Figure 5.2). 
Based on this regulation, AP-1 co-ordinates a variety of signals and consequently 
generates diverse cellular responses, including cell proliferation, differentiation, 
development, apoptosis and other stress responses (reviewed by Karin et al. 1997; 
Wisdom 1999) (Figure 5.1).
DNA binding and transcriptional activation domains are distinct in c-Jun and c-Fos and 
the activation domains are modulated by phosphorylation. For example, c-Jun is 
phosphorylated at Ser^ ,^ Ser^ ,^ Thr^  ^ and Thr^  ^ by members of the c-Jun NHz-terminal 
kinases (JNK) family (Adler et al. 1994). JNK, originally identified as a c-Jun 
associated kinase, is a serine/threonine kinase activated by phosphorylation by various 
stimuli, including DNA damaging agents, inhibitors of protein synthesis, heat shock and 
osmotic stresses (reviewed by Kyriakis et al. 1994). Phosphorylation of c-Jun controls 
its activity in two manners (Figure 5.2). On the one hand, the tight association between 
JNK and c-Jun, which is independent on the activation status of JNK, targets c-Jun for 
ubiquitinylation and on the other hand phosphorylation at Ser^  ^by JNK is sufficient to 
protect the protein from ubiquitinylation resulting in increased protein stabilization 
(Fuchs et al. 1997) (Figure 5.3). This probably occurs through a conformational change 
of c-Jun after phosphorylation which consequently affects its affinity for JNK.
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A few lines of evidence have demonstrated that in fibroblasts the mitogenic response of 
the cell is mediated through AP-1 activity, resulting in modulation of cell growth and 
proliferation (Brown et al. 1998; Kovary and Bravo 1991; Maki et al. 1987). c-Jun and 
c-Fos play also a major role in the cellular response to UV irradiation by protecting the 
cell from UV-induced cell death (Wisdom, 1999) (Schreiber et al. 1995). It was recently 
reported that c-Jun modulates cell proliferation and UV responses by distinct 
mechanisms, both involving modulation of the transcription of the cyclin D1 gene 
(Wisdom, 1999) (Wisdom et al. 1999). Regulation of cell proliferation does not require 
c-Jun phosphorylation, whereas phosphorylation of c-Jun at Ser^  ^ and Ser^  ^sites with 
subsequent activation of the protein is necessary to protect the cell from UV-induced 
cell death.
c-Jun degradation pathways
c-Jun is a short-lived protein with a half-life of approximately 90 minutes (Treier et al. 
1994). Tight temporal control of the activity of many regulators of gene transcription, 
including c-Fos, p53, c-Mos and c-Myc, shares this feature (Rogers et al. 1986). 
c-Jun and c-Fos are both degraded by the 26S proteasome complex (Treier et al. 1994; 
Papavassiliou et al. 1992; Ciechanover et al. 1991). However, several aspects of the 
regulation of AP-1 turnover are controversial, perhaps suggesting the participation of 
multiple pathways. Treier et al. showed that c-Jun is ubiquitinylated and degraded by 
the 26S proteasome pathway in vivo (Treier et al. 1994) and in addition that the ô 
domain, a 27 amino acid sequence located at NHz-terminus of the protein, is essential 
for c-Jun ubiquitinylation and its subsequent proteolysis. In line with these findings, the 
oncogenic counterpart v-Jun, which lacks the 6 domain due to an in frame-deletion, was 
shown to have elevated protein stability in comparison to c-Jun (Treier et al. 1994). JNK
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binds to the ô domain of c-Jun and consequently targets its substrate for ubiquitinylation 
(Fuchs et al. 1996). In contrast, in v/fro studies of AP-1 ubiquitinylation using 
reconstituted enzyme systems showed that c-Jun lacking the 8 domain and c-Fos lacking 
the PEST motif, a common sequence involved in the rapid destruction of short-lived 
proteins (Rogers et al. 1986), can be efficiently ubiquitinylated (Hermida-Matsumoto et 
al. 1996). It was also reported that degradation of c-Jun by the 26S proteasome pathway 
does not require ubiquitinylation of the protein in vitro (Jariel-Encontre et al. 1995). 
Another number of substrates, including ornithine decarboxylase, is degraded by the 
26S proteasome in a ubiquitin-independent manner. c-Jun might contain intrinsic 
signals for ubiquitin-independent recognition by the 26S proteasome complex and 
subsequent degradation. In addition, a role for calpains (calcium-dependent cystein 
proteases) in the degradation of c-Jun and c-Fos has been shown. However, these 
proteases may have only limited involvement in AP-1 turnover, as they are restricted to 
the cytoplasm (Jariel-Encontre et al. 1995).
Taken together, these data imply that the regulation of c-Jun and c-Fos turnover is 
complex and controversial but also establish that the major proteolytic pathway for their 
regulation involves the 26S proteasome pathway. Whether ubiquitinylation is an 
absolute requirement for the proteolyisis in vivo of these proteins, and whether different 
pathways co-exist, possibly depending on the physiological conditions of the cell or the 
cell type, are still open issues.
One interesting general observation that has recently come to light is the inverse 
correlation between the stability of transcriptional activators and their activation domain 
potency in vivo (Molinari et al. 1999). It seems that the rate of degradation of 
transcription factors by the 26S proteasome pathway strongly depends on the degree of
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their activity, as highly potent transcription activators are processed very rapidly in 
mammalian cells. In order to be degraded these activators must interact with their 
targets.
AP-1 and drug resistance
Some studies have suggested a role for AP-1 factors in the modulation of drug 
resistance in cancer cell lines. Multi-drug resistance MCF-7 breast cancer cells 
exhibited elevated expression of c-jun and c-fos genes together with elevated 
transcriptional and DNA binding activities of AP-1 (Daschner et al. 1999). AP-1 
modulation of the MDR-1 gene, which contains a putative AP-1 binding site in its 
promoter region with consequent increase of MDR-1 mRNA and protein level have also 
been documented. Furthermore, c-Jun mRNA level and DNA binding activity of AP-1 
were also reported to be elevated in etoposide resistant human leukemia cells (Ritke et 
al. 1994). Other reports have shown a positive correlation between AP-1 activation and 
glutathione-S-transferase levels in drug resistant cancer cell lines (Moffat et al. 1994; 
Puchalski and Fahl 1990).
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A.4) Vectors maps
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